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FForeword
In this edition of its Insights series, the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) focuses on one
of the most widely discussed drug-related topics in Europe today:
substitution treatment. The EMCDDA has devoted much energy in
recent years to obtaining greater knowledge on this issue and to
disseminating its findings to a wide audience as part of an overall
goal to interpret new issues in the drugs field.
The publication builds on the results of a study undertaken on
behalf of the EMCDDA by the Osservatorio Epidemiologico
Regione Lazio (OERL), Rome, and the National Addiction Centre
(NAC), London, in 1998 and 1999.
The main aim of the publication is to offer an overview of the
latest patterns and trends in substitution treatment at European
level and to present national country profiles on related practices
in the European Union Member States. It also strives to illustrate
the highly complex nature of the issue, to underscore its nuances
and aid comprehension.
At a time when substitution treatment constitutes a topic of
considerable political and public interest, I trust that the pages that
follow will provide an essential contribution to the work practised
and planned in this field of European drug policy.
Georges Estievenart
Executive Director 
EMCDDA
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IIntroduction
Substitution treatment has grown steadily in Europe since its intro-
duction in the 1960s and is now more widespread and accepted
than ever before. Nevertheless, up-to-date information in the
European Union (EU) Member States regarding this issue, and the
evaluation thereof, has been scarce. It was therefore a high priority
for the EMCDDA to shed light on this topic and to publish the
results.
The decision to carry out a study on substitution treatment was
taken when the debate on this issue moved into the spotlight in the
mid-1990s. The main reasons for this attention were: the launch of
a heroin trial in Switzerland in 1994; the start of levo-alpha-acetyl-
methadol (LAAM) treatments in Portugal the same year; the begin-
ning of buprenorphine treatment in France in 1996; and, last but
not least, the rapid extension at that time of already existing
methadone programmes throughout Europe, especially in Spain
and Italy (1). These initiatives led to an increased focus on substi-
tution treatment itself and to the trajectories it was to follow in the
future.
Findings in the field of substitution treatment, and on the evalu-
ation of substitution-treatment programmes, are of high priority to
the EMCDDA in the context of its mission to provide ‘objective,
reliable and comparable information’ on drugs in the EU and to
(1) Definitions of these and other substitution substances are provided in the section ‘Types of
opiate substitution’ on page 24.
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promote a ‘culture’ of evaluation to better guide policy-makers on
what constitutes effective action. Although the Member States
report a growing number of substitution-treatment programmes,
and although evaluation of such measures is also growing, this
evaluation has yet to become routine. What can be said so far is
that substitution treatment, at the individual level, leads to
increased physical, psychological and social well-being and
reduces criminality. However, there is still remarkably little infor-
mation available on the quality of treatment on offer and its influ-
ence on outcome.
Over the past five years (1995–2000), there has been considerable
investment in the development of drug-information systems in all
European countries. The establishment by the EMCDDA of the
Reitox network of national focal points (2) has made the acquisi-
tion of information on individual countries a great deal easier.
However, the nature of the data remains complex, with continued
difficulty in ascertaining reliable estimates, such as the size of the
chronic opiate-dependent population in all countries. In addition,
there is considerable variation in how different countries docu-
ment and monitor data. As regards treatment activity, some coun-
tries carefully document each treatment episode, while others
leave data collection to more locally or regionally based sources,
rendering national estimates more difficult to interpret.
Despite these limitations, a substantial amount of information
exists on the different levels of substitution treatment provision.
However, although this permits cross-national comparison, it does
not adequately allow for regional variations in treatment provision
within countries. There are also substantial differences in the
organisation of health and social services in different countries,
and even the terms used in one country to describe professional
roles may not translate very accurately to other countries or
settings.
(2) Reitox, the European information network on drugs and drug addiction, consists of one
national focal point in each EU Member State, one from the European Commission and one
observer focal point from Norway. The network is coordinated by the EMCDDA. 
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The study, which forms the basis of this book, had three main
goals:
• to provide an overview of recent trends in the field of substi-
tution treatment in the EU, including the substances used, the
range and extent of services and the consumption of substitution
substances;
• to present the main characteristics of such treatment in each of
the EU Member States, including the role of substitution treat-
ment in the national drug strategy, the monitoring of substitution
treatment and the evaluation of substitution-treatment pro-
grammes; and
• to disseminate the information obtained (the data and insights)
to politicians, decision-makers, professionals and others
engaged in the field.
All 15 EU Member States were included in the study. Each coun-
try was invited to provide an overview of its treatment system, with
a specific focus on drug substitution, using key national inform-
ants. These informants subsequently prepared a country report,
which was used as background information in the preparation of
this published overview.
All key informants were invited to a two-day seminar in Rome 
(15 and 16 March 1999), where issues of comparability and dif-
ferences across national programmes were discussed. 
The Rome meeting explored key issues in the delivery of
methadone and other substitution treatment across the EU. The
informants examined the factors influencing the following issues:
• levels of treatment provision;
• accessibility of treatment to users;
• quality of treatment delivery;
• diversification of drug substitution;
• use of primary-care services; and
• delivery of drug substitution within prison settings.
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The study represented another step forward in investigating substi-
tution treatment in the European Union. It is the hope of the
EMCDDA that an ongoing analysis of the subject will be a move
in the right direction towards encouraging an evaluation culture in
the field of drug treatment.
Margareta Nilson
Head of the Demand Reduction Department
EMCDDA
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HISTORICAL BACKGROUND
Substitution treatment made its first appearance in the European
Union in the late 1960s, when drugs such as opium, morphine
and heroin found their way onto the European illegal drug mar-
kets. Despite the overall predominance of drug-free therapy at that
time, some Member States began launching substitution treatment.
However, this only became a major option in the 1980s, mainly in
response to the HIV/AIDS epidemic.
Today, all EU Member States run drug-substitution-treatment pro-
grammes in some shape or form, although the extent and nature of
the treatment vary considerably between countries. Over the last
five years (1995–2000), many Member States have reported an
expansion in this treatment and the trend is still rising. Between
1993 and 1999, the number of persons in treatment roughly
tripled, and, in 2000, it is estimated that over 300 000 drug users
in the EU are receiving substitution care from general practitioners
(GPs), treatment centres, methadone clinics, mobile ‘methadone
buses’ and pharmacies.
The first substitution-treatment programmes launched were
methadone programmes, and methadone continues to be the most
widespread substitution substance. Despite the dominance of
methadone, however, its status has been challenged over the last
few years and many Member States now provide alternatives to it.
Table 1 shows when treatment substances began to be prescribed
in the EU Member States and offers an insight into the diversity of
the substances used in the EU today. Besides methadone, other
opiate-addiction substitution substances now include buprenor-
phine, levo-alpha-acetyl-methadol (LAAM), dihydrocodeine,
slow-release morphine and heroin.
Triggered by the Swiss experiment with prescribing heroin to the
most deprived drug users (1994–97), the substitution-treatment
debate spread to all EU Member States. This led to governmental
policy proposals in some Member States, although, to date, only
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Germany and the Netherlands have actually launched, or are
launching, heroin-prescription trials.
The LAAM trial in Portugal spread to Denmark and Spain, while
the French experiments with buprenorphine, initiated in 1996, led
to small-scale use in Denmark, Germany and Austria and to the
granting of a licence for its use in the United Kingdom.
Dihydrocodeine was used for a number of years in Germany,
although, since 1998, its use has been significantly reduced by
law and it is only used in specific medical cases. Finally, the use
of slow-release morphine was initiated in Austria in 1998.
TABLE 1: LAUNCH OF SUBSTITUTION AND HEROIN TREATMENTS 
IN THE 15 EU MEMBER STATES
COUNTRY METHADONE- INTRODUCTION OF OTHER FORMS OF
SUBSTITUTION SUBSTITUTION TREATMENT (1)
TREATMENT 
FIRST AVAILABLE
Belgium 1997 No other substitution treatment given
Denmark 1970 LAAM and buprenorphine (1998) (2) (3)
Germany 1992 Buprenorphine (2000) (2) (3) and heroin (3) (4)
Greece 1993 No other substitution treatment given
Spain 1983 LAAM (1997) 
France 1995 Buprenorphine (1996) (2)
Ireland 1992 No other substitution treatment given
Italy 1975 Buprenorphine (1999) (2) (3)
Luxembourg 1989 Mephenon® (1989) (5) and buprenorphine (2000) (2)
Netherlands 1968 Heroin (1997) (3)
Austria 1987 Buprenorphine (1997) and slow-release morphine
(1998) (2) (3)
Portugal 1977 LAAM (1994) (3)
Finland 1974 Buprenorphine (1998) (2) (3)
Sweden 1967 No other substitution treatment given
United Kingdom 1968 Buprenorphine (1999) (2)
(1) Only ongoing projects have been included. The year refers to when a political decision was taken. 
(2) Where buprenorphine is mentioned, it is in the form of Subutex® (and not Temgesic®) as this only contains
small amounts of buprenorphine.
(3) As a trial only.
(4) Heroin treatment scientific trial (foreseen for 2001).
(5) Mephenon is methadone in pill form.
Source: Table 2, EMCDDA (2000).
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Substitution treatments are almost exclusively targeted at opiate
addiction. However, substitution treatments targeted at other
addictions do exist, a fact highlighted by the country reports in the
second section of this publication.
A report by Farrell (1995) charted the evolution, organisation and
diversified nature of methadone treatment in the European Union.
Since that report, the use of methadone and other types of substi-
tution treatment has rapidly expanded, particularly in those coun-
tries with low baseline levels of provision.
It is now estimated that approximately 300 000 people receive
substitution treatment in Europe today, 110 000 in the United
States and 20 000 in Australia. While many countries in the world
are involved in different forms of drug substitution, the bulk of this
treatment to date is still carried out in these three areas. These
overall estimates would suggest that approximately half a million
people are involved in drug-substitution treatment globally.
DEVELOPMENT OF OPIATE-RELATED PROBLEMS
IN THE EUROPEAN UNION
There are striking similarities across Europe in the timescale of the
development of illicit drug problems. It is clear that problems
occurred on a very limited scale until the late 1960s in all coun-
tries. Then came a dramatic change in the 1970s and 1980s with
the epidemic growth of heroin addiction.
Greece, Spain, Portugal and Finland appear to have developed
heroin problems at a later date, probably on account of political
and geographical factors. However, some north European coun-
tries, such as Sweden, have experienced higher levels of amphet-
amine abuse and dependence and comparatively low levels of
heroin dependence.
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Number of problem opiate users
Estimates of the size of the opiate-dependent population in differ-
ent countries need to be interpreted with particular caution
(EMCDDA, 1998). Few countries have effective monitoring sys-
tems and prevalence data are generally educated estimates. The
sources of data vary, with some figures derived from national sur-
veys, others from capture–recapture studies (3) and most from the
extrapolation of treatment and criminal justice indicator data.
Given these data limitations, it is not possible to provide clear esti-
mates; thus, for the purposes of this report, the data have been col-
lapsed into comparable groups (Table 2). The data are population
adjusted to represent those aged 15–64. The figures collated orig-
inate from country informants and from the EMCDDA’s Annual
report on the state of the drugs problem in the European Union
(EMCDDA, 2000). Estimates range from 200 to over 600 opiate-
dependent subjects per 100 000 population aged 15–64. The
overall impression is that, despite some variation, each country
now has a sizeable and comparable long-term opiate-dependent
population.
Route of administration
There are considerable variations in the proportions of addicts
who smoke and inject drugs across the EU. Again, accurate infor-
mation is unavailable in most countries. However, in Greece, Italy
and Luxembourg, injecting rates are high, with reports of 70–80 %
of addicts entering drug-treatment programmes being opiate injec-
tors. Conversely, in the Netherlands, it is estimated that only 14 %
of users entering treatment for opiate addiction actually inject
(EMCDDA, 1998).
(3) ‘Capture–recapture’ is one of the major methods used in epidemiology to estimate hidden
populations. Also known as ‘mark–recapture’, it involves ‘capturing’ a random sample of
individuals who are ‘marked’ and returned to their habitat. A second sample is then ‘recap-
tured’ and the marked persons from the first sample are observed.
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HIV and AIDS
In many countries, maintenance substitution treatment developed,
often reluctantly, in response to the HIV risk associated with
injecting opiates and other drugs. As a result, the latter half of the
1990s saw the containment of new AIDS cases among injecting
drug users (IDUs) in most countries. In Germany, for example,
only 12 % of the AIDS cases reported in 1997 were among IDUs
(Robert Koch Institut, 1998). However, some countries still have a
relatively high incidence of AIDS amongst drug injectors. For
example, in Portugal, 45 % of reported AIDS cases recorded in
1997 were IDUs (CNLCS, 1998). The EMCDDA’s annual reports
provide prevalence estimates for HIV and AIDS among injecting
drug users (EMCDDA, 1999; see also Table 3).
TABLE 2: ESTIMATED NUMBERS OF PROBLEM OPIATE USERS 
PER 100 000 POPULATION 
AGED 15–64 IN THE 15 EU MEMBER STATES
COUNTRY NUMBER OF PROBLEM OPIATE USERS 
(ORDERED ACCORDING TO PREVALENCE) PER 100 000 POPULATION AGED 15–64
Lowest Germany 200–400 per 100 000 population (0.2–0.4 %)
Finland 
Sweden
Austria (1)
Netherlands
Greece
Belgium
Denmark
Ireland
Highest France
Portugal (1) 400–600 per 100 000 population (0.4–0.6 %)
Spain
United Kingdom
Italy Over 600 per 100 000 population (over 0.6 %)
Luxembourg
(1) These figures are not research based but estimates provided by country informants and have been added to
this table for the purpose of this Insights publication. 
NB: Given the difficulties in measuring the size of the problem opiate population, many calculations are based
on educated estimates. 
Source: Figure 8, EMCDDA (2000).
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TABLE 3: PREVALENCE OF HIV INFECTION 
AMONG INJECTING DRUG USERS 
IN THE 15 EU MEMBER STATES
COUNTRY PREVALENCE OF HIV INFECTION 
AMONG INJECTING DRUG USERS 
IN THE EU MEMBER STATES (%) 
Belgium
(French Community) 1.6
(Flemish Community) 2.2
Denmark (0–3.4)
Germany 3.8
Greece 0.5–3.2
Spain 32
France 15.5–17.3
Ireland 3.5
Italy 16.2
Luxembourg 3.0
Netherlands (1–26)
Austria 0–(2)
Portugal 14–(48)
Finland (3)
Sweden 2.6
United Kingdom (England and Wales) 1
NB: Comparability is limited because figures are from different sources and reflect different methods.
Figures for Germany and Italy relate to opiate users in treatment and underestimate prevalence among
injectors.
Information based on local data is given between brackets.
Source: Complementary statistical tables to the EMCDDA Annual report 2000 (see http://www.emcdda.org).
The growth in the provision of methadone services has been mir-
rored by a reduction in the incidence of AIDS cases related to
injecting drug use in most EU countries. The link between these
trends is complex, but, overall, there are now reasonable data to
support the case that, at an individual level, methadone treatment,
along with other harm-reduction measures, is an effective com-
ponent of HIV prevention. In parallel, substantial medical
advances have been made in delaying the onset of AIDS.
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Hepatitis
While HIV appears to have been contained, the introduction of
tests for hepatitis C has indicated that there are high rates of the
hepatitis C virus (HCV) among injectors in all countries. In
Germany, for example, a study by Batz (1997) suggested that
around 50 % of IDUs have become infected with hepatitis B and
70–80 % with hepatitis C. In Portugal, recent surveys estimate that
85 % of those who inject drugs are infected with the hepatitis C
virus (Godinho et al., 1996). Similarly, at a drug-addiction out-
patient department in Austria, hepatitis C antibodies were found in
80 % of a random sample of drug users attending the clinic
(Gombas et al., 1998).
Most estimates of the prevalence of hepatitis are based on clinical
samples and need to be interpreted with a degree of caution until
larger community samples have been completed. However, the
high rates of hepatitis C in most countries present a significant
public health challenge similar to that of HIV in the 1980s.
It is likely that strategies for prevention will be similar to those for
HIV, and will include methadone treatment and programmes
aimed at lowering the frequency of sharing and injecting among
IDUs and at reducing the progression to injecting drug use from
other forms of drug use.
Drug-related crime
The rise in drug use in Europe over recent decades has led to a
series of related problems, one of the most significant being the
increasing involvement of drug users in criminal activities. Two
prime issues have come to the fore:
• the increasing number of drug users in Europe, and the con-
sequently increasing visibility of drug-related problems, has
highlighted the issue of drug use and public nuisance; and
• the rise in drug-related crime has led to an increased need for
finding responses to reduce crime.
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Providing drug users with a substitution substance, most often in
the form of methadone, is a way of attempting to reduce and pre-
vent drug-related crime and of dealing with the problem of public
nuisance. Research in recent years confirms that methadone-
substitution treatment reduces crime committed by addicts (Leuw,
1995; Gossop et al., 1998).
Drug- and methadone-related deaths
There are several major problems in assessing methadone-related
deaths:
• the criteria used to classify cause of death differ across countries;
• it is difficult to establish what contribution substitution sub-
stances make to deaths which involve other central nervous sys-
tem (CNS) depressants (such as alcohol and benzodiazepines);
and
• some countries have more vigilant monitoring and investigation
of drug-related deaths than others, which may create the impres-
sion that they have a higher drug-related death rate.
However, it is clear that countries such as the United Kingdom
(Neeleman and Farrell, 1997) and Germany (Heinemann, 1998)
have identified a significant problem associated with methadone-
related deaths. Most studies have found that methadone- and
opiate-related deaths are more common among those not in treat-
ment (Stenbacka et al., 1998). Similarly, in France, there has been
a considerable number of casualties implicating the use of
buprenorphine (Tracqui et al., 1998). In Austria, Seidler et al.
(1996) conducted a survey of opiate-related overdoses amongst
hospital admissions in Vienna. Figures for individual countries are
presented in the second section of this report.
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DEVELOPMENT OF
METHADONE-SUBSTITUTION TREATMENT
Methadone-substitution treatment has a long and varied history
across Europe, where changes in medical opinion and legislation
have led to developments and changes in prescribing practices.
Table 1 above provides an indication of when formal methadone-
substitution treatments began in each country. It is important to
note that, in countries such as Denmark, the Netherlands, Sweden
and the UK, where methadone has been available since the late
1960s, the number of opiate addicts receiving methadone was rel-
atively small in the early years.
Numbers in methadone-substitution treatment
In many countries, it is difficult to establish the exact size of the
methadone-treated population, partly because of the absence of
centralised data-gathering systems. The figures presented in
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FIGURE 1: ESTIMATED NUMBER OF DRUG USERS 
IN METHADONE-SUBSTITUTION TREATMENT 
IN THE 15 EU MEMBER STATES (1997)
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Figure 1 represent the best estimates for those receiving
methadone treatment (whether for maintenance or detoxification)
in 1997. The figures have been population adjusted and range
from a high of 207 treated in Spain (per 100 000 population aged
16–60) to a low of 6 treated in Finland, Luxembourg and Greece
(per 100 000 population aged 16–60).
It is important to note that, in most countries, there are huge
regional variations in the provision, organisation and delivery of
methadone treatments (e.g. Bühringer et al., 1995).
A rapid expansion in services
Over the past five years, all countries except Denmark and the
Netherlands have seen a rapid expansion in the provision of sub-
stitution services. This is most evident in Germany, Spain and
France, and in countries with low baseline levels of provision,
such as Greece, Luxembourg and Finland. The impetus for this
expansion in substitution treatments has largely been a response to
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FIGURE 2: ESTIMATED NUMBER OF ADDICTS 
IN METHADONE-SUBSTITUTION TREATMENT 
PER 100 000 POPULATION AGED 16–60 (1993 AND 1997)
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the HIV epidemic and its links to injecting drug use. In Spain and
Italy, for example, it has been estimated that more than 60 % of
AIDS cases are injecting drug users. Other influences include
growing waiting lists for treatment and the fact that political and
public opinion often favour harm-reduction approaches to opiate
dependency as a way of reducing the public nuisance caused by
drug users and drug-related crime.
Individual country figures illustrating the increase in the number of
addicts treated with methadone are shown in Figure 2. Figure 3
indicates the cumulative increase across the 15 EU Member
States.
While most countries have experienced relatively few problems
during this growth period, concern has been expressed in some
Member States regarding the lack of training and skills of some
practitioners now involved in substitute prescribing, particularly
amongst non-specialist services, including general practitioners
and pharmacists (IMR, 1997; Gerlach and Caplehorn, 1999;
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Sources: EMCDDA (1998) and data from country informants.
FIGURE 3: INCREASE IN THE NUMBERS OF DRUG USERS 
RECEIVING METHADONE IN THE 15 EU MEMBER STATES (1993–97)
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Ministero della Sanità, 1999). There is also concern regarding con-
trols on substitute prescribing and the risk of possible diversion of
substitution substances onto the black market.
Methadone consumption
The amount (weight) of methadone consumed by all countries is
recorded by the International Narcotics Control Board 
(INCB) (4). However, the quality of information is influenced by
national approaches to data gathering. In line with overall increas-
es in substitution treatment and possibly dosage, there has been a
corresponding increase in methadone consumption. Figure 4
shows population-adjusted consumption figures for 1996. Trends
in methadone consumption across the different countries are
shown in Figure 5.
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(4) The International Narcotics Control Board, established in 1968, is the independent and
quasi-judicial control organ for the implementation of the United Nations drug con-
ventions. The board is independent of governments and the United Nations, although it is
funded by the latter (see http://www.incb.org). 
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TYPES OF OPIATE SUBSTITUTION
Buprenorphine
Buprenorphine is a very long-acting agonist-antagonist opioid (5).
France has developed buprenorphine as its main agent for opiate-
maintenance treatment (Auriacombe et al., 1997). Austria has
developed some diversified buprenorphine treatment programmes
(Diamant et al., 1998; Fischer et al., forthcoming). Buprenorphine
is now being marketed in a range of European countries as an
alternative form of opiate-maintenance treatment. In Finland, it is
used for detoxification and, in Denmark, for both detoxification
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(5) Agonists are drugs that activate opiate receptors in the brain’s reward system thereby cre-
ating the effect of drug consumption. Agonist-antagonists also activate opiate receptors in
the brain but simultaneously limit or eliminate the effects of other drugs taken.
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and maintenance therapy. The average daily dose dispensed
across countries where information was available was around 
8 mg daily.
Dihydrocodeine
Dihydrocodeine is a short-acting semi-synthetic ‘weak’ agonistic
opioid.
Dihydrocodeine has been used in many settings, particularly
where restrictions inhibit the use of methadone or where patients
cannot tolerate methadone. There has been very limited evalua-
tion of its use, but practitioners report that it is useful for detoxifi-
cation and for those with low levels of opiate dependence (e.g.
Krausz, 1998). Specific legislation has been enacted in Germany
to restrict and control the use of dihydrocodeine following an
increase in ‘grey substitution’ and codeine-related deaths.
Heroin
Heroin, pharmaceutically diamorphine hydrochloride, is a short-
acting ‘strong’ agonistic opiate.
Heroin has been the subject of heated political debate in relation
to substitution treatment. A large-scale outcome study has been
completed in Switzerland (Uchtenhagen et al., 1997), an experi-
mental trial is under way in the Netherlands and there are pro-
posals for a further study to be launched in Germany in the near
future. Denmark, Spain and Luxembourg have also been involved
in debates about the possible use of heroin for maintenance ther-
apy. There are low levels of heroin provision in the UK (Marsden
et al., 1998).
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
25
42d930_insights_brochure  09-11-2000  14:53  Pagina 25
Levo-alpha-acetyl-methadol (LAAM)
Levo-alpha-acetyl-methadol is a very long-acting synthetic agon-
istic opioid.
Portugal has extensively used and evaluated LAAM (Patrício et al.,
1996) and, outside the EU, the United States has conducted simi-
lar experiments. It is reasonable to predict that there will be a
major expansion in the use of LAAM in the near future in Europe,
as a number of countries (e.g. Denmark and Spain) are beginning
to run trials and introduce LAAM into services.
Methadone
Methadone, pharmaceutically methadone hydrochloride, is a
long-acting synthetic agonistic opioid.
Oral forms of methadone constitute the vast bulk of substitution
prescribing. It is reasonable to estimate that, apart from in France,
over 90 % of opiate substitution is delivered in the form of
methadone hydrochloride. There is some variation in whether it is
dispensed as a concentrate or in a more dilute form. The concen-
trate form probably poses a greater risk for opiate-related toxicity.
Methadone tablets are used in the Netherlands, the UK and some
other countries. In the UK, they have been associated with diver-
sion and injectability, and efforts are under way to control and
restrict the prescribing of this form of methadone.
Injectable medications are provided in some countries. In the UK,
injectable methadone is prescribed in possibly 10 % of
methadone treatment (Sheridan et al., 1996). This has not been
subject to any major evaluation to date. Only one pilot study of
injectable versus oral methadone has been carried out in the UK,
which is yet to be reported on. Swiss studies included injectable
methadone, but clients expressed a strong preference for heroin
and the methadone trial had to be discontinued because of insuf-
ficient sample size.
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Slow-release morphine
Slow-release morphine, sometimes referred to as prolonged-action
morphine, consists of morphine sulphate, which is a long-acting
agonistic opiate.
In Austria, slow-release morphine can be prescribed for main-
tenance therapy, although only in special clinics (Fischer et al.,
1996). In France, a very cautious estimate is that around 2 000
individuals receive slow-release morphine. At the beginning of 
the 1990s, an experiment with morphine was carried out 
in Amsterdam, but the subsequent trajectory of the project is
uncertain.
DEVELOPMENT OF
SUBSTITUTE-PRESCRIBING SERVICES
Community resistance to the development 
of drug-treatment services
Establishing new centres for the provision of treatment can be par-
ticularly difficult. Drug services can be seen to attract undesirable
elements into localities and to be associated with loitering,
drunkenness, intoxication and burglaries. Most countries report
some community resistance to treatment programmes. However,
resistance from the local community has been found to be most
common before programmes and centres are established and,
once they become operational, the neighbourhoods seem to
accept them. In some countries, active protests within the local
community have impacted on the choice of sites and the opening
hours of clinics. For example, in Ireland, services in Dublin were
subject to major restrictions because of court action taken by local
traders. This resulted in low levels of service and severely restricted
opening times.
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Once services were operational, problems centred on nuisance
and it was often reported that groups of clients tended to congre-
gate around the treatment premises. Measures to combat these
problems included the use of mobile units, such as the methadone
buses in Spain, Italy and the Netherlands, and active collaboration
with the police. In addition, processes of community consultation
have been developed to provide information regarding the bene-
fits of service provision, in particular a reduction in neighbour-
hood crime.
The objectives of treatment
Most countries use methadone for a range of purposes, from short-
term use for detoxification purposes to longer-term maintenance
therapy. Today, most countries have accepted the importance of
maintenance as part of a harm-reduction strategy, with particular
relevance for HIV prevention and reducing drug-related crime.
Greece, Finland and Sweden continue to have very high-threshold
services, with limited overall access.
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TABLE 4: THE BALANCE BETWEEN METHADONE MAINTENANCE
AND DETOXIFICATION TREATMENT (1998)
COUNTRY MAINTENANCE OR DETOXIFICATION
France Primarily maintenance (75–100 % of treatment 
Ireland aimed at maintenance)
Portugal
Sweden
Denmark 50–75 % of treatment aimed at maintenance
Germany
Spain
Netherlands
Austria
Finland
` United Kingdom
Greece Primarily detoxification 
Italy (under 30 % of treatment aimed at maintenance)
NB: Data unavailable for Luxembourg and Belgium.
Source: Country informants. It is important to note that these data are not generally based on research but on
informed and educated estimates.
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Table 4 above shows the balance between detoxification and
maintenance prescribing across 13 of the 15 EU Member States. It
is important to note that the estimates provided are not generally
research based but are intended to offer a qualitative overview
based on informed and educated estimates made by country
informants.
Detoxification
Most countries have no clear mechanism to distinguish between
detoxification and other forms of substitution treatment. Some
countries, such as Germany and Sweden, have high levels of pro-
vision of inpatient detoxification facilities. During the 1990s,
forms of non-opiate detoxification, such as the alpha-adrenergic
agonists lofexidine and clonidine (6), have been developed and are
widely used in some countries. There is also interest in the use of
buprenorphine, which is a partial agonist that may play a role in
both detoxification and maintenance.
In addition, some countries have seen an explosion of interest in
other forms of rapid opiate detoxification, some using light seda-
tion and others general anaesthetic. These procedures sometimes
include antagonisation with naltrexone (7).
Maintenance prescribing
Most countries now appear to have a significant population of
heroin users on methadone-maintenance treatment and to place
greater emphasis on long-term maintenance. It is also clear, how-
ever, that abstinence is the ultimate goal of treatment in most
countries.
(6) Alpha-adrenergic agonists such as lofexidine and clonidine are antihypertensive agents; that
is, they suppress withdrawal symptoms such as restlessness, lacrimation, rhinorrhea and
sweating.
(7) Naltrexone is an opioid antagonist that hinders, or drastically decreases, the effect of 
opiates taken. 
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Access to methadone treatment
The demand for treatment has continued to increase faster than
investment in, and expansion of, services. There has also been a
rise in polydrug use, particularly involving stimulants and benzo-
diazepines, for which there is currently little evidence of any ben-
efit from substitution treatment.
Access to treatment is largely dependent on treatment provision.
In Sweden, for example, in 1997, only 600 maintenance places
were available across the whole country, and only 650 were avail-
able in Greece. Waiting lists are also common in many countries.
There are huge regional variations in the provision of treatment
within countries, as services tend to be developed primarily in
major cities.
Access is also dependent on the inclusion criteria of treatment pro-
grammes. In some countries, strict criteria are imposed (e.g.
Sweden: four years’ intravenous use, age 20 +, opiate as main drug
and not incarcerated. In other countries (e.g. Denmark, Spain and
Italy), addiction to opiates (as defined by the World Health
Organisation’s 10th edition of the International Classification of
Diseases — ICD-10) is the only entry criterion.
Many countries report limited access to treatment for specific pop-
ulations, most notably the young (under 18), mentally ill and
homeless. On the other hand, pregnant women and those with
HIV infection have priority access in most countries.
INTEGRATION OF SERVICES
Specific legislation in a number of countries has attempted to
enhance links between the criminal justice and health sectors. The
growing size of the addicted population in prisons has also
emphasised the need for better links between criminal justice
agencies and drug services. The challenge of combining alcohol
and drug services also remains a key dimension of service devel-
opment. In some countries with increasingly large numbers of
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HIV-positive drug users, integration with general medical and HIV
services has become a necessity. In other countries, concern
regarding tuberculosis has resulted in good links between drug
services and respiratory and tuberculosis services. In the long-term
drug-dependent population, the growth of morbidity of clients
with both major psychiatric and physical problems is becoming
more evident and the need for a mixture of skills to address these
problems is a key part of a long-term service planning strategy.
Mental health services
There is now substantial recognition of, and greater clarity con-
cerning, patterns of overlap in psychiatric morbidity in the drug-
dependent population. Two cohorts are well described in
Germany and Greece, indicating high rates of psychiatric morbidity
among this population (Krausz, 1998) and in the UK (Farrell et al.,
1998). All countries reported co-morbidity as being problematic
for treatment.
The care of drug-using clients with mental health problems
depends on the links between psychiatric and drug services. In
Italy, Finland and Sweden, good links have been established, with
specialist dual diagnosis wards. In other countries, links between
services are poor. In France, integrated care is restricted, as legis-
lation prevents practitioners from prescribing substitution treat-
ment and psychiatric medication simultaneously.
Primary care and general practitioners
There are major variations in the concept of primary care in the
different countries and this renders it difficult to draw compar-
isons. Some countries, such as Ireland and the UK, use primary
care as a gateway to secondary-care services, whereas in other
countries, such as Germany and France, the primary-care and
secondary-care interface is not so clear.
In many countries (e.g. Spain and Italy), general-practitioner (GP)
involvement is low, due partly to a perception of clients being
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difficult and unstable and partly to legal constraints. Denmark has
initiated new controls on primary-care involvement and has
restricted the capacity of primary-care practitioners to prescribe
methadone. The UK has seen a push for a major expansion in
shared care, involving general practitioners in the provision of
drug services.
Prisons
It is estimated that 15–50 % of prisoners in European countries
have a history of drug use. Prisons contain a unique concentration
of severe drug problems and require particular attention to ensure
provision of a broad range of treatment interventions. The past
decade has seen substantial growth in both the development of
approaches to divert individuals away from prison to treatment
alternatives and in the development of a range of services within
prisons.
Provision of methadone treatment within prisons varies consider-
ably across countries. Spain and Austria have high levels of provi-
sion. In Spain, it is estimated that 60 % of drug users in prison
receive methadone. In Austria, maintenance treatment has been
offered in all prisons since 1991, and social and psychotherapeutic
approaches are also offered. On the other hand, no prisons in
Sweden provide methadone and, in Belgium, Germany, Greece,
Ireland, Italy, the Netherlands, Portugal and the UK, provision is
minimal, apart from when used for the purposes of detoxification.
Eligibility for entering a methadone programme in prison largely
depends on levels of treatment provision. In all countries where a
programme is available, a user receiving treatment outside the
prison setting can continue treatment inside. In the UK, where pro-
vision is low, it is estimated that a third of those who are receiving
methadone treatment before entering prison also receive it in
prison. In Austria and Spain, however, a drug user can begin treat-
ment on entering prison.
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There have been a number of problems with providing methadone
in the prison context. In the UK, inappropriate use in non-tolerant
individuals has resulted in a number of deaths, with one prison
medical officer losing his licence to practise as a result.
In Ireland, there have been two reported deaths amongst prisoners
who were not prescribed methadone in prison. On release from
prison, their tolerance had fallen and, consequently, they over-
dosed.
Pregnancy and childcare
Methadone maintenance is currently the recommended treatment
for pregnant drug-using women, as opposed to detoxification
(Fischer et al., 1998). In all countries, pregnant women are offered
a fast track into drug-misuse services and, in many countries (e.g.
Austria, Sweden and the UK), specialist services have been devel-
oped in order to help pregnant women. For many opiate-dependent
pregnant women, problems begin after the child is born. There
have been few studies of neonates, although it has been estimated
that up to 60 % of neonates born to opiate-dependent women suf-
fer from abstinence syndrome. Many countries operate foster
schemes for individual children or for whole families, whereas
other countries rely on the more traditional extended family struc-
tures to arrange appropriate childcare.
LEGAL CONTROLS AND SERVICE DEVELOPMENTS
Over the past decade, substitute prescribing of methadone or
other opiate agonists has become available in all 15 European
Union countries, albeit with considerable variation in levels of
provision. All countries are signatories to the Vienna conven-
tions (8) and conduct appropriate monitoring of the production,
distribution and consumption of these drugs in order to minimise
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(8) 1961 Single Convention on Narcotic Drugs; 1971 Convention on Psychotropic Substances;
1998 United Nations Convention against the Illicit Traffic in Narcotic Drugs and
Psychotropic Substances.
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the risk of diversion onto the black market. There is considerable
variation across countries as to who can prescribe substitute med-
ication for the treatment of drug dependence (Table 5). Key aspects
of these changes are briefly outlined below.
Country-by-country (9)
Belgium: There is no legal framework regarding the provision of
methadone in Belgium. Methadone is available through general
practitioners, and criteria for entry to substitution programmes aim
to be flexible. Substitution with other substances is marginal,
although the introduction of buprenorphine is under discussion.
Denmark: A law was introduced in 1996 with the aim of tighten-
ing controls and improving the quality of treatment by handing
over the responsibility for substitution treatment to the Danish
counties. The result of this is that the general practitioners’
involvement in substitution treatment has been significantly
(9) See also the country reports in the second section of this publication.
TABLE 5: PRESCRIPTION PRACTICE IN THE 15 EU MEMBER STATES
COUNTRY PRESCRIPTION PRACTICE
Greece Specialised centres, limited number
Finland
Sweden
Denmark Specialised centres
Spain
France (methadone)
Italy
Netherlands
Portugal
Belgium General practitioners (GPs)
Germany
France (buprenorphine)
Ireland
Luxembourg
Austria
United Kingdom
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reduced and that the counties now run the units that hand out
methadone. There has been an overall drop in the numbers in sub-
stitution treatment, but this has not impacted on the opiate-related
mortality rate.
Germany: A rapid expansion in the number of addicts prescribed
methadone has been observed in Germany. There have been sev-
eral key changes in legislation and the regulations regarding sub-
stitution treatment. Legislative changes have also occurred which
attempt to restrict the provision of dihydrocodeine.
Greece: A change in the law in 1993 allowed for the development
of methadone services. Four specialist treatment centres with over
650 patients have been established and are run by a single central
State organisation. General practitioners are not permitted to pre-
scribe methadone.
Spain: A major expansion of services has occurred in response to
high rates of HIV among injecting drug users in the country.
Although methadone treatment on a larger scale only started in the
mid-1990s, Spain appears to have the highest level of substitution
provision in Europe. This is primarily provided in specialist
centres, with very little general-practitioner involvement. There is
substantial regional variation in service provision.
France: There has been no actual legal change in France, but a
change in prescription regulations has meant that the numbers
receiving methadone have increased from 50 to 5 000 and those
receiving buprenorphine have risen from 0 to 60 000 over the past
five years. Methadone is currently approved for prescription by
any doctor working within specialist substance-abuse services,
and buprenorphine is approved for prescription by any doctor in
any facility. Over 90 % of methadone is given in specialist settings,
but it is also possible for stabilised individuals to transfer to
primary care.
Ireland: A law was introduced in 1998 to facilitate the rapid
expansion of drug services with primary-care involvement. A sys-
tem was introduced whereby each individual seeking substitution
treatment requires a treatment card containing a photograph and
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details of identity, which is issued by a central coordination unit
and bears the name of both the patient and the general practitioner
providing treatment. This has resulted in a substantial expansion of
general-practitioner and community-pharmacist involvement. It
has also reduced both the number of drug users with individual
practitioners and overall methadone diversion. At the same time,
this approach has maintained a good degree of confidentiality.
Italy: Methadone treatment has been permitted since 1980 and is
offered through specialised centres. In 1993, there was consider-
able variation in provision, with an estimated 33 % of addicts
receiving methadone in one region and 77 % in another.
Approximately 50 % of methadone treatment is offered as part of
a detoxification schedule. The proportion of clients receiving
methadone in public treatment centres in Italy increased from
30 % in 1991 to 47 % in 1997 (Ministero della Sanità, 1999).
Luxembourg: The law was changed in 1999 in order to formalise
existing practice. The majority of treatment is provided by general
practitioners.
The Netherlands: The number of addicts receiving methadone and
the level of methadone consumption have been more stable over
the last five years than in many other EU Member States.
Legislative changes were made in 1995 in order to reduce public
nuisance caused by problem drug use. It is part of the national
drug policy to make methadone widely available, thus methadone
buses drive around the streets of many Dutch cities.
Austria: The Narcotics Maintenance Decree of 1987 permitted the
prescription of narcotics in the treatment of drug dependence. All
practitioners, both specialist and general, can prescribe, but the
general practitioners have little training and support in this area of
clinical activity. A new law in 1998 made substitution treatment
(mainly with methadone) more readily available.
Portugal: Specialised services are provided through the government-
funded organisation, the Serviço de Prevenção e Tratamento da
Toxicodependência (Service for the Prevention and Treatment of
Drug Addiction), which provides both methadone and LAAM
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treatment. There are plans to develop more low-threshold ser-
vices (10), with the participation of non-governmental organisations
(NGOs) and general practitioners.
Finland: Since 1997, Finland has run a specialist university hospi-
tal centre where 40 patients receive treatment. Initiation involves
a two-week hospital admission for detoxification and methadone
induction and subsequent attendance at a specialised outpatient
clinic. There is no general-practitioner involvement.
Sweden: Methadone services were established in the late 1960s
and have been subject to periods of major restriction in develop-
ment. The services are now located in four specialist centres and
there are substantial data on those receiving ‘high-threshold’ inten-
sive treatment, including the somatic and psychological services
provided. No general practitioners are permitted to prescribe
methadone.
United Kingdom: New clinical guidelines for the treatment of drug
dependence have been developed. These stipulate that patients
should be administered with supervised consumption of medica-
tion in at least the first three months of treatment. There are also
proposals for the development of a new licensing system, where a
special licence would be required for any prescribing other than
an oral methadone mixture for the purposes of drug-dependence
management.
In central and eastern Europe, the availability of methadone-
substitution services has also increased. Methadone maintenance
constitutes one of the main treatment modalities in Slovenia and
Lithuania, while, in Bulgaria, the Czech Republic, Estonia, the
Former Yugoslav Republic of Macedonia (FYROM), Latvia and
Poland, substitution programmes are generally operated on a pilot
basis or as a single-treatment service. In Hungary, psychiatrists and
general practitioners can prescribe methadone on an individual
basis (EMCDDA, 1998).
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(10) Low-threshold services are those allowing relatively unrestricted access. High-threshold
services, on the other hand, are those allowing access according to specific entry require-
ments and criteria.
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While there is much discussion on the regulation and control of
substitute prescribing across the EU Member States, it appears that
the actual mechanisms of monitoring such activities are rather lim-
ited and that, once substitution programmes are established, they
have considerable freedom in the day-to-day organisation of their
activities. However, limited attention has been paid to maintaining
high standards or developing methods to ensure that even mini-
mum standards are achieved across the broad range of services.
The link between such guidelines and the operational details
around the organisation of services will be an important influence
on the development and evaluation of these programmes.
PROBLEMS FOR SERVICES
Alcohol and polydrug dependence
The issues of alcohol and polydrug dependence remain a major
problem for treatment services. Estimates suggest that approxi-
mately one quarter of service users have major problems with
alcohol or with cocaine, amphetamines and benzodiazepines.
This type of dependence is associated with high-risk behaviour,
management problems, higher rates of mortality from drug over-
doses and poorer outcome overall. To date, there has been very
limited research to indicate the optimal approach to the manage-
ment of this group.
Diversion and methadone-related deaths
There is very little information on methadone-related deaths, as
classifying the cause of death is difficult. It is known that
methadone reduces mortality, but it is reasonable to assume that
the more methadone is consumed, the higher the risk of death. In
the UK, a study revealed that, in 1992, 45 % of opiate overdose
deaths involved methadone. However, deaths from methadone
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were more common amongst those not enrolled in methadone
treatment (Hall et al., 1998).
Measures to prevent diversion include supervised consumption
(where an addict takes his/her methadone in the presence of drug
clinic staff), short dispensing intervals (e.g. daily pickup) and cen-
tral registration of all methadone prescribed (as in the
Netherlands). All new methadone patients across most countries
are generally supervised during consumption for the first few
months of treatment 
The distribution of naloxone (a short-acting antagonist) amongst
drug users in Italy, where it is available without a medical
prescription, was a measure introduced to prevent overdosing.
Other countries (e.g. Greece, Spain, the Netherlands and Austria)
educate drug users on how to prevent an overdose or how to deal
with it when it happens. In Greece and Italy, special ambulances
are available for those who have overdosed.
MONITORING AND EVALUATION
Despite considerable evidence that programme organisation is a
major influence on outcome for substitution treatment, there is a
striking absence of quality control, monitoring and evaluation of
individual programmes. The following two strategies need to be
implemented:
• routine gathering of clinical data in a fashion that can account
for the activities of the organisation and delivery of services; and
• development of a range of diverse interventions.
There is a striking dearth of activity on both fronts.
Some countries, however, have conducted evaluation projects.
Current levels of provision at national level have been surveyed in
Spain (Domingo-Salvany et al., 1999), where the roles of indi-
vidual professionals and their treatment impact have also been
studied (Observatorio Español sobre Drogas, 1998).
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In Germany, a number of evaluation projects have been conduct-
ed in different regions (e.g. Auts, 1996; Raschke et al., 1996). In
France, there has been some evaluation of changes in bupren-
orphine prescribing and also some detailed evaluation of certain
individual programmes (Segal and Schuster, 1995). In the UK, a
national treatment outcome study (Gossop et al., 1998) was initi-
ated in 1996 which plans to follow a cohort of drug users entering
treatment over time. In Italy, besides some local evaluation studies
(D’Ippoliti et al., 1996, 1998), a national treatment outcome study
began in 1998 which also plans to follow a cohort of drug users
entering different types of treatment over time.
CONCLUSIONS
Over the past five years, there has been considerable convergence
in the models of drug-service delivery in most European countries,
with a major expansion in drug-substitution treatment, mainly
methadone maintenance. At the same time, the predicted HIV epi-
demic among injecting drug users appears to have been momen-
tarily contained.
A broader range of accessible substitution-treatment programmes
has been developed. These low-threshold programmes are now
quite widely delivered in many countries. Those countries that
have expanded methadone treatment more recently (such as
Greece and France) have followed a more specialised high-
threshold approach. However, in France, the use of bupren-
orphine in a low-threshold service runs parallel to a high-
threshold methadone service.
As a point of divergence, countries such as Denmark have moved
to restrict the overall activity of general practitioners, in contrast to
many countries (such as Ireland and the UK) where significant pol-
icy initiatives have been taken to involve general practitioners in
the management of drug dependence.
Prisons remain an area where there is major variation in levels of
provision. There are limited evaluation data to guide policy-makers
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in determining the best course of action for the future. More eval-
uation of delivered prison treatment is needed.
Training for generalists and specialists and good models of co-
operation are necessary if services are to be developed and main-
tained at a high standard. There are limited formal training pro-
grammes and equally limited mechanisms of accreditation for
workers in this field, in most settings. Models of delivery range
from purely specialist to predominantly primary care, and there is
a need for better integration between primary-care and specialist
approaches. Pharmacists are playing an increasingly active role in
this form of treatment and have the potential to make a major con-
tribution to substitution services. Regular monitoring, and
improved communication among the various individuals involved
in treatment provision, could significantly improve these services.
Diversion, drug-related deaths and methadone-related deaths con-
tinue to be a substantial problem in some countries, but levels of
diversion are extremely hard to quantify. Countries with lower lev-
els of supervision are more likely to report higher rates of diver-
sion. There is a tendency for countries with very high levels of
control to reduce these in order to increase levels of access and,
conversely, for countries with low levels of supervision to increase
controls.
Over the past five years, substantial growth has been seen in the
evaluation of treatment that has been undertaken. The science and
treatment evaluation culture continues to grow and has been pro-
moted through research and training networks across the
European Union. There have been large-scale national treatment
evaluation projects, such as the ‘National treatment outcome
research study’ (NTORS) in the UK, as well as many smaller-scale
outcome evaluation studies. Awareness of the importance of
evidence-based approaches to the planning and delivery of drug
treatment is also growing. The Cochrane Collaboration (an inter-
national collaborative group aiming to promote evidenced-based
practice through the organisation of systematic reviews of key
areas of health interventions) is developing a register of trials and
reviews of treatment interventions.
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Given the extent of current services across Europe, very limited
research and evaluation of the treatment process has been carried
out to date. Such research would provide good data, not just to
confirm the benefits of treatment but also to identify factors asso-
ciated with good treatment. Factors might include:
• quality of management and organisation of services;
• quality and skill mix of staff; and
• the level of multidisciplinary and inter-agency work (to ensure
good links across a range of community agencies).
A substantial consensus now exists on the benefits of methadone
maintenance. Systematic reviews indicate that such treatment can
improve psychological and social well-being, and reduce crim-
inality and HIV transmission. There is a need for further research
to determine the role of such treatment in reducing hepatitis C
transmission.
In conclusion, the last five years have represented a period of con-
siderable change and development in response to drugs. It is now
generally recognised that treatment for drug dependence requires
multiple approaches that combine drug-substitution with drug-free
treatment. The challenge for the next decade is to determine the
optimal methods for delivering high-quality treatment and ensur-
ing that this is provided in all settings. Also, evidence regarding the
cost-effectiveness of drug treatment strongly supports the case for
further investment in this activity in all countries. Current work on
developing models for evaluating cost-effectiveness needs to be
strengthened.
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PREPARING THE COUNTRY REPORTS
This section consists of country reports from the 15 European
Union Member States which, among others, demonstrate how
substitution practice differs in Europe, both according to the sub-
stances used as well as to national legislation and policy (11).
A national expert or informant was appointed in each of the coun-
tries concerned and asked to provide information according to
specific guidelines. These guidelines consisted of six headings:
• Introduction;
• Strategy;
• Substitution;
• Surveillance;
• Problems;
• Evaluation.
The first of these sections offers a general introduction to substi-
tution treatment in the country concerned and situates it in the
overall political context.
The second provides an overview of the national drug strategy;
that is to say the national policy in the field of drugs and other
drug-related areas (e.g. health-related issues and social security).
The third section provides information on the substitution services
available in each country and has a number of subheadings. These
subheadings may vary per country, but in general deal with: the
development of substitution services, their history and characteris-
tics; the current situation and the number of persons currently
receiving treatment; legislation on substitution treatment; substitu-
tion clients and the entry criteria for receiving treatment; the role
of pharmacies; primary healthcare involvement in services; the
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(11) The EMCDDA’s Annual report on the state of the drugs problem in the European Union —
2000 may also be consulted for a brief overview of substitution treatment in the EU
Member States. This was compiled on the basis of data from national reports submitted by
the 15 national focal points of the Reitox network.
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various substances used in the country; and, finally, whether
injectable substances can be prescribed.
The fourth section, on surveillance, provides an overview of how
national monitoring is carried out in each country.
The fifth identifies current problems in the field of substitution
which pertain to the particular situation in each Member State.
Finally, the sixth section focuses on the evaluation of substitution
treatment and presents findings of recent relevant studies and
research. These data address the implementation and organisation
of substitution services, the substitution substances currently used,
and other related aspects of substitution treatment.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
51
42d930_insights_brochure  09-11-2000  14:53  Pagina 51
BELGIUM
Juan Tecco and Isy Pelc, Hôpital Brugmann, Brussels
Introduction
In 1994, the Belgian Ministry of Public Health organised a
methadone consensus conference. This conference was a key
moment in the field of addiction in Belgium as it concluded that
access to substitution treatment was desirable. Due to the absence
of a legal framework in the country on this issue, the conclusions
of the conference became a reference point for both the clinicians
and authorities working in the area of substitution treatment. An
evaluation of the conclusions of the conference was performed
between October 1997 and June 1998, under the auspices of
Professor Isy Pelc of the Hôpital Brugmann, Brussels. The method-
ology used consisted of auditioning national experts from various
backgrounds in order to access various points of view. Most of this
country report draws on the conclusions of that evaluation.
Strategy
In 1997, the Belgian Parliament and the Council of Ministers
adapted the existing drug-enforcement law (12), by making penal
justice the ‘last resort’ in cases of serious nuisance.
At this time, Belgium’s drug policy priorities were also redefined.
They included:
• prevention and reduction of drug use;
• reduction of the number of new drug users;
• protection of the community and its members against the drug
phenomenon and its consequences; and
• provision of care to drug users and readiness to guarantee them
a better life despite their use of drugs.
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(12) Ministry of Justice directive of 5 June 1997 on the policy to be applied in the prosecution
of drug users.
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Belgium’s federal internal affairs policy is embedded in a philoso-
phy of crime prevention. Meanwhile, in the communities and
regions, a growing effort is being invested in striving for ‘global’
prevention, with a focus on general health and welfare.
In 2000, three types of service exist in Belgium, which are low
threshold in nature and offer treatment for drug use. They are:
• inpatient centres;
• outpatient centres; and
• primary-care services.
These promote abstinence, harm reduction and methadone
maintenance.
Substitution
Methadone substitution in Belgium is considered to be an efficient
therapeutic strategy for:
• enhancing the general well-being of opiate-addicted patients;
and
• promoting their social and psychological stability.
Today, in Belgium, the promotion of methadone substitution for
treating physically, psychologically and socially addicted patients
has three specific goals:
• to increase professional opportunities;
• to reduce criminal behaviour; and
• to prevent the spread of HIV and hepatitis.
Current situation
Considerable diversification and flexibility have evolved within
the field of substance substitution in Belgium in recent years,
specifically in the following cases.
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• Methadone is now used extensively in general medical practice
and is no longer confined to specialised centres.
• Flexibility exists in the traditional criteria for methadone main-
tenance, such as age, previous treatment and history of heroin
dependence (these are simply guidelines for evaluating each
individual case).
• Treatment programmes are flexible, due to a lack of data sup-
porting successful outcome in specific programmes.
• Methadone substitution can be continued in prison. For the
moment this only concerns patients who were in substitution
treatment before being incarcerated. At present, treatment in
prison consists of progressive withdrawal, but it is anticipated
that substitution will soon be initiated in prison and used, not
only for withdrawal, but also for maintenance.
• Between 1983 and 1992, substitution treatment was impossible
without psychotherapeutic or psychosocial counselling. The
setting for treatment was either a specialised centre or a network
of clinical practitioners (the latter started in 1989). Due to the
general trend towards flexibility, a change has occurred in the
traditional therapeutic framework. Outpatient methadone pre-
scription is losing some of its hitherto psychological focus while
the somatic point of view, including treatment of associated
somatic diseases, is gaining ground. The consequences of this
change cannot yet be quantified, but it is probably partially
responsible for the exponential increase in methadone treatment
in the last few years.
• Opiate substitution involving substances other than methadone
is rare in Belgium. It is recommended that other opiates be
replaced by methadone (and eventually buprenorphine).
Benzodiazepines and barbiturates are not accepted for opiate
substitution.
Recommended clinical practice
In 2000, methadone treatment is started at a dose of 30 mg. This
is evaluated within 48 hours in order to adapt the treatment, if nec-
essary. It is recommended that, for the first six weeks, patients have
their methadone administered by a pharmacist on a daily basis. 
An exception to this rule are patients who have professional
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commitments which are incompatible with daily visits to the phar-
macy. Substances other than methadone (and eventually
buprenorphine) are avoided. Benzodiazepines and barbiturates
are not considered for opiate substitution.
Accidents have occurred, particularly when an adult’s treatment
was accessible to a child. Patients should be informed of the
potential dangers for children. General practitioners (GPs) should
limit the number of patients following a substitution regime and
favour medium- and long-term perspectives. Registration on a spe-
cific clinical-case register is strongly recommended.
Development of substitution services (low threshold)
The type and number of formal and informal restrictions for admis-
sion to treatment define a threshold. When the threshold is low,
only minimal conditions for being accepted on a substitution pro-
gramme are imposed.
A threshold always exists because the process involves admission
to a programme and delivery control (the quantity of the substance
delivered at a time is limited). The purpose of the low-threshold
policy in Belgium is to allow less-motivated or socially marginal
patients access to methadone substitution and its related harm
reduction.
Pioneers of the low-threshold policy, the organisation Médecins
sans frontières (Doctors without Borders), have developed a pro-
gramme in Brussels offering free consultation in strategic geo-
graphic areas. Their target population includes those who are
excluded from the healthcare system and the social system in
general.
Another and very different initiative is the ‘Maisons d’accueil
socio sanitaires’ (MASS) project (‘Socio-sanitary shelters’). Co-
financed by the Ministry of Health and the Ministry of the Interior,
this project favours the integration of various professions, although
the focus and role of each have to be clearly defined. The centres
run by the project offer temporary accommodation to drug addicts
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who are severely socially excluded, and often even excluded from
specialised centres. Not all of the shelters provide methadone sub-
stitution. However, if they do not have the qualified medical per-
sonnel, they collaborate with outside resources willing to initiate
or pursue methadone treatment.
Substitution clients
A system was established in the 1960s to register the transactions
of pharmacies, based on distributors’ sales to them. Due to a lack
of resources, this covers only 68 % of the sales. If the available
data are extrapolated, it is found that 111.8 kg of methadone were
sold in Belgium in 1996, 106.9 kg of which were used for main-
tenance treatment. This can be confirmed through other sources.
In 1996, only one pharmaceutical company was selling
methadone in Belgium, and this company estimates its sales for
that year at 114 kg. In 1994, a survey of over 500 patients in the
city of Liège estimated the average methadone-maintenance dose
at 40 mg/day.
There is considerable variation in maintenance prescription across
the different regions of the country:
• methadone is prescribed less in the Flemish provinces than in
the southern part of the country;
• methadone prescription in the region of Brussels is four times
higher than the national average; and
• the region of Hainaut rates second, with a delivery twice as high
as the rest of the country.
The Hainaut province borders France, and the French cities of
Lille, Roubaix and Tourcoing are close by. It is estimated that 680
French patients underwent methadone maintenance in the Belgian
province of Hainaut in 1994.
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Period before methadone use
It appears that heroin addicts are seeking methadone treatment
sooner than in the past. In 1996, a survey of 345 methadone users
in the city of Charleroi revealed that:
• 18 % started methadone within the first year of beginning her-
oin use;
• 19 % started methadone between one and two years after;
• 26 % started methadone between two and three years after; and
• 37 % started methadone at least three years after.
Methadone in prison
Since 1995, methadone has been used in most prisons.
Methadone is usually used as a progressive withdrawal treatment
and not as a substitution treatment. It should be noted that around
one half of prisoners have experienced problems related to the
consumption of illegal drugs and that one third have experienced
heroin-consumption problems.
Substances prescribed
The consensus conference in 1994 recommended methadone (or
buprenorphine) for substitution treatment. When patients are tak-
ing substitution opiates other than heroin, it is recommended that
they be switched to methadone. In 2000, other therapeutic strate-
gies are being developed through pilot studies.
Injectable prescribing
Three universities are currently involved in a pilot study of med-
ically controlled heroin delivery in the city of Liège. Injected
methadone is forbidden.
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Surveillance
Belgium is a heterogeneous country with three official languages,
and many health-related issues are not federally, but regionally,
planned. Regions have a great deal of autonomy in their political
decisions, which has the advantage that surveillance activities in
the country are closely tailored to local conditions. However,
heterogeneity also brings structural disadvantages such as difficul-
ties in implementing general plans and policy.
Problems
Heterogeneity results in inequalities in treatment provision across
the country. Much attention has focused on variations in thera-
peutic strategies across market areas and the related question of
whether differences in attitudes are due to socioeconomic/cultural
variables or to uncertainty about making specific recommendations.
Evaluation
An interministerial commission, under the auspices of the Minister
for Health, and a Belgian agency dedicated to the promotion of
prevention and implementation of drug programmes, is trying to
implement evaluation programmes for substitution treatment and
to overcome the abovementioned obstacles.
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DENMARK
Peter Ege, Municipality of Copenhagen
Introduction
Denmark has a population of just under 5.3 million, and demo-
cratic elections take place at three levels: national, regional and
local. The regional level comprises 16 counties and the local level
275 municipalities. The responsibilities of regional and local gov-
ernment are defined by legislation passed by the Danish
Parliament.
Since 1996, the county authorities have been responsible for the
health services (primary care and hospitals) and for the treatment of
drug users, including methadone prescription. Local authorities are
responsible for general social welfare. In accordance with the law,
the treatment of drug users is carried out in close cooperation with
the county authorities, and responsibilities are allocated according
to action programmes which have been previously agreed.
Strategy
Drug abuse is considered a complex problem, requiring coordina-
tion across job demarcation lines and sectors. The campaign
against drug abuse is conducted both locally and centrally, and is
based on:
• persistent and targeted preventive action;
• multi-pronged, optional, coordinated treatment; and
• effective control.
The Ministry of Health is responsible for coordinating drug policy
at national level. Under the Serviceloven under den sociale
lovgivning (Social Welfare Act), the Ministry of Social Affairs 
is responsible for treatment carried out in in- and outpatient
institutions, and rehabilitation and care units. Questions relating to
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medical treatment, including methadone prescription and the
links between HIV and drug abuse, are the responsibility of the
Ministry of Health. The Narkotikarådet (Council on Narcotics) is
an interdisciplinary, advisory specialist body which monitors the
development, secures the quality and improves the coordination
of overall action against drug abuse within the areas of prevention,
treatment and control. The council was set up under the Ministry
of Social Affairs and is an advisory body to parliament and the
ministries involved.
The level of local autonomy in planning, development and inno-
vation is substantial, and so marked differences exist between
counties in the organisation of treatment.
In 1997, 542 inpatients and 3 215 outpatients received treatment.
In 1995, DKK 170.3 million (EUR 22.8 million) and in 1998 DKK
445.8 million (EUR 59.7 million) were spent on treatment.
Substitution
Development of substitution services
In the 1970s and early 1980s, the publicly funded addiction serv-
ices were abstinence oriented, and therefore stubbornly against
any form of substitution treatment. Methadone was only used for
detoxification. However, as early as the late 1960s, methadone
was used by general practitioners (GPs) as a substitution treatment
for the growing number of addicts. The number of addicts
increased sharply in the 1980s and, at the beginning of the 1990s,
around 2 500 drug addicts were receiving methadone substitution
from GPs, a figure that remained stable until 1996. In 1984, the
Council on Narcotics, under the Ministry of Social Affairs, pub-
lished a report on the treatment of drug addiction which recom-
mended that methadone-substitution treatment be viewed as ‘nor-
mal’ and just as useful and legitimate as abstinence-based treat-
ment. From that point onwards, methadone treatment gradually
became integrated into publicly funded addiction care. There is
still some resistance to the concept of substitution treatment, even
among the personnel who provide such treatment.
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Several reports by the Sundhedsstyrelsen (National Board of
Health) and the Council on Narcotics discouraged (but did not
prohibit) the involvement of general practitioners in substitution
treatment. In reality, this was not enforced, and no action was
taken against doctors who offered treatment. Attitudes varied from
GP to GP. Many were (and still are) reluctant to treat drug addicts,
whereas others saw it as a normal part of medical practice. Many
saw it as a necessary evil which they were forced to adopt because
of pressure from the patients and/or a lack of relevant substitution
treatment in the public health system.
On 1 January 1996, Danish legislation rendered methadone treat-
ment a county council remit (see ‘Legislation on substitution treat-
ment’ below). The objectives of the change were to ensure that
methadone prescription be coordinated with other treatment, that
the circumstances of the user be scrutinised before prescribing and
that alternative treatment be offered. Another objective was to
limit the diversion of methadone. This change in legislation
implied that only doctors employed in the county treatment sys-
tem (including hospitals) could be authorised both to decide if a
person were to be offered methadone treatment and to initiate the
treatment. However, the treatment of stabilised persons may be
delegated to a GP (15 % of all cases), but the county still has the
final responsibility for the treatment and has an obligation to keep
both the patient and the doctor under surveillance. The legislation
represents a dramatic shift from a period of total permissiveness to
one of strong regulation. As a result of this legislation, the capaci-
ty of the treatment system doubled, and sometimes even tripled,
between 1996 and 1998, an expansion which was not without its
problems.
Current situation
At present, 4 500 persons are in methadone-substitution treatment.
Of these:
• 75 % are men;
• the mean age is 36 (interquartile range 29–42);
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• 90 % are on transfer income (welfare payments, disability pen-
sions); and
• between 10 and 30 % are homeless.
Only a small percentage belong to ethnic minorities.
It is estimated that there are currently 15 000 drug addicts in
Denmark. The total treatment capacity (substitution and
abstinence-based treatment) comprises 542 inpatient and 3 215 out-
patient places. Staff/client ratios vary considerably, but, on aver-
age, it is about 1:20. Almost all substitution treatment is carried
out at outpatient clinics.
As a rule, cooperation between the criminal justice system and the
county treatment systems is good. Treatment is not disrupted by
imprisonment. Collaboration between the treatment system and
the health service is more problematic. In practice, drug users are
often excluded from inpatient care in particular, on the grounds
that their behaviour is unacceptable.
Drug problem surveys estimate the addict population (defined as
individuals dependent on one or more illegal substances) to be
about 15 000, of which 5 000 are living in the city of Copenhagen
(7 500 in Greater Copenhagen — city and suburbs). HIV infection
is estimated to affect 4 % of drug users and 80–90 % are estimat-
ed to be infected by hepatitis B and/or C. Statistics regarding drugs
and crime show that 35 % (1 300) of the prison population are
drug users. The number of persons charged with drug-related
crime was 8 700 in 1996.
Legislation on substitution treatment
Until 1996, the right to prescribe methadone treatment lay with
physicians. Some physicians tried to coordinate action concerning
methadone treatment, for example by establishing cooperation
with district medical officers. In addition, the municipal and county
council treatment systems employed physicians who, apart from
assessing the individual person’s medical state, also decided on
any methadone treatment. While the majority of drug users were
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prescribed methadone by their GP and others received it from
physicians at public treatment centres, physicians in the
Copenhagen area set up special private clinics which were almost
exclusively targeted at drug users (numbering about 400) receiving
methadone treatment.
The new legislation on methadone treatment which came into
force on 1 January 1996 (see above) aimed to ensure that
methadone treatment takes place within the context of a more
comprehensive approach. This included scrutinising the overall
circumstances of the user before prescribing methadone and offer-
ing the methadone user supplementary treatment (including coun-
selling, psychosocial support, rehabilitation, etc.).
No special licence is required for prescribing, but the above-
mentioned legislation dictates that only doctors employed in the
counties public treatment institutions are allowed to initiate the
substitution treatment.
Monitoring procedures are laid down by the National Board of
Health. According to their guidelines, urine tests for relevant legal
and illegal substances should be carried out at least monthly.
Treatment registers have been established in every county. In
1996, a new national register of drug users in treatment was estab-
lished by the National Board of Health in cooperation with the
treatment centres in the counties. The register includes all persons
treated for drug abuse by the county and/or municipal centres,
irrespective of the form of treatment.
The degree of control and sanction varies considerably from
county to county. In some treatment centres, clients are monitored
very closely, with frequent urine controls. Expulsion from
treatment is a real threat in cases of contaminated urine. Other
centres use urine testing on a small scale, and do not use sanctions
against, but simply react to, the use of illegal drugs.
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Substitution clients
Opiate dependency (as defined in the World Health
Organisation’s 10th edition of the International Classification of
Diseases — ICD-10) is the only entry criterion for substitution
treatment in Denmark. Psychotherapy and social care are, as a
rule, both required and available. Appropriate support (education,
employment) is offered, although not systematically, and generally
only to a limited extent.
Pharmacy activity
Pharmacies have dispensed prescribed methadone to addicts
since the late 1960s. The greater part of methadone dispensing
took place at pharmacies until 1997, when the treatment institu-
tions gradually began to take over. However, pharmacies still play
an important role in substitution treatment, although there is no
specific training given.
The professional bodies have been divided in their attitude to the
pharmacies’ role as a service to drug addicts. All of them dispense
methadone, but many of the professional bodies believe that phar-
macies should play a limited role, except in cases where addicts
are stable. From 1986 to 1996, pharmacies dispensed needles and
syringes to addicts (paid for by the county), but most pharmacies
have since stopped this activity because of nuisance problems. In
fact, there has been some reluctance on the part of pharmacies 
to become further involved in treatment on account of these
problems.
Primary-care involvement
In Denmark, all citizens have access to free medical care and are
assigned to a local GP. Since the late 1960s, GPs have been
involved in the treatment of drug addicts. One important reason
for this was the refusal by treatment institutions to offer
methadone-substitution treatment. As a result of the new legislation
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in January 1996, many patients in methadone treatment were
transferred from their GP to the public treatment institutions, and
GPs were no longer permitted to initiate methadone treatment.
However, as mentioned above, treatment of stabilised patients
may be delegated to the GP and this has now occurred in about
15 % of all cases. A significant outcome of this law has been that
the number of patients in methadone treatment with their GP has
greatly diminished. Only one local study has been undertaken of
primary-care involvement (in 1983) in Copenhagen (Winsløw and
Ege, 1985; Winsløw et al., 1986).
Primary care is only offered to patients who have been delegated
by the county to the GP. The county (and its treatment and social
institutions) still has responsibility for the overall treatment plan,
so the GP can obtain any support necessary from the local treat-
ment centre. If a GP finds it difficult to manage a patient in sub-
stitution treatment, he can always refer the patient back to the
county treatment centre. GPs currently do not receive training 
in substitution treatment.
The view of the Almindelige Danske Lægeforening (Danish
Medical Association) is that drug users should be treated primarily
in public treatment institutions, but that GPs also have an impor-
tant role to play:
• as the drug user’s primary contact with the health system; and
• as a provider of substitution treatment to the socially and med-
ically stable patient.
However, many GPs refuse to engage in substitution treatment.
Substances prescribed
Methadone has almost exclusively been the substance of choice
for substitution treatment in Denmark. However, from 1998,
LAAM was also used in substitution treatment and buprenorphine
in substitution and detoxification.
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Methadone is prescribed at 50–120 mg daily. LAAM is prescribed
at 50–120 mg three times weekly and buprenorphine at 1–12 mg
daily. Methadone is usually dispensed as a mixture but sometimes
as tablets. LAAM is also prescribed as a mixture and bupren-
orphine as sublinguettes (tablets placed under the tongue).
Substitution treatment is generally not provided for addictions
other than heroin addiction, although, in practice, benzo-
diazepine substitution is given to some patients where detoxifica-
tion is deemed impossible.
Surveillance
Since the mid-1970s, monitoring of the drug situation in Denmark
has mainly been based on indirect sources (indicators). At present,
the following indicators are used:
• clients in treatment for drug abuse;
• persons in lengthy methadone treatment (more than five
months);
• drug users in prison;
• persons admitted to somatic and psychiatric hospitals with an
abuse-related diagnosis;
• drug-related mortality;
• infectious diseases (HIV, hepatitis);
• the number of seizures and amount of confiscated drugs;
• the price and purity of drugs seized on the streets; and
• charges for violation of drugs legislation.
These indicators offer time-series data, making comparisons over
time possible.
There is a great need to render the collection and validation of
data, and the analysis of the data and indicators, more scientific.
There has been some progress in this direction, especially as
regards data on clients in treatment for drug abuse, and also with
regard to drug-related mortality. A drug database is being de-
veloped, which, by pooling individual-related data from four
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registers, should facilitate estimations of the numbers of drug users
and monitor developments in the various cohorts.
Problems
Services face many problems, such as:
• lack of capacity;
• insufficient medical services;
• antagonism towards substitution treatment, even among some of
the personnel who administer the treatment; and
• problems with handling the control aspect of the treatment.
Furthermore, there has often been great resistance to the estab-
lishment of new clinics (the ‘not in my backyard’ attitude).
However, as a rule, established clinics seem to have good rela-
tionships with their neighbours. Generally, there is no problem
with nuisance, such as loitering around the clinics.
The number of drug users in prison has increased since 1986, now
comprising 35 % of all prisoners (approximately 3 000 in all). The
policy of the Direktoratet for Kriminalforsorgen (Directorate for
Prison and Probation Services) is that drug users in prison should
be offered treatment coordinated with the social services and
treatment institutions outside the prisons. Thus, in principle, treat-
ment (including substitution treatment) should not be interrupted
because of imprisonment.
Diversion is not perceived to be a great problem in Denmark.
Evaluation
Since the evaluation of substitution treatment in general practice
(Winsløw and Ege, 1985), there has been no systematic evaluation
of substitution treatment in Denmark, except for small qualitative
investigations into consumer satisfaction. This can be ascribed to
a general lack of interest in research and evaluation in the social
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services, lack of funding, etc. However, plans to evaluate the area
are under way.
It is known that, for Copenhagen, the retention rate in treatment is
very high, at approximately 90 %. The mortality rate, which was
less than 1 % in 1997, went up to 1.7 % in 1998 and 1.2 % in
1999. This increase is probably due to an increase in mortality
from somatic diseases, primarily hepatitis C.
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GERMANY
Ralf Gerlach, Institut zur Förderung qualitativer
Drogenforschung, akzeptierender Drogenarbeit und rationaler
Drogenpolitik (INDRO e. V.), Münster
Introduction
Germany has a population of about 81.5 million. Several methods
of estimating prevalence of drug use have been implemented in
the country with varying techniques and definitions. There is a
hidden population of controlled and recreational heroin users that
can hardly be estimated by number, let alone be recorded statisti-
cally (Weber and Schneider, 1997). Taking all estimates as a basis
for estimating the total number of opiate users, we can arrive at an
approximate figure of between 100 000 and 200 000 heroin users,
at least half of which are compulsive users (Hoffmann, 1998).
Thus the rate per 1 000 inhabitants is between 1.2 and 2.5.
In a European context, Germany was relatively late as regards the
introduction of substitution treatment, having introduced
methadone treatment in 1992. Germany has taken legal steps
which favour harm reduction and assistance over law enforce-
ment. As a result, Germany now allows the use of other substitu-
tion substances, such as LAAM and  buprenorphine, and treatment
with heroin. However, it has to be borne in mind that Germany is
a federal State and hence the use of these substitution substances
is not evenly spread across the country.
Strategy
Drug addiction is considered an illness in Germany following a
decision by the Bundessozialgerichtshof (German Federal Social
Court) of 18 June 1968 which, within the social law, recognised it
as such. This has been the basis of German drug policy ever since.
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A variety of measures and activities are seen as necessary in order
to reduce individual and social risks connected to drug problems.
Under the coalition agreement of the German Federal
Government in 1998, education, prevention and assistance for
drug addicts, as well as law enforcement for criminal drug
trafficking, are cited as ways of tackling drugs and addiction.
The Parlamentarischer Staatssekretär im Bundesministerium für
Gesundheit (Parliamentary Secretary of State of the Federal
Ministry of Health) is the Drogenbeauftragte der Bundesregierung
(Drug Commissioner of the Federal Government), following a
decision taken by the federal cabinet on 18 November 1998. The
fact that responsibility for drug policy shifted from the Ministry of
the Interior to the Ministry of Health at that time indicated that
health and social aspects of addiction were to take precedence
over enforcement, following the general rule ‘help comes before
law enforcement’. Prosecution of those involved in the produc-
tion, distribution and possession of drugs, however, remains the
responsibility of the Ministry of the Interior, the state ministries and
customs authorities, which operate across borders.
Over recent years, preventive activities have increased, both in
number and quality, and will be of considerable value in the
future. Preventive measures will be targeted at specific groups. The
services offered for drug addicts have been much developed over
recent decades and today are both differentiated and professional.
Self-help groups in the field of drugs are seen as an important ele-
ment in achieving and sustaining a drug-free life and mental and
social stability for substitution clients.
Policy developments in the field of substitution treatment
The federal government has identified harm reduction and practi-
cal survival support as important objectives of the new drug and
addiction policy. This was motivated by the poor health status and
social impoverishment of many drug addicts, especially injecting
heroin addicts, in the open drug scene in some capitals. Infections
such as HIV, hepatitis B and C, as well as psychiatric or somatic
diseases, are special risks. Through different measures which are
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described below, the plan is to reduce health risks, by addressing
the risk factors associated with drug use, and to reduce pressures
caused by drug supply and drug-related crime, while still observ-
ing the overall strategy of a drug policy oriented towards absti-
nence from drugs.
Substitution
In July 1999, the federal cabinet passed a bill for the 
3. Betäubungsmitteländerungsgesetz (third amendment of the
Narcotics Act). This was designed to close gaps concerning the
authorisation of prescribing narcotics. On the one hand, quality
standards will be formulated for the medical doctors who pre-
scribe substitution substances. On the other, a registration system
for patients in substitution will be installed.
In general, qualified substitution of opiates by methadone (and, in
exceptional cases, codeine) will be continued and will also be
extended to where it has previously been unavailable. One effect
of medical prescription and administration of substitutes has been
that the medical aspects of methadone treatment have demanded
increased attention. A lack of standards has been mentioned by
critics concerning psychosocial care, which is seen as insufficient
in quantity and quality in many cases.
Heroin-supported treatment
In recent years, through the rapid expansion of low-threshold
treatment, as well as through inpatient and substitution-based
treatment and rehabilitation, a high-quality system of drug treat-
ment has developed. In many cases, this has offered opiate addicts
a chance to withdraw from the drug scene and successfully
progress towards abstinence. However, it is also of concern that
certain drug addicts are still not being reached.
This has also been the experience of other countries and, as a
result, they have investigated other methods of intervention ori-
ented towards motivation and substitution. Based on the results
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and experiences of the Swiss and Dutch models, a clinical multi-
centre study of ambulatory heroin-supported treatment of heroin
addicts is scheduled to be launched in Germany in 2001. The
study under consideration will include the clinical trial of heroin-
based prescriptions, and, in addition, is expected to clarify
whether heroin-supported treatment can help those opiate addicts
for whom the existing services have failed. The main aims of such
treatment would be:
• to stabilise the health and social situation of such addicts;
• to integrate them successfully into the help system;
• to keep them within the help system; and
• to motivate them to undertake further treatment.
The study will also research if and how:
• heroin-supported treatment may be incorporated into the treat-
ment offered to opiate addicts; and
• risks for public security may be limited.
At a later stage, the study will examine the development of drug
use in opiate-addicted clients, their motivation for treatment and
the psychosocial consequences, as well as the consequences of
heroin-supported treatment for public order and penal law. On the
basis of paragraph 3.2 of the Betäubungsmittelgesetz (German
Narcotics Act), the Bundesinstitut für Arzneimittel und
Medizinprodukte (Federal Institute for Drugs and Medical
Devices) can sanction such a scientific study. The study will need
to take account of the following factors:
• national and international narcotics law;
• the Arzneimittelgesetz (Pharmaceutics Law), which aims to pro-
tect people in clinical trials;
• the Arzneimittelprüflinien (regulations for the testing of pharma-
ceutics); and
• the rules of good clinical practice.
In February 1999, under the responsibility of the Ministry of
Health, a coordination group was created, composed of represen-
tatives of interested municipalities and the German federal states
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as well as a representative of the Bundesärztekammer (Federal
Medical Association). This group has developed a framework out-
lining the general targets of the trial, its legal basis and so on. On
the basis of this framework, a call for tender was agreed upon by
all participants and published in the Bundesanzeiger (Federal
Gazette) and on the Internet. Cologne, Essen, Frankfurt, Hamburg,
Hanover, Karlsruhe and Munich are expected to participate in the
trial initially, and other cities may join later. Parallel scientific
research in this framework is fully funded by the Federal Ministry
of Health.
Development of substitution services
Until the early 1990s, methadone could only be administered to
drug users when highly specific indication criteria were met (e.g.
emergency cases, such as life-threatening conditions of withdrawal
or severe pain). In general medical practice, however, German
doctors were not allowed to prescribe methadone to treat heroin
addicts (Gerlach and Schneider, 1994).
The 1970s and 1980s were dominated by a rigid adherence to the
abstinence paradigm. The therapeutic ideal of permanent absti-
nence for all opiate users was considered the only valid premise
for providing practical survival support and the only valid criterion
for successful drug treatment. Long-term participation in drug-free
therapeutic communities was proclaimed as the ‘royal road to
recovery’. There was general opposition to drug-substitution treat-
ment from politicians, medical professionals and authorities,
researchers (scientists), therapists, counsellors, and social (drug)
workers (Gerlach and Schneider, 1991; Kalke, 1997a).
Methadone-maintenance treatment was considered to be medical
malpractice. However, there were a few general practitioners
(GPs) who ignored the legal regulations and prescribed
methadone to opiate addicts, but most of these lost their medical
licence in court as a result of evidence presented by medical
experts. As a result, some GPs began prescribing legal substitute
opioids such as codeine or dihydrocodeine, as these substances
were not restricted by law. Other doctors followed this example
and, over many years, in fact until February 1998, codeine was
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prescribed to large numbers of addicts through a loophole in the
narcotics regulations.
In the mid-1980s, the emergence of a variety of factors finally pro-
voked demands for alternative, harm-reduction approaches to the
treatment of drug addiction. These factors included:
• HIV/AIDS;
• increasing addict criminality;
• increasing mortality rates among drug users; and
• the narrow range and lack of attractiveness of abstinence-
oriented services.
However, it was only after several pilot programmes showed
methadone-maintenance treatment (MMT) to be effective that the
Gesetzliche Krankenversicherung (GK — German Social Health
Insurances (SHI)) approved this treatment modality and intro-
duced, in 1991, the Neue Untersuchungs- und Behandlungs-
methoden-Richtlinien (NUB-Richtlinien — new guidelines for
diagnosis and treatment). These guidelines were drawn up by the
Bundesausschuß der Ärzte und Krankenkassen (Federal
Association of Physicians and Public Health Insurance Organ-
isations). The German Narcotics Act was revised in 1992. The
guidelines only concern the reimbursement of treatment costs by
the public health insurers. (For a detailed description of the
German healthcare and insurance system, see Weil and Brenner,
1997, and Busse et al., 1999.)
Current situation
Compared with 1997, the number of first-time registered users of
so-called ‘hard drugs’ (opiates, cocaine, amphetamines, ecstasy)
increased by 1.7 % in 1998 to a total of 20 943. The
Bundeskriminalamt (Federal Bureau of Criminal Investigation)
reported a slight decline (1.3 %) in first-time registered heroin
users in 1998 compared with 1997 (amphetamines: + 20.2 %;
cocaine: + 10.6 %; ecstasy: – 25.5 %) (Bundeskriminalamt,
1998a). In 1997, 240 554 criminal offences were committed by
users of hard drugs. According to investigations by the German
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police, 1 criminal offence in 13 was committed by hard drug users
in 1997 (Bundeskriminalamt, 1998b).
Drug-related deaths have been registered since 1969. Table 1
shows the annual figures from 1969 to 1998. Drug-related deaths
increased from 0 in 1969 to 623 in 1979. After 1979, mortality
rates decreased and remained relatively stable over the next 10
years. Since 1989, drug-related deaths have increased dramatical-
ly, reaching their highest level in 1991 with a figure of 2 125. From
1992 to 1997, death rates decreased again. However, the 1998
figures once again showed a slight increase in drug-related deaths.
It is estimated that about 20 % of all injecting drug users (IDUs)
are HIV positive. The percentage of infection rates differs between
various regions and study settings. The annual number of AIDS
cases among IDUs decreased from 228 in 1989 to 125 in 1997.
Regarding the routes of infection, intravenous drug use made up
14 % of all diagnosed AIDS cases in 1998 (and 12 % in 1997)
(Robert Koch Institut, 1998, 1999).
While the rate of new HIV infections has stabilised over recent
years, there is yet another serious challenge to the drug aid system.
The rates of infection with different forms of the hepatitis virus
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TABLE 1: DRUG-RELATED DEATHS IN GERMANY (1969–98)
YEAR NUMBER OF YEAR NUMBER OF YEAR NUMBER OF
DRUG-RELATED DRUG-RELATED DRUG-RELATED
DEATHS DEATHS DEATHS
1969 0 1979 623 1989 991
1970 29 1980 494 1990 1 491
1971 67 1981 360 1991 2 125
1972 104 1982 383 1992 2 099
1973 106 1983 472 1993 1 738
1974 139 1984 361 1994 1 624
1975 195 1985 324 1995 1 565
1976 344 1986 348 1996 1 712
1977 392 1987 442 1997 1 501
1978 430 1988 670 1998 1 674
Source: Jahrbücher zur Frage der Suchtgefahren, Bundeskriminalamt.
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have long been underestimated and have now reached alarming
proportions. Recent studies on hepatitis among IDUs suggest that
about 50 % become infected with hepatitis B and 70–90 % with
hepatitis C (Bätz, 1997).
Despite strong restrictions on substitution treatment (described
below), the number of patients receiving methadone maintenance
funded by public health insurance (SHI) increased from about
1 000 in April 1992 to around 20 900 in April 1998. The data pre-
sented in Table 2 give an overview of the growth in methadone
substitution in the 11 old federal states of former West Germany
since the implementation of the new guidelines. The latest data
available on the number of SHI-funded substitutions in the eastern
parts of Germany date back to 31 December 1996. According to
Zerdick (1997), the number of methadone patients was 4 in
Brandenburg, 4 in Mecklenburg-Western Pomerania, 31 in
Saxony, 2 in Saxony-Anhalt and 5 in Thuringia.
The total number of methadone patients, including all those with-
out public health insurance, increased from about 1 000 in 1991
to an estimated 45 000 in April 1999. The figures mentioned
above suggest that a large proportion of methadone patients
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TABLE 2: GROWTH OF THE NUMBER OF METHADONE PATIENTS 
IN STATUTORY (PUBLIC) HEALTH INSURANCE (SHI) IN GERMANY
(1991–98)
YEAR (RANDOMLY SELECTED DATES) NUMBER OF PATIENTS (1)
October 1991 Introduction of the NUB guidelines
April 1992 c. 1 000
July 1992 c. 1 500
October 1992 c. 3 100
March 1993 c. 4 500
April 1994 c. 9 700
April 1995 c. 13 500
April/June 1996 c. 19 000
April 1998 c. 20 900
(1) All figures relate to the old German federal states.
Source: Weber (1998a). 
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receive treatment without public health insurance support.
Methadone patients without health insurance either pay for their
medication or receive funds from the social welfare system. It is
estimated that the total number of patients in codeine or dihy-
drocodeine treatment decreased over 15 months from 25 000–
30 000 in early 1998 to approximately 15 000 by April 1999, due
to a change in the Betäubungsmittel-Verschreibungsverordnung
(regulations on the prescription of narcotics) in February 1998 (see
‘Legislation on substitution treatment’ below). Since practitioners
who prescribe methadone and/or codeine/dihydrocodeine need
not notify the local health authorities, the total numbers of patients
in substitution treatment can only be estimated. It must be point-
ed out that, currently, no reliable monitoring and registration
system exists. Proceeding from the prevalence estimate of 
100 000–200 000 opiate users (including controlled and recre-
ational users), the estimated total number of 60 000 substitution
patients suggests that at least 33 % of all heroin users participate
in substitution treatment, and perhaps even 60 %.
It is estimated that at least 90 % of patients receive their medica-
tion from doctors in independent practice (GPs). In a survey car-
ried out by Gerlach and Caplehorn in spring 1996 in the
Westfalen-Lippe region of Germany, 70 % of all SHI-approved
methadone prescribers (598 physicians) in the area were GPs,
20 % specialists in internal medicine and 6 % psychiatrists
(Gerlach and Caplehorn, 1999). While the majority of methadone
prescribers had less than 10 maintenance patients, a few treated
up to 100 addicts (particularly specialist surgeries). Weber et al.
(1997) have reported similar data (Table 3). In their survey, 80.3 %
of doctors had less than 15 methadone patients. In major cities
such as Berlin, Bochum, Cologne, Dortmund, Essen, Frankfurt,
Hamburg, Munich and Stuttgart, there are also specialised out-
patient centres for substitution treatment, some of which have over
200 patients.
Nationwide, more than 3 000 physicians (mostly GPs) are author-
ised to provide methadone-maintenance treatment under public
health schemes, about half of which do in fact prescribe
methadone.
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So far, there has been only one survey, carried out in the region of
Westfalen-Lippe in 1996, on the attitudes and beliefs of German
methadone prescribers and their knowledge of the effects of
methadone. Of the 247 SHI-approved doctors included in the
survey, around 50 % supported and 25 % strongly supported
abstinence-oriented policies. The strength of support that doctors
gave to these policies probably reflects the domination of the
abstinence paradigm in German addiction-treatment services.
Their attitudes and relative lack of knowledge of the basic pharma-
cology of methadone are probably due to the country’s relatively
short experience with methadone maintenance. These attitudes
are likely to affect adversely the quality of care given to heroin
addicts (Gerlach, 1999; Gerlach and Caplehorn, 1999).
Provision can be made for methadone patients travelling for holi-
day or business reasons to continue treatment. Patients are
allowed to receive take-home medication for seven days, after six
months of compliant behaviour in treatment. In cases where con-
tinued (daily) methadone administration is required, doctors can
refer the patient to a methadone-prescribing colleague near the
place they intend to stay.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
78
TABLE 3: PROPORTION OF DOCTORS’ OFFICES WITH REGARD 
TO THE NUMBER OF PATIENTS TREATED WITH METHADONE 
(DATA COLLECTED FROM 895 METHADONE-PRESCRIBING
DOCTORS IN SIX WESTERN REGIONS OF GERMANY IN 1996)
NUMBER OF PATIENTS PER OFFICE PROPORTION OF OFFICES (%)
1–4 38.9 
5–9 25.5 
10–14 15.9 
15–19 5 
20–24 5.4 
25–29 2.7 
30–49 4 
50 or more 2.6 
Source: Weber et al. (1997). 
42d930_insights_brochure  09-11-2000  14:53  Pagina 78
There are some 50 000 prisoners in Germany, 30–50 % of whom
were IDUs at the time of imprisonment. Despite rigid controls,
around 50 % of all imprisoned IDUs continue using drugs. It is
estimated that the drug-using population in prisons is at least 
10 000. However, these are only rough estimates, since there are
no clear (generalisable) data available. Also, no information is
available on the number of methadone patients in penal institu-
tions. Only 6 out of the 16 federal states provide methadone treat-
ment in prisons (Berlin, Bremen, Hamburg, Hesse, Lower Saxony
and North Rhine-Westphalia). Entry criteria vary between states,
and substitution treatment is not available in all of the prisons of
these states (Keppler and Stöver, 1997).
Legislation on substitution treatment
The German Narcotics Act was passed in 1971 and modified in
1982. Several amendments have since been passed. This act has
priority over all other regulations regarding narcotics. Drugs/
substances are assigned to three categories.
• Schedule 1 lists all non-prescribable and non-marketable drugs
(e.g. heroin).
• Schedule 2 contains marketable but non-prescribable drugs and
their vegetable substances (e.g. Papaver bracteatum,
Erythroxylum coca).
• Schedule 3 lists all marketable and prescribable drugs, such as
morphine, opium, methadone, codeine, dihydrocodeine, LAAM
and buprenorphine. Cocaine, which is used as an anaesthetic, is
also categorised under Schedule 3 but must not be prescribed to
drug users as a substitute in medical maintenance.
Regarding substitution treatment with methadone, it was only in
1992 that an amendment to the regulations on the prescription of
narcotics was introduced which clarified the position of
methadone prescribers. The latest modification of these regula-
tions (effective from 1 February 1998) entitles doctors to prescribe,
per patient, the following maximum quantities of narcotics over a
period of 30 days:
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• 3 000 mg of methadone;
• 1 500 mg of levomethadone;
• 30 000 mg of codeine and dihydrocodeine;
• 150 mg of buprenorphine; and
• 2 000 mg of LAAM.
These maximum quantities can be exceeded only if necessary for
medical reasons. Since February 1998, substitution treatment with
codeine or dihydrocodeine is now officially treated in the same
way as methadone. However, codeine and dihydrocodeine are
regarded as inappropriate medications for maintenance purposes
(‘second-choice substitute substances’) and their use is limited to
those (very few) patients who physically cannot tolerate
methadone. Unfortunately, as these are only interim regulations
for codeine treatment, the old regulations remain legally in effect.
Initially, they were to be phased out in July 1998, but were extended
until the end of 1998. Finally, they were extended until 
1 January 2000, because it was impossible to transfer all codeine
patients to methadone-maintenance treatment before that date.
The main rules regarding substitution treatment, as documented in
Section 5 of the regulations, are summarised below.
In accordance with Section 13(1) of the Narcotics Act, substitute
drugs may be prescribed for the following regulation purposes
(treatment goals):
• treatment of opiate addiction with the goal of step-by-step
recovery to abstinence, inclusive of improvement and stabilisa-
tion of the general health status;
• treatment of patients addicted to opiates who have to undergo
medical treatment for serious medical illnesses; and
• reduction in the risks of opiate addiction during pregnancy and
after delivery.
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Doctors are authorised to prescribe substitute substances if and as
long as:
• the patient is eligible for substitution treatment;
• substitution treatment is embedded in a comprehensive treat-
ment concept incorporating the necessary accompanying
psychiatric, psychotherapeutic or psychosocial care;
• the doctor works towards the realisation of necessary accom-
panying treatment and care;
• there is no evidence that the patient:
• (a) receives substitution substances on prescription from another
doctor,
• (b) does not participate in necessary accompanying treatment
and care,
• (c) uses substances that endanger the purpose of substitution
treatment,
• (d) does not use the substitute as directed by law; and
• the patient sees his/her doctor at least once a week.
Doctors are obliged to document all relevant patient and treat-
ment data. Upon request, doctors must show their files to the rel-
evant state authorities (local health authorities, public prosecutors’
offices). Prescriptions must be written on special prescription pads,
and they must be marked with the letter ‘S’. When maximum
quantities are exceeded, the prescription must also be marked
with the letter ‘A’. The laws on narcotics come under criminal law.
A doctor who violates the regulations on the prescription of nar-
cotics may face a fine of up to DEM 50 000 (EUR 25 000) or a
prison sentence of up to five years.
Substitute substances must not be prescribed for parents to admin-
ister. The substitute may be dispensed and/or taken under super-
vision in a GP’s surgery, or in a hospital, pharmacy or other facil-
ities approved by the relevant state authorities.
It is possible to take home medication for up to seven daily doses
after six months in treatment:
• when the maintenance dose has been fixed;
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• when the patient does not use other substances in quantities that
do not allow for responsible self-administration of the substitute;
or
• when the patient uses the substitute as directed (for a detailed
commentary on the new regulations on the prescription of nar-
cotics, see Ulmer, 1998).
Additional guidelines (NUB guidelines) for SHI-funded substitu-
tion treatment have been drawn up by the Federal Association of
Physicians and Public Health Insurance Organisations which reg-
ulates the reimbursement of treatment costs. These guidelines may
be ignored where patients have no public health insurance.
Compared with the regulations on the prescription of narcotics,
the core of the NUB guidelines is discrimination according to indi-
cations. The SHI have not approved heroin addiction per se as an
indication for methadone maintenance. The guidelines provide
seven indication categories. SHI-funded methadone maintenance
is possible if one of the following criteria is met:
• drug dependence in the case of life-threatening conditions of
withdrawal;
• drug dependence in the case of severe illness (e.g. cancer);
• drug dependence with pain that has to be treated with opioids;
• drug dependence in case of AIDS;
• drug dependence of patients needing to undergo medical treat-
ment for serious illness but who cannot be withdrawn from
drugs at the same time (‘bridging’ or interim substitution);
• drug dependence during pregnancy, in childbirth, and up to six
weeks after birth; and
• drug dependence in cases of severe illness for which the com-
mission considers methadone administration to be indicated as
part of the treatment plan.
Doctors are required to control maintenance patients’ urine and to
monitor polydrug use. There are no rules regulating frequency of
urine sampling. In practice, during the first weeks of treatment,
doctors usually control their patients’ urine once a week. The NUB
guidelines require that continued collateral use of other drugs (no
substances listed) must result in the termination of treatment.
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All doctors seeking to provide SHI-funded methadone-
maintenance treatment need to be authorised to do so by the
regional branches of the Kassenärztliche Vereinigung (KVs), an
association of medical doctors recognised by the German health
insurance system. The doctors must have received sufficient training
in pharmacology and drug addiction provided by special training
programmes. The mode and scale of these programmes vary enor-
mously between the different branches of the association. While
several of them accept participation in a one-day seminar, others
expect doctors to participate in a three-day training course.
Training covers topics such as:
• opioid dependence and the role of methadone;
• understanding and caring for the methadone patient;
• assessment and management; and
• clinical practice dosing procedures.
There have been criticisms that substitution-treatment training in
the different branches of the association is inadequate. A study
conducted in the region of Westfalen-Lippe came to the conclu-
sion, among others, that ‘many doctors had surprisingly little
knowledge of the effects of methadone’ (Gerlach and Caplehorn,
1999).
Depending on the number of methadone-treatment providers in a
given area, doctors can be authorised to treat 10, 20, 30 or up to
50 patients funded by the SHI (Zerdick, 1999). There are no such
limitations given in the regulations on the prescription of nar-
cotics. Thus, doctors who are approved to treat 10 SHI patients
may have, for example, another 20 methadone patients funded by
social welfare or paying for treatment themselves.
Doctors treating methadone patients according to the NUB guide-
lines also have to meet the regulations on the prescription of nar-
cotics and the Narcotics Act. While NUB patients have to be reg-
istered with the regional KVs, other patients need not be. It should
be noted that the regulations and guidelines given above drasti-
cally limit a doctor’s choice of medical treatment. There are no
such rigid regulations for any other disease or treatment modality.
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Despite the fact that the NUB guidelines are effective nationwide,
there are still variations between the federal states in the organis-
ation and delivery of methadone treatment and accompanying
psychosocial care (Bühringer et al., 1995). There are, for example,
state-specific agreements and contracts in Berlin, Hamburg and
North Rhine-Westphalia.
On 26 April 1999, the Federal Association of Physicians and
Public Health Insurance Organisations passed the Anerkannte
Untersuchungs- und Behandlungsmethoden-Richtlinien (AUB-
Richtlinien — guidelines for recognised diagnosis and treatment
methods), which were approved by the Secretary of State for
Health.
Substitution clients
Entry criteria for methadone patients have already been described
above. In short, while SHI-funded patients and most patients sup-
ported by social welfare have to suffer from illnesses other than
drug addiction itself to be accepted for substitution treatment, it is
sufficient for patients paying for treatment out of their own pock-
ets to be diagnosed as being addicted to heroin. There are no reg-
ulations regarding the length of addiction and the minimum age of
patients. In general practice, drug users will be accepted for treat-
ment when there is a documented history of drug use of about one
to two years and when they are (at least) 18 years old.
The total number of 60 000 patients in substitution treatment,
together with the high retention rates reported in several German
studies, speaks for the acceptability of MMT among the patients.
In North Rhine-Westphalia, for example, the retention rates were
87 % after one year, 66 % after three years, 53 % after five years
and 48 % after seven years (Ministerium für Arbeit, Gesundheit
und Soziales des Landes Nordrhein-Westfalen, 1998). An evalua-
tion of methadone-maintenance treatment in Hamburg showed
retention rates of 84.1 % after three years, 77 % after four years
and 71.2 % after five years (Raschke et al., 1996).
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Both the regulations on the prescription of narcotics and the NUB
guidelines demand mandatory participation of patients in psy-
chosocial care, although there is no empirical evidence of the
necessity for psychosocial support for all patients (Ullmann, 1996;
Gerlach, 1997). However, these regulations do not provide any
instructions on the frequency, mode and scope of psychosocial-
care provision and, to date, there are no nationwide standards of
how to organise and structure accompanying support.
‘Psychosocial care’ is a collective name for a number of different
areas. These may include, for example:
• legal advice;
• managing financial problems (e.g. debts, rents);
• recreational activities;
• crisis intervention;
• (psychotherapeutic) group sessions;
• assistance with finding accommodation and jobs; and
• augmenting poor school and vocational qualifications (learning
new skills).
Psychosocial care is not funded by the SHI. There are great varia-
tions in psychosocial provision between different states and com-
munities, along with variations in quality and funding. While in
Hamburg, for example, psychosocial care is paid for by the muni-
cipality, in other regions accompanying support is only partially
state funded (e.g. North Rhine-Westphalia) and sometimes even
has to be provided by the resources available (drug agencies,
drop-in centres) without any funding at all.
The labour market is not easy to access for methadone patients,
due to a high general unemployment rate (10.7 % in April 1999)
and negative attitudes towards methadone patients on the part of
employees. Also, the socio-demographic and biographical char-
acteristics of MMT patients (e.g. low school and vocational quali-
fications, criminal records) reduce the chances of finding employ-
ment. Although there are several educational and vocational proj-
ects (e.g. in Bielefeld, Frankfurt, Ludwigshafen and Munich),
accompanying support regarding education and employment is
still not generally available. There is great demand for further
action in this field.
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There has been little research on the subjective views of patients
participating in substitution treatment. The main disadvantage of
methadone maintenance reported by patients is mandatory daily
attendance at a doctor’s surgery, a pharmacy or other dispensing
site over the first months of treatment (‘take-homes’ can only be
granted after six months in treatment). Patients living in rural areas
or regions with low provision of substitution treatment, in particu-
lar, are worst hit by this regulation. Due to a lack of availability of,
and access to, substitution treatment in their neighbourhood, these
patients often have to make long and time-consuming journeys to
their doctor or dispensing pharmacy. In such cases, day-to-day life
is determined, to a great extent, by these obligatory appointments.
In a study of randomly selected MMT patients in North Rhine-
Westphalia, 86.7 % (n = 113) reported that they wished to have
more rights within their treatment settings (Gerlach and Schneider,
1994). Patients interviewed in a Hamburg survey (n = 182)
described the following as disadvantages of methadone-
maintenance treatment:
• ‘inner void’, loneliness or boredom (67 %);
• numerous obligations (55 %);
• confronting reality (42 %);
• lack of euphoria (37 %); and
• loss of former ‘scene contacts’ (11 %) (Raschke, 1994).
Pharmacy activity
Dispensation of methadone in pharmacies is backed by the
umbrella organisation of the German associations of pharmacists,
the Bundesvereinigung Deutscher Apothekerverbände (BDA).
Since the introduction of the new regulations on the prescription
of narcotics on 1 February 1998, methadone may be legally dis-
pensed via pharmacies. In Hamburg, however, local pharmacies
have been involved in dispensing methadone since the intro-
duction of MMT in 1988, due to state-specific regulations.
According to a study conducted in 1996, 80 % of all Hamburg
methadone patients received their medication in pharmacies.
Pharmacy dispensing is patient-friendly and saves methadone
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patients long or time-consuming journeys to, and/or periods of
waiting in, doctors’ surgeries (because they can choose a pharm-
acy in their own neighbourhood) and makes flexible dispensing
hours available to them. Nearly all the patients interviewed (95 %;
n = 451) were satisfied with their pharmacy and its setting
(n = 451). Also, 77 % of the pharmacists involved in methadone
dispensing had a positive opinion of their customers. Fears that
methadone patients would steal, use violence or harass not only
the pharmacist but also other customers had proved to be wrong
(Kalke, 1997b). So far, the Hamburg study on the dispensing of
methadone in pharmacies is the only one that has been conducted
in Germany. Except for Hamburg, where methadone dispensing
takes place in pharmacies in almost 100 % of cases, methadone is
usually dispensed on-site in GPs’ surgeries (90 %).
Needle exchange or purchase of new syringes is possible at all
drop-in centres, at most drug aid services and many AIDS support
agencies. Moreover, in major cities there are also vending
machines. Due to the wide range of these services, pharmacies
play only a minor role in needle exchange. In fact, pharmacies do
not exchange used needles for new ones. They sell insulin
syringes, but, as many pharmacies sell only packs containing 10
insulin syringes costing DEM 6–10 (EUR 3–5), they are less attract-
ive to drug users than other services.
Substances prescribed
Methadone is the substance most frequently prescribed in substi-
tution treatment. As described above, there is an estimated total
number of 45 000 methadone patients. In contrast to other coun-
tries, there are two forms of methadone available in Germany, the
racemic (13) mixture (d,l-methadone), which has only been avail-
able since 1 February 1994, and levomethadone (l-methadone or
purified methadone known as polamidon). Table 4 provides data
on the quantities of methadone and levomethadone ordered by
pharmacies between 1989 and 1996. In line with the increasing
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(13) Racemic refers to a mixture of different isomeric forms of the same substance. Racemates
are different optically active forms of a molecule that are either turning to the left or right.
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numbers of methadone patients (Table 2), there was a correspon-
ding increase in consumption quantities. According to the regula-
tions on the prescription of narcotics, the maximum dosage of
methadone to be prescribed over a period of 30 days is 3 000 mg
of d,l-methadone or 1 500 mg of l-methadone respectively. This
suggests an average maximum daily dosage of 100 mg of racemic
methadone in maintenance. The maximum quantities may only be
exceeded if medically necessary. However, some patients are
receiving more than 300 mg daily (Ullmann, 1999).
Apart from maintenance treatment, methadone is also used during
detoxification in qualified detoxification units. The doses are grad-
ually reduced over a period of one to three weeks. Detoxification
is accompanied by psychological and social-care provision.
Since February 1998, codeine or dihydrocodeine can only be pre-
scribed to those patients who cannot be treated with methadone
(i.e. patients who physically cannot tolerate methadone).
However, these are interim regulations for codeine treatment
which, in effect, leave the former regulations in place (patients
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TABLE 4: QUANTITIES (KILOGRAMS) OF RACEMIC METHADONE,
LEVOMETHADONE AND CODEINE 
ORDERED BY PHARMACIES IN GERMANY (1989–96)
YEAR RACEMIC LEVO- TOTAL CODEINE/
METHADONE (1) METHADONE QUANTITY OF DIHYDRO-
METHADONE CODEINE
PER YEAR
1989 — 10 10 —
1990 — 20 20 38
1991 — 36 36 242
1992 — 70 70 1 061
1993 — 107 107 2 616
1994 174 133 307 4 014
1995 353 129 482 6 020
1996 419 140 559 5 631
(1) Approved as a Schedule 3 substance on 1 February 1994 (available on the German pharmaceutical market
since that date).
Source: Schinkel (1998).
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need not be switched to MMT). As mentioned above, these provi-
sional regulations were extended until 1 January 2000. This situa-
tion has caused considerable uncertainty among many codeine
prescribers and their patients. There are no studies yet on the con-
sequences of this development, but experiences reported from
Frankfurt show that there were ‘panic reactions by single physi-
cians who terminated codeine treatment from one day to the other,
despite the provisional regulations ... Some of their patients were
located on the streets where they bought black market codeine
and/or methadone, others switched back to heroin ... Other
patients were immediately switched to methadone by their physi-
cians, regardless of their non-tolerance of methadone. These
patients also switched to black market codeine and/or heroin and
no longer showed up at their GPs’ (Weber, 1998b).
The maximum daily dosage of 1 000 mg of codeine in main-
tenance may be exceeded if medically necessary. There are
patients receiving more than 2 000 mg daily. As is the case with
methadone patients, doses may vary considerably between indi-
vidual codeine patients. Table 4 above presents data on the quan-
tities of codeine/dihydrocodeine ordered by pharmacies between
1990 and 1996.
Naltrexone, an opioid antagonist that hinders, or drastically
decreases, the effect of opiates taken, is also used in substitution
treatment, but only on a small scale. There are no estimates avail-
able on the number of naltrexone patients.
A heroin trial is scheduled to be initiated in Germany in 2001.
Buprenorphine has now been approved by the Federal Institute for
Drugs and Medical Devices. Data are not yet available on the use
of buprenorphine.
LAAM was first used within the setting of a controlled, randomised
multi-centre study in 1998 (Finkbeiner, 1999). The overall results
have not yet been published. It is expected that LAAM will be
more widely used in the future.
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Injectable prescribing
By law, substitute substances cannot be prescribed in injectable
forms.
Surveillance
No data provided.
Problems
Methadone-related deaths and diversion
In 1998, a few cases of iatrogenic methadone deaths (i.e. deaths
caused by the doctor) were reported for the first time in the early
days of MMT. Servais and Erkens (1998) investigated six cases of
methadone-related death in which the initial dose of methadone
was too high (overdoses). Two patients, who died on the first day
of treatment, were prescribed 100 mg of racemic methadone.
Another patient, who was given 75 mg on the first and second
days, died on the second day. Three deaths occurred with 
l-methadone: two patients who were prescribed initial doses of
35–40 mg died on the first day; in the third case, the doses were
increased over three days (30 mg the first day, 35 mg the second,
and 50 mg on the third day). The doctors in charge of these cases
had started treatment with initial doses recommended for racemic
methadone, probably not knowing that l-methadone is twice as
strong as racemic methadone. In another three deaths, methadone
had been prescribed to non-opioid-tolerant patients.
According to the Federal Bureau of Criminal Investigation,
methadone was detected in 240 of a total of 1 674 drug-related
fatalities in 1998 (compared with 100 in 1997). It remains unclear
how many of these deaths can be attributed to methadone and
how many of the deceased were enrolled in MMT. Methadone
was detected, often together with cocaine (‘cocktail fatalities’), in
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approximately 25 % of all 1998 deaths registered in Berlin and
Stuttgart.
Schmoldt et al. (1999) investigated 78 of the total number of 132
drug-related fatalities in Hamburg in 1998. Methadone was
detected in the blood in 46 of the 78 deaths investigated. No her-
oin was detected in the blood of 38 dead persons, which led the
authors to the conclusion that these cases were ‘methadone fatal-
ities’. The study findings have to be looked at with caution, since
no data are provided on the extent of collateral use of cocaine,
benzodiazepines or alcohol. Furthermore, the question arises as to
whether it is appropriate to infer a lethal effect from methadone
levels in the blood. In an earlier paper, the same team of investi-
gators reported that the highest methadone blood levels were
found in non-fatalities (Heinemann et al., 1998). Moreover, the
majority of ‘methadone deaths’ occurred with individuals not
enrolled in MMT.
Several experts have already voiced the opinion that an apparent
increase in diversion to the black market is due to the latest
change in take-home regulations (before February 1998, take-
home doses for up to three days were possible after one year of
participation in treatment; since February 1998, take-home doses
for up to seven days are possible after six months of compliant
behaviour in treatment). Even if these experts are right, this says
less about the take-home regulations and more about lax pre-
scribing practices of the doctors in charge of treatment. The
demand for black market methadone also clearly demonstrates
that the admission criteria regarding MMT are still too rigid, leav-
ing many drug users either untreated or treating themselves with
(black market) methadone.
Evaluation
Methadone treatment has been comprehensively evaluated in
Germany. On account of different methodological approaches,
different evaluation periods and different sample sizes and sample
populations, the research results are only partially comparable.
Project-specific findings are not provided here. However, the
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following important common aspects regarding the overall results
— despite the heterogeneity mentioned above — can be pre-
sented (Poehlke et al., 1997).
• The average age of methadone patients is above 30 years. The
duration of heroin use before starting MMT is between 10 and
12 years on average.
• More than two thirds of the patients had received treatment in
inpatient, drug-free therapeutic communities (usually several
attempts at treatment) prior to MMT but could seldom stay in
treatment as long as expected. One third of the few who left reg-
ular therapy relapsed into heroin use.
• Methadone treatment shows considerably higher retention 
rates than therapeutic communities (around 65 % of clients
leave therapeutic communities within the first four months of
treatment).
• Even during the initial phase of treatment, there is a remarkable
improvement in the general health status of methadone patients.
The health status of patients infected with HIV or hepatitis also
stabilises in the course of treatment. HIV seroconversion rates
are well below 1 % during MMT.
• The risk of mortality is drastically reduced. The survival rate of
methadone patients is three to five times higher than untreated
heroin users.
• There is also a reduction in the use of illegal drugs. The decline
in illegal use of opioids comes about in a linear way: final ces-
sation is dependent on the duration of participation in treatment.
After one year in MMT, positive urinalysis ceases with 80–90 %
of methadone patients. With increasing length of time in treat-
ment, there is also a decline in, or termination of, the collateral
use of other psychotropic substances.
• About 10 % of treatment participants become totally abstinent
(including from methadone). At present, no follow-up studies are
available on the stability of abstinence. However, experiences so
far demonstrate that methadone treatment (detoxification or
maintenance-to-abstinence) which is limited in time usually
results in a relapse into illegal opioid use and physical as well as
psychological instability.
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There has been very little research regarding codeine or di-
hydrocodeine treatment. The main reason for this is that project
funding usually comes from the State. The conservative govern-
ment which was in power for 16 years, until 1998, was very reluc-
tant to promote maintenance therapy, and codeine/
dihydrocodeine treatment would have been regarded even less
favourably, as it had always been considered as a loophole in nar-
cotics regulations or as ‘grey substitution’ (where codeine patients
did not have to be notified to the local health authorities and
psychosocial care was not mandatory), ‘with the connotation of
being at best semi-professional and semi-legal’ (Weber, 1998b).
Only one important study on the effectiveness of codeine/
dihydrocodeine treatment has been undertaken, the results of
which suggest that the outcomes of treatment with codeine 
can be favourably compared to methadone (Degwitz et al., 1996;
Krausz et al., 1998). This means that codeine- or dihydrocodeine-
substitution treatment should be further investigated in clinical
and controlled trials.
There has been a remarkable lack of qualitative research on the
subjective views of patients participating in substitution treatment
(one exception was a study by Gerlach and Schneider, 1994). The
attitudes and views of participants in treatment should be carefully
studied, because it can be assumed that orienting treatment
philosophies, policies and settings towards patients’ needs might
result in more successful outcomes.
Information in this chapter was updated by the EMCDDA.
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GREECE
Athanassios Douzenis, OKANA, Athens
Introduction
Greece was late in introducing substitution treatment for opiate
addiction for historical reasons. From the 1960s, the treatment of
addictions was considered unimportant, since opiate addiction
was viewed as a small problem that did not present a serious threat
to society. As the number of opiate addicts increased, therapeutic
communities, which had been specifically set up for addiction
treatment, emerged as the main treatment option. Heavy empha-
sis was placed on abstinence, which, in turn, influenced public
opinion. As a result, abstinence-oriented treatment was consid-
ered the only option that could deal successfully with addiction.
In recent years, the number of addicted individuals has increased.
Addiction and its treatment have attracted enormous publicity and
media exposure. Recent research shows that the majority of
people consider drug addiction to be the biggest single social
problem in Greece. The HIV epidemic intensified public fears. It
became obvious that the treatment offered by the therapeutic
communities did not attract the ‘heavy injecting heroin users’,
who refused to enter this type of treatment.
Substitution treatment became possible in July 1993 when a law
(2161/93) regulating the use of psychoactive substances was
passed unanimously by the Greek Parliament. Until then,
methadone treatment, or possession of methadone, was illegal in
Greece and incurred severe penalties. The same law established
the national organisation against drugs, OKANA, a self-regulated,
legal entity which comes under the jurisdiction of the Ministry of
Health and Welfare.
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In particular, the goals of OKANA are as follows:
• to plan, promote and effect interministerial coordination and
implementation of national policy concerning the primary, sec-
ondary and tertiary prevention of drug dependence;
• to undertake scientific research into the drug problem at nation-
al level, provide valid and reliable information and educate the
public; and
• to establish and operate effectively the community drug-prevention
centres, treatment units, vocational training centres and socio-
professional rehabilitation programmes.
Strategy
In the field of primary prevention, OKANA intervenes in two ways.
First, the organisation  implemented a three-year plan of action
(1997–99) which aimed:
• to establish 83 community drug-prevention centres at the pre-
fectural level (26 centres planned for the Sanitary Prefecture of
Attika — the region in which Athens is situated — and 57 for
health districts outside Greater Athens; 36 of these centres have
already been established, on a three-year contract, with the
financial support of OKANA);
• to offer scientific support, and provide and update educational
material; and
• to carry out scientific and financial supervision of the primary-
prevention activities implemented in the community by desig-
nated prevention agents.
Second, OKANA has established a training centre for the preven-
tion of drug use and the promotion of health with the cooperation
of the University Mental Health Research Institute (UMHRI) in
Athens, the Greek focal point in the EMCDDA’s Reitox network.
The objectives of this collaboration are:
• to train prevention agents from the local authorities who will
implement prevention programmes under the supervision of
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OKANA (130 health professionals have already been trained);
and
• to produce educational materials which will be put at the dis-
posal of the community drug-prevention centres (Standing on
my own two feet has already been published for secondary
education teachers and Communication within the family for
parents).
Also in the field of primary prevention, OKANA cooperates with
the following government ministries, both to deal with the prob-
lem and to coordinate activities more effectively:
• the Ministry of National Education and Religion, for planning
and implementing training programmes for teachers and pro-
ducing educational materials;
• the Ministry of National Defence, in order to address use-related
problems and self-destructive behaviours in general in the
armed forces;
• the Ministry of Public Order, for training police officers in
primary-prevention interventions;
• the Ministry of Merchant Marine, for training harbour police
officers;
• the Ministry of Justice, in the running of a therapeutic centre for
drug-addicted prisoners; and
• the Ministry of Culture, supporting the cultural and sports events
which are part of the prevention activities.
Substitution
Development of substitution services
In the field of secondary prevention, OKANA developed two pilot
therapeutic programmes, in Athens and Thessaloniki, in January
1996. The substitution-treatment unit in Athens caters for 200
clients and the substitution-treatment unit in Thessaloniki (the sec-
ond largest city in Greece) caters for another 100 clients. Neither
unit offers maintenance treatment, as their orientation is towards
abstinence.
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The aims of the Greek substitution programmes are:
• harm reduction;
• intensive treatment with psychosocial and medical supports;
and
• abstinence.
The opening of these units received much publicity and attracted
a vast number of applications from injecting heroin users. In order
for a client to receive methadone, he/she has to abstain from
opiates, cocaine and benzodiazepines. The clients receive
methadone in liquid form under the supervision of a nurse. Urine
samples are collected under supervision and every client of the
unit gives a urine sample at least once a week. Psychotherapy of
a supportive nature is offered.
The aim of every treatment unit is to meet the needs of its clients
and treat them in the most comprehensive way. The treatment
offered is multidisciplinary. The full-time staff consists of three psy-
chiatrists, one pharmacist, one pathologist, five social workers,
four psychologists, five nurses and nine administrative members of
staff (secretaries, guards, cleaners and a computer programmer).
The psychiatrists in the team prescribe any psychiatric medication
deemed necessary and take special account of the dual diagnosis
clients. Physical problems are dealt with by the resident pathol-
ogist, who prescribes accordingly or refers the patient to another
hospital. Clients have to attend weekly meetings with their key
worker, who is either a social worker, psychologist, nurse or psy-
chiatrist. The clients also attend group-therapy meetings and
relapse-prevention groups. Clients who continue to use illegal
substances are given a formal warning. If they ignore this warning,
they are detoxified from the methadone.
On the basis of the recommendations of an external evaluation,
OKANA decided to underline the abstinence orientation of the
substitution programmes in Greece by setting a time limit of two
years for clients to receive methadone. If clients do not achieve
detoxification from methadone within these two years, they are
put on slow compulsory detoxification that can last for up to six
months.
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Current situation
In February 1997, a team of external experts evaluated the pro-
grammes. This evaluation committee consisted of a professor of
psychiatry, a professor of criminology and the Greek coordinator
to the EU for combating drugs. The evaluation committee’s con-
clusions were so positive that OKANA decided to establish two
more substitution (methadone) units (also in Athens and
Thessaloniki). Overall, the four therapeutic programmes offer 650
places, 400 in Athens and 250 in Thessaloniki. In June 2000, a
new unit for long-term methadone (maintenance) treatment start-
ed in Athens with a capacity for 200 clients. The unit plans to raise
its numbers to 600 by the end of 2001.
Following the opening of the new substitution units, OKANA was
inundated with applications for treatment from heroin users. In
2000, there have been 3 000 applications for treatment in Athens.
So far, only 1 120 of these clients have been invited to participate
in the programme and 980 have received methadone. In
Thessaloniki, there have been 980 applications and, of these, 560
have been invited to participate; 420 have received methadone.
Clearly, the demand for treatment is enormous. OKANA and the
units themselves are subject to considerable pressure to accept
clients who are obviously in great need.
Substitution clients
All opiate users are encouraged to apply for methadone treatment
in Greece, but, because of the great demand and the limited num-
ber of places available, the units are unable to offer treatment to
all applicants. Some reasons for not availing of the programme
when a place is offered are as follows:
• some clients are not in the country when they are called;
• others have been sent to prison; and
• a small, yet important, minority die before they are called.
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Clients must fulfil the following criteria to enter the methadone
programme:
• must be at least 22 years of age;
• must be using heroin daily;
• must have previously attempted a therapeutic programme
(unsuccessfully); and
• must show no evidence of any psychopathology that would
make treatment in an open unit impossible (i.e. overtly violent
or criminal behaviour).
Almost all of the applicants fulfil these criteria.
At present, the substitution units operate a waiting list. Applicants
who fulfil the abovementioned criteria are accepted on a first-
come, first-served basis. As a result, they usually have to wait for
two or more years to enter the programme. OKANA only accepts
applicants for immediate treatment if they are:
• HIV positive;
• suffering from metastatic cancer or gangrene (threatening imme-
diate loss of a limb) or bacterial endocarditis;
• pregnant injecting heroin users who have completed the first
trimester of pregnancy; or
• related to a client receiving methadone or married to a patient
in the methadone unit (if living together).
Pharmacy activity
In Greece, methadone is dispensed legally only in the substitution
units of OKANA. Pharmacies are not permitted to dispense
methadone.
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Primary-care involvement
In Greece, primary care is not involved in the substitution treat-
ment of opiate-addicted individuals. General practitioners (GPs)
are not allowed to prescribe methadone.
Substances prescribed
OKANA is planning to introduce the use of LAAM and bupren-
orphine in the substitution-treatment units. This will involve some
changes in the legal classification of these drugs, which is proving
cumbersome. However, these substances are expected to become
available for use in the substitution-treatment units in 2001.
OKANA also uses the opioid antagonist naltrexone in its substitu-
tion programmes for clients who have successfully completed
withdrawal from methadone. Naltrexone is believed to enhance
the client’s chances of remaining opiate free. It is also used for
clients who have applied for substitution treatment but have not
yet entered the programme because of the long waiting list.
Occasionally, clients who have managed to stop using opiates —
by their own efforts — request help and support from the units.
These clients are offered naltrexone and psychological support.
At the end of the programme, clients are required to attend
OKANA’s rehabilitation unit for up to another year. The aim of this
unit is to ease the client’s social reintegration and continue
psychotherapy.
Injectable prescribing
Injectable prescribing is illegal in Greece.
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Surveillance
The amount of methadone given to patients is strictly controlled
by the Greek State (the Greek ‘monopoly of substances’). Every
three months, each unit submits detailed records of methadone
dispensed. They also submit similar records to OKANA about the
naltrexone used.
OKANA’s substitution programmes are evaluated externally by an
evaluation committee. Internal checks are provided by specialists
in the field of psychotherapy and addiction who do not work in
the substitution units. OKANA seeks the committee’s opinion at
every stage of service development.
Problems
The main problem that the substitution units face on a daily basis
is the overwhelming demand for treatment. Drug users come into
the units asking for treatment, and staff (and OKANA) have to deal
with their frustration and anger when they are told that there is a
waiting list.
Problems arising from clients demanding to continue receiving
methadone indefinitely are fairly recent. The demand for
methadone-maintenance programmes is gaining momentum.
Problems can also arise because of the differences in therapeutic
approach between the various treatment units. This has been
addressed by developing a set of common rules for all units and
by trying to improve the services offered in the units.
Evaluation
OKANA aims in the next three years to set up a system that will
identify gaps in information in order to support and provide the
various treatments it oversees. It has recently set up a research and
evaluation department. Information on the evaluation of the sub-
stitution programmes is expected to be published in 2001.
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SPAIN
Marta Torrens, Hospital del Mar, 
Instituto Municipal de Investigación Médica, Barcelona
Introduction
General health services in Spain are financed by the Ministry of
Health and are free to everyone. They include hospital stays, out-
patient services and medication, which are free in hospitals and
partially paid (60 %) in outpatient treatment clinics. Drug-related
treatment is also covered, including hospitalisation and medica-
tion related to HIV infection. The Constitution of 1978 divided
Spain into 17 ‘autonomous communities’ and two ‘autonomous
cities’. Each of these may develop its own policy on health to vary-
ing degrees. In some autonomous communities, health provision
falls directly under the Sistema Nacional de Salud (National
Health Service), while, in others (such as Catalonia and the
Basque Country), it falls under the administration of their own
autonomous health service. Some of these autonomous adminis-
trations contract private clinics and other services for public use.
The Ministry of Social Services finances the social services in
Spain, but, in some autonomous communities, these services also
depend on the autonomous administration departments, which
constitute a different network of health services. Links between
health and social services are maintained through individual pro-
fessionals working in both networks. In general, health services
have social workers who liaise with social services. Furthermore,
health and social services are provided by the private sector,
although these represent less than 15 % of all services.
Strategy
Due to major political changes in Spain in the 1970s, illicit drug
problems appear to have arrived later than in other west European
countries. Serious concerns in this area do not seem to have
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developed until the late 1970s, when there was a marked increase
in intravenous heroin consumption. In response to this growing
drug problem, a number of services were developed in the large
cities, but there was little overall integration between general pub-
lic health services and services which had developed in response
to drug-abuse problems.
In 1985, the Plan Nacional sobre Drogas (National Plan on Drugs
— the Spanish focal point in the Reitox network) was established,
with the aim of developing a network of services. Various institu-
tions, including the Ministries of Health, Justice and Education,
autonomous administrations (through their own plan on drugs)
and non-governmental organisations (NGOs) developed the plan.
More than 90 % of all services for drug addicts were developed
after 1986. Autonomous plans on drugs were developed by the
autonomous administrations to facilitate the provision of resources
to address drug addiction in every region. Some large cities, such
as Madrid and Barcelona, developed their own local plan on
drugs.
The majority of drug services fall under the public health sector
and are either organised through the public health system or by
non-profit-making NGOs. Probably less than 1 % are in the
private sector. These services are funded through the health ser-
vice and/or through the autonomous or local plan on drugs which
contracts the individual providers. Each autonomous plan has its
own priorities in planning and financing drug resources, accord-
ing to the situation in different regions of the country regarding
drug use. In most autonomous communities, new services provid-
ed for drug addicts were found to generate a parallel network for
addiction-related problems. In a few autonomous communities,
addiction problems were treated by the mental health services.
From 1990, in response to the HIV epidemic, a variety of harm-
reduction strategies, including substitution treatments and needle-
exchange programmes, were gradually implemented. These var-
ied in timing and extent between communities. As described
below, extensive substitution treatments have been developed
over recent years. At the end of 1996, the number of patients
admitted to methadone-treatment programmes accounted for
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27 % of the total number of admissions to the various drug-
treatment services (Figure 1).
Substitution
Development of substitution services
The history of substitution services in Spain is linked to changes in
legislation regarding the use of opioids. The heroin epidemic
began in Spain in the late 1970s and, at that time, opioid-
maintenance treatment was only available for pain relief in termi-
nally ill patients. Later, in 1983, legislation approved the use of
methadone in the treatment of opioid dependence, and it then
became possible to obtain methadone prescription both in the
public and private sector. Methadone was also dispensed in phar-
macies. At that time, about 5 000 patients were in methadone
treatment. However, the majority of prescribing by doctors was
located within the private sector and concern was expressed that,
in some cases, this was for personal gain.
In response to this situation, subsequent legislation in 1985 in the
form of the Orden Ministerial 1985 (Ministerial Order 1985)
restricted the prescription of methadone within the private sector.
This new legislation decreed that methadone treatment had to be
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FIGURE 1: NUMBER OF PATIENTS IN THE VARIOUS 
DRUG-TREATMENT SERVICES IN SPAIN (1998)
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prescribed by doctors working in the public sector, in specially
licensed centres (prescribing centres). The doctors were required
to propose patients for methadone treatment to an ‘autonomous
commission’ which constituted representatives of the autonomous
and national administrations. This commission assessed every new
case. Once approved, the subject had to receive methadone in a
centre designated for the administration of methadone only (a dis-
pensing centre) run by the relevant autonomous administration.
The results of this legislation were a highly restrictive policy
towards the prescription of methadone over a long period of time
(only about 1 000 patients were registered in 1986 and 1987).
However, because the HIV epidemic hit drug addicts in Spain so
hard (Figure 2), and because of the growing evidence that harm-
reduction strategies were effective in decreasing both the spread
and morbidity of HIV infection, changes were brought about in the
national drug strategy.
Legislation in 1990 in the form of Real Decreto 75/1990 (Royal
Decree 75/1990) substantially modified the regulations governing
opioid-maintenance programmes. The new law made it easier for
patients to be admitted to methadone-treatment programmes.
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2 033 (65.7 %)
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3 902 (63.8 %)
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Source: National register of cases of AIDS (31 March 1998).
FIGURE 2: NUMBER OF CASES OF AIDS AMONG INJECTING 
DRUG USERS IN SPAIN ACCORDING TO YEAR OF DIAGNOSIS
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Criteria for admission included a diagnosis of opioid dependence
and the fact that patients must have tried and failed on at least one
other previous intervention. Exceptions were made if patients were
pregnant or if there was evidence of HIV infection or serious sys-
temic disease. In these instances, treatment could be automatically
initiated by doctors working in autonomous commission centres
licensed for prescribing and dispensing methadone. All the
licensed centres had to be public facilities or run by non-profit-
making organisations. Under this new legislation, the number of
patients in methadone maintenance increased significantly 
(Figure 3). National and autonomous plans for drugs encouraged
provision of methadone programmes in most of the country and
many centres for drug addicts included methadone among the
treatment options.
Although this new law was much more permissive, the long wait-
ing lists demanded another change in the legislation in 1996 in 
the form of Real Decreto 5/1996 (Royal Decree 5/1996) 
making admission to methadone-treatment programmes easier. 
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A diagnosis of opioid dependence was now the only requirement
for enrolment. In addition, autonomous administrations could
license private doctors and pharmacies to prescribe and dispense
methadone, respectively.
Current situation
Methadone is currently available in every Spanish autonomous
community, although the distribution of centres and their organ-
isation are somewhat different in each community. In some com-
munities, both methadone prescribing and dispensing are carried
out at the same centre, whereas in other communities these activ-
ities are allocated to different centres or sometimes even to differ-
ent networks (from specific drug-addiction to general health net-
works). At the end of 1997, a total of 631 independent centres
were offering methadone treatment throughout the country:
• 44 % were of the ‘prescribing and dispensing’ type;
• 40 % were ‘dispensing only’; and
• 16 % were ‘prescribing only’.
Prescribing and dispensing centres were those offering a variety of
treatment, including methadone provision (i.e. dosage, treatment
duration, urinalysis, counselling, dispensing). Prescribing-only
centres were those offering most of the aforementioned facilities
except dispensing. Dispensing-only centres were those which
were exclusively involved in providing the patients’ daily dose of
methadone.
At present, most prescribing-only and prescribing and dispensing
centres are located in specific addiction services where other
treatment modalities for drug addiction are also offered (i.e. nal-
trexone, drug-free programmes, detoxification, etc.). The majority
of dispensing-only centres are located in primary healthcare ser-
vices. Mental health centres also have some involvement. Current
figures regarding the involvement of the private sector are unavail-
able, but, in general, there are few institutions involved (in
Catalonia, only 3 % of methadone-related activities are found in
the private sector).
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Most of the centres (83 %) are totally or partially financed by the
relevant autonomous community administration. They are gener-
ally managed at the autonomous administration level, although
about 13 % are run by non-governmental organisations (mainly
the Red Cross).
In prescribing-only and prescribing and dispensing centres, the
ratio of staff to client is around 1:58. Treatment with methadone
accounts for 40 % of all the treatment places for drug addicts.
Nevertheless, at the end of 1997, in 33 % of centres there was still
a waiting list for inclusion on a methadone programme, with a
mean waiting time of 60 days.
There is a facility for patients in methadone maintenance to move
around within Spain. Arrangements have to be made by the
patient’s original centre with the centre the patient will be moving
to next, and this is usually done very easily. Contact has to be
made by phone or fax, and specific data have to be supplied,
including the following:
• patient’s name;
• methadone dosage;
• take-home privileges; and
• length of time to be spent in the new location.
A list of the centres is provided by both the National Plan on Drugs
and the autonomous plans on drugs. Subjects with special
circumstances, such as those who are hospitalised for medical ill-
ness or committed to prison, are able to continue methadone
treatment.
From the time when methadone-treatment programmes were first
available up to 31 December 1997, a total of 87 828 patients had
received substitution treatment. At the end of 1997, there were 
51 000 patients on methadone, most of them men (83 %), and the
mean age was 29 years. Positivity to HIV was found in 43 % of
cases, to hepatitis B virus in 63 % and to hepatitis C virus in 68 %.
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Legislation on substitution treatment
Since 1996, only a definitive diagnosis of opioid dependence is
required for enrolment on a methadone-treatment programme.
There are no restrictions on dosage nor on duration of treatment.
Each autonomous regulatory authority, through its plan on drugs,
authorises specialised centres, private doctors and pharmacies to
be involved in methadone-treatment programmes. Services are
required to report to the autonomous authority when an individual
enters and leaves the programme. This information is collated into
a national report of the Sistema Estatal de Información en
Toxicomanías (SEIT — State System of Information on Drug
Addiction). This information-gathering system covers any form of
drug prescribing and is not specifically methadone-related,
although methadone is by far the most commonly used drug for
substitution.
There are no published national or autonomous guidelines for
methadone services. Also, there is no specific legislation about
urine controls and take-home regulations.
The National Plan on Drugs supported two national studies on
methadone practices in Spain which were conducted in 1994 and
1997.
Substitution clients
Under current legislation, Spanish drug policy on treatment with
opioid agonists is not restrictive, and diagnosis of opioid depend-
ence is the only criterion for entry to a methadone-treatment pro-
gramme. However, when the specific policy of different centres
was assessed, it was found that pregnancy, diagnosis of AIDS and
other severe physical illnesses were the most important criteria for
enrolment, whereas absence of HIV infection or a patient’s self-
request were less frequently considered. Most of the centres con-
sidered that violence or drug use and trafficking in the centre were
sufficient reason for the patient to be discharged from the pro-
gramme. In 5 % of the centres, the provision of methadone is only
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abstinence oriented, in 17 % provision is not abstinence oriented
and in 78 % both approaches are offered.
General medical care is almost universally offered in methadone-
treatment programmes, although in more than 50 % of the centres
these services are provided at a different institution. This care
would include:
• physical examination;
• laboratory tests;
• diagnosis of HIV, hepatitis B and C virus infection;
• detection, prophylactic and treatment of tuberculosis;
• diagnosis of sexually transmitted diseases; and
• pregnancy tests.
Patients are usually referred to primary-care physicians for an ini-
tial evaluation. Mental healthcare (pharmacological treatment,
counselling, psychopathological assessment, individual and group
psychotherapy) and social services (liaison with legal and labour
resources) are provided in the same centre, in most cases.
Sixty-five per cent of the centres use urinalysis to detect illegal use
of drugs, mainly heroin (in 99 % of the centres) and cocaine (in
93 % of the centres). Urine screening is generally performed under
direct supervision, between once and four times a month.
Pharmacy activity
New regulations on substitution treatment in 1996 permitted phar-
macies to be involved in dispensing methadone, but only a few
currently do so. In these instances, public drug-addiction centres
prescribe the methadone and the autonomous administration pays
the pharmacy for every patient receiving methadone (very few
pharmacies are involved in administering methadone prescribed
by private doctors). More pharmacies are involved in needle-
exchange programmes, particularly in the Basque Country.
In 1998, the Programa Nacional para Prevención del SIDA y
Dispensación de Metadona en Farmacias (National Programme
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for AIDS Prevention and Methadone Dispensing in Pharmacies)
was promoted by the Delegación del Gobierno para el Plan
Nacional sobre Drogas (State Office for the National Plan on
Drugs), the Plan Nacional del SIDA (National Plan on AIDS) and
the Consejo General de Colegios Oficiales de Farmacéuticos
(General Council of Official Colleges of Pharmacies). The aim is
to stimulate the implementation of needle-exchange programmes
and methadone dispensing in pharmacies.
Primary-care involvement
In general, primary-care centres have very little involvement in
methadone-treatment programmes. Most patients are treated in
specific drug-treatment centres. The one exception is Andalusia (in
the south of Spain), where most methadone is provided in the pri-
mary healthcare setting (such as dispensing centres). In some com-
munities, such as Catalonia, some primary-care centres are
involved in needle dispensation and/or needle-exchange
programmes.
Substances prescribed
At present, methadone is by far the most frequently prescribed
drug for maintenance treatment. LAAM is not available in Spain.
Buprenorphine is marketed as a very small dose (tablets of 0.2 mg)
and, in general, is not used for maintenance treatment.
Methadone is more often administered as an oral solution (syrup)
or in tablet form. Most centres (91 %) do not use the maximum
dose of methadone and, in 78 % of the centres, the mean daily
dose of methadone was ‡ 60 mg (mean dose measured against
number of patients/centre was 69 mg/day). Methadone is dispensed
every day under direct supervision. Take-home treatment is also
provided by all centres.
One autonomous community (Andalusia) is currently planning
experimental substitution treatment with heroin. Some experimental
clinical trials with buprenorphine have also been performed. A
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national study of LAAM, commissioned by the National Plan on
Drugs, is also under discussion.
Injectable prescribing
Although the legislation only recommends the use of oral
methadone, other forms of administration are not forbidden. At
present, however, there is no injectable prescribing of opioids for
maintenance.
Surveillance
National data on drug-related problems in Spain are regularly pub-
lished in the Memoria anual del Plan Nacional sobre Drogas
(Annual report of the National Plan on Drugs), in the SEIT reports
and, recently, in the reports of the Observatorio Español sobre
Drogas (Spanish Observatory on Drugs). Also, autonomous plans on
drugs regularly publish their own reports on drug-related matters.
Recent data regarding the drug-use situation in Spain are available
from different sources, including the following surveys:
• encuesta domiciliaria sobre drogas 1997 (1997 survey on the
use of drugs among the general population);
• encuesta sobre drogas en la población escolar 1996 (1996 sur-
vey on the use of drugs among the school population);
• encuesta a consumidores de heroína en tratamiento de 1996–97
(1996–97 survey of heroin addicts in treatment); and
• encuesta domiciliaria sobre consumo de drogas 1999 (1999 sur-
vey on the use of drugs among the general population).
The following treatment indicators were reported on by the SEIT:
• start of new treatments for opioid or cocaine abuse in outpatient
centres for drug addiction;
• emergencies related to heroin and/or cocaine use; and
• mortality related to heroin and/or cocaine acute reaction (over-
dose).
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Other studies are available in the field of drug addiction, such as
on the following:
• characteristics of patients in methadone-maintenance treatment
in Spain (1997 study);
• confiscations of illicit drugs (opiates, cocaine, cannabis, crack,
LSD, ecstasy, speed);
• number of arrests due to drug trafficking;
• number of fines for drug consumption;
• level of distribution of alcoholic beverages;
• analysis of the usefulness of alternative treatments to imprison-
ment; and
• number of juridical processes due to drug trafficking.
Figures on the use of services and trends in service utilisation for
inpatient, residential and community or ambulatory services,
according to the 1997 Annual report of the National Plan on
Drugs, are shown in Figure 1 above.
Problems
Outpatient centres are generally well accepted by their local
neighbourhood (mean of 7 on a scale of 0–10), although dispens-
ing centres rated lower than other types of centres (mean 5.7).
It is estimated that around 30–50 % of prisoners are drug addicts.
The 1990 law included a paragraph on methadone use in prisons
and, in August 1997, all the prisons except two had already devel-
oped methadone-maintenance programmes. Data of August 1997
showed that 11 605 (27 %) prisoners were enrolled in methadone
treatment. Most cases (86 %) were men, with a mean age of 29
years. Seropositivity to HIV infection was found in 66 % of the
cases, to hepatitis B virus infection in 79 % and to hepatitis C in
70 %. Most subjects (84 %) received a daily dose of ‡ 60 mg of
methadone. Methadone-maintenance programmes were not absti-
nence oriented; they prescribed a mean dose of ‡ 60 mg/day and
there was no time limit on treatment. In most centres, when treat-
ment for tuberculosis was indicated, antituberculous agents were
administered together with methadone. When subjects are
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discharged from prison, they are referred by the prison to continue
methadone maintenance in an outpatient centre.
Evaluation
The National Plan on Drugs promoted two studies (in 1994 and
1997) on the characteristics of current methadone-treatment pro-
grammes in Spain. Moreover, other studies on factors influencing
retention rates in methadone-maintenance programmes, such as
health-related quality of life and usefulness of plasma levels of
methadone in clinical practice, have been carried out. Evaluation
studies of methadone-treatment programmes are currently under
way in some autonomous communities (e.g. Andalusia), as well as
cost-efficiency studies of different levels of healthcare methadone-
maintenance programmes.
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FRANCE
Marc Auriacombe, Université Victor Segalen, Bordeaux II
Introduction
France holds an original stand regarding substitution treatment for
opiate-dependent subjects. Until 1994, less than 1 000 subjects
were considered for treatment by specific substitution treatments,
mainly involving methadone. At the start of 1999, it was estimated
that a realistic minimum of 60 000 such subjects might have been
receiving treatment. The total population of opiate-dependent sub-
jects in France is estimated at between 150 000 and 300 000.
Hence, somewhere between 20 and 40 % of opiate-dependent
subjects in France might be under substitution treatment at any
given time. Also noteworthy is that the majority of these subjects
are under buprenorphine treatment and not methadone treatment,
as is the case in other European countries.
Until recently, most healthcare providers in the field of substance
abuse believed that the use of medication in general, and
especially of opiate agonists, was undesirable for helping drug-
dependent subjects achieve abstinence. Although this attitude is
still quite prevalent, it is changing.
Strategy
The healthcare system for treating substance abuse in France is
organised differently to the general French healthcare system. The
standard French healthcare system (Fielding and Lancry, 1993) is
organised on the basis that patients pay for medical services (con-
sultation, laboratory investigations, medications) and are reim-
bursed through a universal State medical insurance (social secur-
ity). The level of reimbursement can range from 40–60 % of
expenses. For a limited number of conditions considered chronic
and expensive (i.e. diabetes), or acutely expensive (i.e. myocardial
infarction), the State medical insurance will cover 100 % of the
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expenses. Patients may also pay voluntarily for private medical
insurance that will cover those expenses not reimbursed by the
State medical insurance. In the general healthcare system, treat-
ment providers (medical doctors, nurses, etc.) are paid according
to two modalities. In private practice (most of the office-based sys-
tem), healthcare providers are paid directly by patients. In the pub-
lic system (mostly inpatient and hospital-based), healthcare
providers are employed by the State and receive a salary.
The healthcare system for substance abuse is not paid for through
the universal State medical insurance. Instead, the State allocates
an annual budget for this which is paid directly to private organ-
isations that care for substance users. Consequently, treatment 
for substance abuse is considered to be free (providers are com-
pletely paid for by the State, so patients have nothing to pay,
directly or indirectly) and anonymous (potential patients do not
need to reveal their identity for the sake of reimbursement, as 
there is nothing to pay).
However, these obvious advantages have some drawbacks. One is
the fact that these organisations are entirely dependent on State
money, which makes the system extremely vulnerable. Another
drawback is that many State-approved substance-abuse healthcare
centres employ psychologists and social workers (less expensive)
but no medical doctors or nurses (more expensive). A conse-
quence of this has been a lack of interest in a medical approach to
substance-abuse problems and consequent neglect of the somatic
consequences of drug use such as infections (e.g. hepatitis and
AIDS). These problems are taken care of by the general healthcare
system, constituting hospital-based specialists and office-based
general practitioners (GPs). In some instances, the general health-
care system has encouraged the use of opiate agonists for the care
of heroin addicts. A consequence of this situation is a hiatus
between the two systems regarding the use of medication and opi-
ate agonists in the care of substance abusers. Opiate agonists are
only considered useful for the prevention of infectious complica-
tions resulting from intravenous drug use, whereas they are con-
sidered contraindicative in the treatment of substance (particularly
opiate) dependence. This results in an underuse of opiate agonists
in substance-abuse treatment programmes and, even when they
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are used, they are often not integrated into a comprehensive
substance-abuse treatment plan.
Since methadone was only available to the substance-abuse spe-
cialist, it has always been, and still is, little used — less than 50
subjects received methadone in 1993 and less than 5 000 in 1996,
for an estimated 150 000–300 000 opiate-dependent subjects
(Facy and Verron, 1989). This helped fuel the search for an opiate
agonist that could be used by practitioners other than psychiatrists
and substance-abuse specialists (i.e. mainly interns and GPs).
From 1988, buprenorphine was available in 0.2 mg tablets and it
has since been used in limited experimental substance-abuse
treatment programmes (Daulouède and Tignol, 1993; Carpentier,
1994).
Substitution
To date, four pharmacological agents are used for substitution
treatment in France:
• codeine;
• morphine sulphate;
• methadone; and
• buprenorphine.
However, only the last two are officially approved for such use.
Thus, the two main substitution agents currently used in France
are methadone and buprenorphine, but these fall under very dif-
ferent regulations. Methadone can only be used for treatment by
substance-abuse specialists and buprenorphine is primarily pre-
scribed by GPs. Since these two treatment possibilities are so dif-
ferent, from a regulatory and social perspective, they will be
described separately.
Methadone
Methadone treatment was introduced in France in 1972 as an
experimental drug. Of the four State drug-dependence treatment
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centres that were offered access to this then new treatment, only
two — located in Paris — accepted. Each centre was authorised to
treat a maximum of 50 patients at one time. Although the initial
report on the impact of methadone treatment, published in 1975
(Denicker et al., 1975), was encouraging, the status and access-
ibility of methadone treatment remained unchanged until 1993
(Ministère de la santé et de l’action humanitaire; Olié et al., 1991;
Laqueille, 1992).
In 1992, the Ministry of Health initiated some changes. State drug-
dependence treatment centres were encouraged to apply for
authorisation to offer methadone treatment (Ministère des affaires
sociales, 1992), and a request for approval of methadone as a
medication was filed through the Agence du médicament (the
French medication approval authority). Methadone was licensed
as a standard approved medication for the temporary treatment of
severe pharmacodependent subjects in 1995. Following this, the
original request procedure for access to methadone for State drug-
dependence treatment centres was dropped, and all medical doc-
tors working in such centres were authorised to prescribe
methadone to as many patients as necessary (Ministère des affaires
sociales, 1995). There are three restrictions on centres offering
methadone treatment:
• methadone must initially be administered within the treatment
centre;
• this centre must own a safe; and
• urine testing must also be carried out.
Another advance in treatment provision is that the general practi-
tioner who initiates methadone substitution can have the treat-
ment delivered in a community pharmacy. Once he decides that
the patient is stabilised, he can authorise any GP to continue the
initial prescription privileges for that patient.
Since 1995, the number of methadone treatments has increased
dramatically due to a change in regulations. The number of
patients treated was reported to be between 5 000 and 6 000 in
1998 in official documents from regulatory bodies (e.g.
Observatoire français des drogues et des toxicomanies, the French
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focal point in the EMCDDA’s Reitox network). However, by div-
iding the amount of methadone sold by the average daily dose 
(60 mg), the estimated number of subjects treated was 659 in 
early 1996, 1 862 at the end of 1996 and 2 345 at the end of 1997
(Lert et al., 1998). The estimate for 1999 was approximately 
6 000 methadone patients.
A nationwide survey of the first 5 000 such patients was attempted
by the Institut national de la santé et de la recherche médicale
(Inserm — the National Institute for Health and Medical Research).
In April 1998, a preliminary report was released (Facy, 1998)
which showed that 5 360 subjects had been admitted for treat-
ment since 1993. Of these:
• 3 963 had at least one follow-up report;
• 1 744 were in treatment for less than 12 months; and
• 659 had been in treatment for more than two years (and 155 of
these for more than three years).
This report stated that, overall, patients have a positive outcome
over time.
Buprenorphine
Since methadone treatment was so restricted, and State treatment
centres initially were not very eager to have such treatment
extended, substitution treatment evolved outside specialist drug
treatment. Buprenorphine began to be used in university-based,
research-oriented settings (Auriacombe et al., 1992, 1997;
Auriacombe and Tignol, 1997) and by individual GPs who were
concerned about the lack of availability of methadone treatment
and the reluctance of most specialists at the time to change such
availability (e.g. Carpentier et al., 1994; Mucchielli and Reisinger,
1997).
Hence buprenorphine, in its analgesic form, was trialled for sub-
stitution treatment of opiate-dependent subjects. Since the initial
results were encouraging, and also based on preliminary National
Institute on Drug Abuse (NIDA) funded clinical trials (Segal and
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Schuster, 1995), sublingual tablets of buprenorphine (of 0.4, 2 and
8 mg) were registered to be used exclusively for opiate-dependent
subjects by the French medication approval authority in 1995.
Following this, in February 1996, buprenorphine was marketed
under the brand name of Subutex®.
Since 1996, the regulations for prescribing buprenorphine to
opiate-dependent subjects were quite different to those for
methadone (Ministère des affaires sociales, 1996). Any GP, regard-
less of speciality and whether practising privately or publicly, can
initiate buprenorphine treatment. The prescription may be
delivered at any pharmacy. The only restrictions are that the pre-
scription must be written on a special prescription form, the same
as that used for prescribing controlled substances such as mor-
phine. The prescription cannot be for more than 28 days at one
time, and, unless requested otherwise, the pharmacist is allowed
to hand over 28 days’ treatment at one time. However, prescrip-
tions for shorter time periods are encouraged, and it is possible to
request daily supervised delivery at the pharmacy. Some of the
doctors who were involved in the initial trials for buprenorphine
treatment in the late 1980s have produced clinical guidelines (e.g.
Tignol et al., 1998). However, these are not currently widely
accepted. According to pharmacy-based surveys, most treatments
are unsupervised and treatment is delivered for periods of more
than a week (Auriacombe and Tignol, 1997). Urine testing for
those treated with buprenorphine is not encouraged.
On account of this very relaxed approach, buprenorphine treat-
ment for opiate-dependent subjects is very accessible, and it is
estimated that in 1999 as many as 50 000 subjects were receiving
treatment at any given time. This estimate is calculated on the
basis of the quantity of buprenorphine sold by the company to
pharmacists and the average dose prescribed, which, according to
a few limited surveys conducted by motivated GPs, is between 8
and 12 mg daily (De Ducla et al., 2000). Based on these calcula-
tions, the number of subjects ranged between 2 800 and 4 300 at
the beginning of 1996, between 21 000 and 32 000 at the end of
1996 and between 34 000 and 51 000 at the end of 1997 (Lert et
al., 1998).
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It was estimated in the autumn of 1996 that approximately 24 000
patients had been prescribed buprenorphine, which represents
approximately 15 % of the total addict population in France. In
June 1997, it was estimated that up to 40 000 patients were being
prescribed buprenorphine. The average prescribed dose seems to
be 8 mg daily.
Within two months of the launch of Subutex®, patients on low-
dose (0.2 mg) analgesic tablets (Temgesic®), which were pre-
scribed when substitution was indicated, had transferred to high-
dose buprenorphine tablets (Subutex®), as demonstrated by the
decrease in Temgesic® sales and the growth in Subutex® sales.
However, the most interesting change was that addicts who were
treating themselves with over-the-counter codeine (so-called
‘wild’ substitution) transferred to medical substitution with pre-
scribed buprenorphine. This was indicated by a 5–15 % decrease
in codeine sales five months after the launch of Subutex®.
Pharmacy survey
In June 1996, four months after the launch of Subutex®, a face-to-
face survey of 2 646 pharmacies was conducted, in order to deter-
mine levels of substitution-treatment prescription as well as to
gather information about subjects using Subutex® (Picard, 1997).
The survey gathered the following data.
• Close to 60 % of the pharmacies had delivered Subutex®, mor-
phine sulphate, codeine or methadone to drug addicts during
the previous month, compared with 10 % some years before;
30 % had specifically delivered Subutex®.
• Approximately 40 % of pharmacies had previously supplied
only 1–3 subjects, whereas 40 % now supplied 6–20 subjects.
• Those pharmacies supplying large numbers of addicts were, in
general, working with drug subjects in the AIDS-prevention and
needle-exchange programmes, whereas those pharmacies with
few subjects were new to substitution dispensing.
• When asked specifically about Subutex® prescription, few phar-
macies had more than three patients taking Subutex® and
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almost 50 % had none of the 20 000 patients currently treated
with this medication.
• The most popular medication taken by Subutex® patients prior
to its launch was codeine, followed by low-dose analgesic
buprenorphine (Temgesic®).
The survey also revealed information about the prescribing prac-
tices of the many GPs that were now treating heroin subjects.
During the induction phase, Subutex® was prescribed to be taken
daily in 40 % of all cases. The length of time for which it was pre-
scribed on one prescription was usually one week in 39.3 % of
cases. However, 20.6 % of prescriptions were written for four
weeks. It is possible that some of these patients had previously
been treated with Temgesic® and that this was not, in fact, an
induction phase but a continuation of the earlier maintenance
therapy. During the maintenance stage of Subutex® therapy, four-
week prescriptions were the most common (38.4 %), at daily
doses of 2–6 mg, which is relatively low. Once-daily treatment
occurred in over 50 % of cases, but 25 % almost never took the
medication daily. This is a cause for concern, since daily adminis-
tration appears to be an important condition for successful treat-
ment. Communication between GPs and pharmacists was not as
good as originally hoped, since, in 40 % of cases, the GP did not
contact the pharmacist prior to the patient presenting the pre-
scription. Also, the prescribing GP should have specified on the
prescription the particular pharmacist to be used, but this only
occurred in 30 % of cases.
The survey also addressed the problem of diversion. When
Subutex® was launched, its street value was FRF 100 (EUR 15) for
an 8 mg tablet retailing at FRF 25 (EUR 4). In 1999, this street
value dropped to FRF 30 (EUR 4.5), indicating a high level of legal
availability of the drug and also its low euphoric effects compared
with heroin. Pharmacists felt that, in 80 % of cases, Subutex® was
used in the prescribed way and that 70 % of prescriptions were not
resold. From these data, it can be estimated that a minimum of
10–15 % of subjects injected Subutex® intravenously. Overall,
patient compliance was considered to be good in 71 % of cases
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and both pharmacists and subjects expressed a positive opinion
about the treatment programme. Results from a survey in October
1996 indicate that this figure had since risen to 74 %.
Reports of adverse effects
Since June 1997, some reports have emerged of adverse effects of
buprenorphine treatment. The most important of these was a
report of six deaths thought to result from the combined use of
buprenorphine injected intravenously with benzodiazepines and
alcohol (Tracqui et al., 1997). All six subjects used illegally
obtained buprenorphine and were not included in a comprehen-
sive treatment programme. These deaths underline the importance
of making buprenorphine available in a way that reduces diver-
sion, as this is often associated with abuse of other potentially
lethal drugs. However, it should also be noted that, during an 
18-month period when the number of buprenorphine prescrip-
tions reached over 40 000, the number of overdoses reported
decreased from over 500 deaths annually to less than 300 (Office
central pour la répression du trafic illicite des stupéfiants, 1998).
Another reported adverse effect concerns increases in liver
enzymes among subjects treated with buprenorphine (Réseau des
centres de pharmacovigilances, 1997). There have been a number
of different clinical responses to this phenomenon, including cases
where the buprenorphine treatment has been continued and a sec-
ondary reduction of liver enzymes has been observed. Overall, the
incidence of liver enzyme increase currently reported does not
appear to be higher than that reported with non-liver-toxic med-
ications. These reports, however, highlight the need for close mon-
itoring of patients receiving buprenorphine treatment, as over
75 % of opiate drug users in treatment in France have tested pos-
itive for the hepatitis C virus.
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Development of substitution services
Traditionally, specialist substance-abuse treatment providers in
France have been reluctant to offer substitution prescription. Non-
specialists, particularly GPs, were explicitly discouraged from
treating substance-abusing or dependent individuals, as these
were considered to be unreliable and manipulative. Prescribing to
such individuals was considered non-therapeutic. Some changes
have occurred since the early 1990s, but the process of change in
attitude is still ongoing.
Current situation
The population of France currently stands at 60 million. It is esti-
mated that the country has between 150 000 and 300 000 drug-
dependent subjects. Approximately 40 000 subjects a year will
request help from the State drug-abuse treatment centres. The
average age of subjects is 25–30, and two thirds are male. Overall,
20 % are HIV positive. However, this number is believed to be
dropping over time. Two thirds appear to be hepatitis C positive.
Legislation on substitution treatment
There was a dramatic change in legislation between 1990 and
1995 (current legislation was set in place in 1995). All GPs work-
ing in substance-abuse State-approved centres may now prescribe
methadone. There are no regulatory requirements for a GP recruited
in such centres. Buprenorphine may be prescribed by any GP and
delivered in any pharmacy. There are no licensing requirements
for prescribing either methadone or buprenorphine, and there are
no consensus guidelines but only individual initiatives. The only
limitations are those determined by the regulations as described
above. In 1996 and 1997, two-day training sessions were organ-
ised for GPs, pharmacists and other health professionals, which
were funded by the State. However, this initiative was discontin-
ued. Urine controls (also State funded), at a clinically determined
frequency, are required of subjects treated at methadone-treatment
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centres. Although urine testing is possible for buprenorphine-treat-
ed subjects, and some local guidelines specifically recommend
such testing, it is discouraged by the regulatory bodies.
Minimal evaluation of subjects treated with methadone is imple-
mented. However, appropriate support for data collection and
quality control is not available. For buprenorphine treatment, no
standard evaluation is undertaken. However, individual research
initiatives conduct evaluations of either methadone or bupren-
orphine and sometimes both.
Substitution clients
There are no explicit entry criteria for methadone or bupren-
orphine treatment, except that the client is expected to adhere to
the regulations. Consequently, buprenorphine is much more
accessible. Subjects treated with buprenorphine are generally
younger and better socialised than those treated with methadone.
Polydrug use is increasing among all clients, whether or not they
are treated with methadone or buprenorphine.
Pharmacy activity
Pharmacists are mainly involved in buprenorphine treatment.
Over two thirds of all pharmacies deliver buprenorphine.
Pharmacy involvement is generally received positively.
Primary-care involvement
GPs are the main prescribers of the estimated 50 000 bupren-
orphine-treated subjects. Half of these subjects are cared for by
12 % of GPs. It is estimated that 11 000 GPs have prescribed
buprenorphine (20 % of all GPs), half of whom treat over 20 000
of these subjects. GPs, pharmacists and other professionals have
been encouraged to organise themselves into networks to facilitate
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professional support and offer more comprehensive treatment
plans to patients prescribed buprenorphine.
Substances prescribed
Buprenorphine and methadone are regularly prescribed for the
treatment of opiate-dependent subjects. Morphine sulphate pre-
scription, although tolerated, is illegal. There are no data available
regarding the number of subjects using morphine sulphate.
Clinical observation suggests that most morphine sulphate pre-
scription is diverted to intravenous injecting.
Injectable prescribing
Injectable prescription is not accepted practice in France. How-
ever, it is estimated that 10 % of those treated with buprenorphine,
and most of those receiving morphine sulphate prescription, prob-
ably regularly divert their prescription to the intravenous route.
Prisons
Treatment by either methadone or buprenorphine can be contin-
ued in prison. Such treatment can also be started in prison.
Surveillance
A survey is conducted every year in November of all substance-
dependent subjects that request help from the healthcare system
(whether substance-abuse specialised or not and regardless 
of which substitution treatment is used) to collect data on the
following:
• socio-demographic characteristics;
• drug use;
• medical and infectious status; and
• treatment regimen.
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Problems
There are currently three main problems in the area of substitution
treatment in France. For buprenorphine, there is the lack of con-
trol and specialist involvement, particularly of psychiatrists; diver-
sion to intravenous injecting; and its availability on the street mar-
ket. For methadone, only a small number is willing to use this
treatment and there is lack of funding. Finally, most substance-
abuse specialists are still slow to accept methadone or bupren-
orphine as treatments that can be integrated into a comprehensive
substance-abuse treatment plan. This is a major problem in terms
of facilitating contact between specialists and buprenorphine-
prescribing GPs with difficult-to-treat patients.
Evaluation
Some work has been undertaken both locally and nationally on
evaluating substitution treatment.
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IRELAND
Joe Barry, Baggot Street Hospital, Dublin
Introduction
Ireland is a parliamentary democracy with a population of 3.5
million. Historically, it has been one of the poorer countries of
western Europe, but there has been a period of sustained eco-
nomic growth, colloquially referred to as the ‘Celtic tiger’, over
recent years. Ireland has been one of the 11 countries to join the
single European currency. For almost the past decade, the country
has been governed by a variety of centrist coalition multiparty
governments.
The health service is funded out of general taxation. At central
level, the Department of Health and Children is the government
department responsible for the health services and for policy
development in the area of health and personal social services.
Health and personal social services are managed and delivered by
health authorities, of which there are eight in the country. The
largest health authority, in population terms, is the Eastern
Regional Health Authority (which replaced the former Eastern
Health Board on 1 March 2000), which comprises the counties of
Dublin, Wicklow and Kildare. The total population of this health
board region is 1.2 million, of which 1 million live in the county
of Dublin.
Strategy
Illicit opiate use became a public health problem in Dublin in the
early 1980s, and throughout that decade the dominant form of
healthcare response was one of abstention. In 1991, the
Department of Health embraced the ‘harm-reduction model’ of
treatment for opiate use because of the relatively high HIV sero-
prevalence in Dublin’s injecting drug users. This shift in policy
was made explicit by the publication, in 1991, of the government
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strategy to prevent drug misuse. One provision of this strategy was
to set up a national drug-misuse database. This is being main-
tained by the Health Research Board (the Irish focal point in the
Reitox network).
While a national drug-treatment centre had existed in Ireland
throughout the 1980s, explicit responsibility for the development
of the new strategy was vested in the local health board, 
the Eastern Health Board. Development funding for the harm-
reduction approach to drug services was given to the body. 
Most coordination efforts after the 1991 government strategy to
prevent drug misuse were in the area of substitution treatment.
There was little in the way of a coordinated response in relation 
to primary prevention or rehabilitation.
As a result of the growing recognition of the link between poverty
and opiate use, and also of the multisectoral nature of problem
drug use, this national strategy was succeeded by a new strategy
which was published in 1996. This was the report of the
Ministerial Task Force on Measures to Reduce the Demand for
Drugs. This strategy document was published in two parts. The list
of recommendations presented in the two parts of this report were
more explicit than those in the 1991 publication, and it could be
argued that it was a more political document. The five-year inter-
val since the production of the government strategy document had
afforded an opportunity for the experiences of the developing
harm-reduction model to be evaluated. An external evaluation of
the Eastern Health Board’s response to its coordinating role had
been published in 1995, prior to the writing of the ministerial task
force report.
The main recommendations of the ministerial task force were sub-
divided into different government department responsibilities. The
overall structural changes are dealt with in more detail below. The
government provided expanded funding for evaluative research in
relation to substitution treatment, as a result of which some evalu-
ation studies are currently in progress and some have been com-
pleted. The government has also made available extra funding to
one third-level institution to run a Master’s course in addiction
studies. Recommendations on the treatment side include expanding
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
136
42d930_insights_brochure  09-11-2000  14:53  Pagina 136
locally based treatment centres. This was recommended by the
external reviewers and considerable success has been achieved in
this regard. They also recommended that the Methadone
Prescribing Protocol in relation to methadone prescribing in pri-
mary care should be expanded, evaluated and strictly regulated,
which, in turn, has been carried out. The ministerial task force
report made a commitment to eliminate treatment waiting lists
during 1997. It also recommended that a telephone helpline be
established.
Major deficiencies in the area of rehabilitation were detected at
that time and it was acknowledged that a coordinated approach
and priority status should be given to developing rehabilitation
services. As a result, a lengthy list of recommendations was com-
piled in relation to primary prevention. There had long been con-
cern that the education sector was not responding in an appropri-
ate fashion to the opiate epidemic, despite the fact that the Health
Research Board had shown that the age at which people began
injecting was consistently dropping and that the concentration of
opiate addiction was confined to a limited number of districts of
Dublin.
Under the new arrangements, the Office of the Taoiseach (Prime
Minister) coordinated government policy on drug misuse on the
demand-reduction side. Epidemiological evidence in the strategy
document highlighted the concentration of opiate use in 12 areas
of the capital city of Dublin, and local drug task forces were estab-
lished in each of these areas. Another task force was established in
the northern suburbs of the city of Cork (the second largest city in
Ireland). A sum of IEP 10 million (EUR 12.6 million) was made
available to develop locally based responses to problem drug use
in all of these 13 task force areas.
Task forces comprise independent chairpersons, full-time coordi-
nators, six representatives of the various statutory organisations,
six representatives of community groups and two representatives
of voluntary drug-treatment agencies. The brief of these task forces
is to promote consensus and develop imaginative responses to
opiate use in the areas of prevention, early intervention and reha-
bilitation. Treatment remains the responsibility of the Department
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of Health and Children and the health boards. A formal evaluation
of the task force working processes has recently been carried out
by management consultants.
Most of the initiatives in relation to problem drug use in Ireland are
concentrated in Dublin, where most opiate use takes place. Other
health boards are in the process of setting up local drug strategy
teams to address drug use in rural Ireland.
Level of central planning and direction
The task force process has been very much a consensus approach.
Due to the informal nature of Irish society in general and the close
physical proximity of the inner-city drug problem areas and cen-
tral government offices, there is substantial direct personal contact
between civil servants, officials of the health boards and other
authorities and task force members.
A degree of flexibility has been allowed in the evaluation of the
drug services by task forces, while at the same time standardised
methods of evaluation are being put into place. As well as the task
force in each area, each statutory arm of the State (i.e. health ser-
vices, public housing authority, employment and training organis-
ations, the education sector and the criminal justice system) have
their own statutory responsibilities, which are complemented by
task force responsibilities.
Trends in funding
There has been a marked increase in funding of drug services. As
well as the annual IEP 10 million (EUR 12.6 million) granted to the
local drug task forces, the Eastern Health Board’s budget for drugs
increased from IEP 750 000 (EUR 952 000) in 1992 to IEP 14 mil-
lion (EUR 17.8 million) in 1997. A service plan for the board cost-
ing IEP 17.6 million (EUR 22.3 million) was approved for 1999.
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The overall thrust of Ireland’s response is that substitution treat-
ment is well funded at an outpatient and inpatient level.
Substitution
As well as substitution treatment provided by general practitioners
(GPs), there has been a rapid expansion of substitution therapy
(i.e. methadone maintenance, stabilisation and detoxification) in
more structured treatment settings. These treatment settings are
classified in two ways:
• addiction centres, where a full range of treatment responses,
including methadone dispensing, are available; and
• satellite clinics, where methadone is prescribed.
Attempts are currently under way to standardise admission criteria
to treatment services (an outline of the criteria for acceptance on
methadone programmes is given in Table 1).
Development of substitution services
While methadone treatment was available in a limited fashion in
the 1980s, it became widely available after the publication of the
government strategy to prevent drug misuse in early 1992. Until
that year, there were only two locations in the city where
methadone was available, and, in both situations, this was in
strictly controlled dispensing clinics. While there were no official
figures, it was estimated that less than 10 GPs were prescribing
methadone, and these were not linked to any formal drug-
treatment service. When the government strategy was published,
one of the recommendations was that a protocol for the prescrib-
ing of methadone by GPs would be instituted. This protocol was
published in 1993.
In spite of the fact that the Methadone Prescribing Protocol was
published in 1993, the vast majority of primary-care doctors were
still reluctant to become involved in this type of work. There were
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
139
42d930_insights_brochure  09-11-2000  14:53  Pagina 139
approximately 600 GPs in the Dublin area and, by the end of
1993, there were 15 prescribing methadone.
A revised version of the Methadone Prescribing Protocol was pub-
lished in 1997, following a pilot evaluation of the initial guide-
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TABLE 1: CRITERIA FOR ACCEPTANCE ON TO A
METHADONE-MAINTENANCE PROGRAMME — POLICY NO 6
Methadone maintenance
The following are the criteria for inclusion of a person on a methadone-
maintenance programme.
• They must meet physical, emotional and behavioural criteria for addic-
tion as set down by the 10th edition of the International Classification of
Diseases.
• They must be aged over 18, but those between the ages of 18 and 20
will require a more extensive investigation before being commenced on
methadone. This would require an extensive drug history going back
more than two to three years, which will need careful clarification.
• They must have an extensive one-year history of intravenous drug use.
Special cases that need not meet the above criteria for admission will
include the following:
• patients who are HIV positive;
• partners; and
• patients who are pregnant.
These patients will be offered detoxification, maintenance or inpatient
services as appropriate.
Young people, 18 years or younger
Young persons under the age of 18 will need their parents to attend and
give parental consent. There should be a history of at least one failed
detoxification, usually two or three preferably at inpatient level. However,
where patients have a very long history that can be verified, this condition
may be waived.
Young persons 18 years or younger will require very careful assessment
and consideration at team meetings and will need the formal decision of a
consultant psychiatrist before commencing methadone maintenance.
Dosages above 80 mg can only be offered after consultation with the con-
sultant psychiatrist.
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lines. There has been a gradual increase in the number of doctors
prescribing. The guidelines for 1997 recommend that ‘no doctor
should prescribe methadone unless they have undergone training
organised by the Irish College of General Practitioners’. Two lev-
els of prescribing doctors were established:
• level 1, where doctors could have up to 15 patients and do not
initiate methadone treatment; and
• level 2, where a higher level of training is required and doctors
could have 35 patients on their list (if in a partnership, level 2
doctors could have a combined total of 50 patients).
From time to time, individual GPs have been brought before the
Fitness to Practise Committee of the Medical Council and have
been censured for their prescribing practices.
Current situation
A study is being carried out in 2000 on the 350 people who
entered substitution treatment in 1993, when the system was first
set up, and on the first 150 people admitted to the then Eastern
Health Board’s inpatient detoxification and stabilisation unit. A
cross-sectional survey has been carried out on hepatitis B and C
seroprevalence and HIV seroprevalence in the cohort of drug
users who were in maintenance treatment with the Eastern Health
Board in the autumn of 1997. A mortality study is currently being
carried out on the cohort of people who have entered substitution
treatment since 1993.
Legislation on substitution treatment
New methadone regulations came into effect in October 1998.
The impact of the new legislation is being evaluated in 2000. In
September 1998, approximately 700 persons who were in treat-
ment with four GPs were absorbed into the structured services and
an evaluation of the care of these 700 patients is currently being
carried out. The thrust of the new legislation is two-pronged:
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• a more controlled environment for the prescribing and dispens-
ing of methadone should be developed; and
• the number of patients that individual GPs can treat should be
limited.
GPs do not require a specific licence. The relevant health board
maintains a register of those doctors who are approved to pre-
scribe. This approval is only granted after the doctor has under-
gone training organised by the Irish College of General
Practitioners in conjunction with the relevant health board. At an
operational level, this process is run by a combination of health
board management, the Public Health Department and the psy-
chiatrists and GPs who work in the health board drug service. The
process is open to audit. Persons on methadone are recorded on a
central treatment register and new software, which has recently
been installed, will enable the process of substitution treatment to
be more accurately monitored and researched. The Minister for
Health is statutorily responsible for the monitoring of prescribing
and health boards carry this out at an operational level.
Substitution clients
The entry criteria to substitution treatment are published and
disseminated. Many who are addicted to opiates use other
substances, in particular benzodiazepines and alcohol, and stabil-
isation of benzodiazepine use is often more difficult than that of
opiate use.
Pharmacy activity
The situation with regard to the control of pharmacies is linked to
the control of GPs. The Pharmaceutical Society of Ireland has
been represented on all initiatives related to the prescribing and
dispensing of methadone over the last five years and their recom-
mendations are incorporated into the regulations and guidelines.
Training is organised by the Pharmaceutical Society in conjunction
with the regional health boards. The new regulations provide for 
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a range of pharmacy involvement, including daily supervised
consumption, daily dispensing, biweekly dispensing or weekly
dispensing.
Primary-care involvement
There has been one formal evaluation of GP prescribing; its find-
ings were very favourable. Non-medical primary care is not as sys-
tematically available as medical primary care, but counselling
support is provided by the health boards.
Substances prescribed
All substitution is provided by means of methadone. Opiate addic-
tion is the only form of addiction for which substitution treatment
is provided. Benzodiazepine, amphetamine or other addictions do
not lead to substitution treatment. The average dose of methadone
prescribed is 55 mg.
Injectable prescribing
There is currently no injectable prescribing in Ireland.
Prisons
There are just over 2 500 prisoners in Ireland’s 15 prisons. A fact
sheet produced by the Department of Justice in 1996 estimated
that over 40 % had a history of serious drug misuse (i.e. opiate
use). In theory, prison policy is to provide the same level of sub-
stitution treatment within prison as without, but in practice this
does not happen. There is one detoxification unit and one small
maintenance clinic in the largest prison. A major prevalence study
of blood-borne viruses in the Irish prison population was carried
out in 1998. Prevalence data from this survey have been published
recently (Allwright et al., 2000).
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Surveillance
National statistics are collected by the Health Research Board. In
addition, the Eastern Regional Health Authority maintains a
national methadone-treatment list.
One capture–recapture study has been carried out, and this exam-
ined anonymised data from the central methadone-treatment list,
police data and acute hospital-discharge data.
Problems
Community acceptance
One of the main difficulties faced by service providers is the neg-
ative societal attitude to opiate users. It is generally felt that the
opiate problem needs to be particularly bad in an area before the
community accepts that there is a need to provide a related ser-
vice. This has serious implications in that the time interval from
initiation into drug use to access to treatment services is length-
ened, with consequent risk of damage to health and spread of
infection, in particular hepatitis C.
In common with other countries, Ireland has experienced a history
of community resistance. There are currently 52 locations where
methadone is prescribed through clinics run by health boards,
which is a considerable improvement on the situation in autumn
1996 when the Ministerial Task Force on Measures to Reduce the
Demand for Drugs was established. In two of the larger clinics,
there have been attempts to curtail the activities of the clinic
through legal action. One of these cases was based on private
property rights to a shared laneway, while the other was related to
the problem of nuisance congregation of drug users. The Eastern
Regional Health Authority, together with the three area health
boards, follows a proactive policy of consultation with communi-
ties to try to reach consensus. A clinic is only opened when a bal-
ance of public opinion in favour of this is achieved.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
144
42d930_insights_brochure  09-11-2000  14:53  Pagina 144
Evaluation
A number of major evaluative studies are under way at present,
some of which have been completed. These include:
• an evaluation of the first 150 inpatients in the detoxification
unit;
• a five-year follow-up of the first 350 patients in outpatient
methadone maintenance;
• a four-year follow-up of the first 150 patients in inpatient detox-
ification and stabilisation;
• an assessment of the care process for 700 patients referred to
health board services as a result of regulatory changes in 1998;
• an analysis of the first decade of first-time needle-exchange
patients;
• a review of the level of care of female users at a city centre 
clinic;
• an evaluation of outpatient satellite clinics; and
• a study of seroprevalence of blood-borne viral infections in
methadone patients.
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ITALY
Marina Davoli, Fabio Patruno and Antonella Camposeragna,
Osservatorio Epidemiologico Regione Lazio (OERL), Rome
Introduction
Italy is a constitutional republic composed of regions with
autonomous administrative and legislative capacities. The parlia-
ment consists of two chambers, which are directly elected by the
people. The government consists of the Prime Minister, the minis-
ters and the Council of Ministers. Drug-treatment policies fall
under the jurisdiction of the Ministry of Health and the Ministry of
Social Solidarity.
Funding of the National Health Service is managed at regional
level and is based on a per capita quota. A special annual national
fund for interventions on drug issues was established in 1990. The
regions decide on the level of integration of resources and on the
mechanisms of funding.
Regions are divided into local health districts which supervise and
coordinate projects funded by the Fondo Nazionale per la Lotta
alla Droga (National Fund for the Fight against Drugs) and pro-
mote specific interventions in their own territories. All interven-
tions are conducted by both public and private services.
Strategy
The national system of drug services is organised through servizi
per le tossicodipendenze (SerT — public treatment centres (PTCs))
and non-governmental organisations (NGOs). The PTCs operate
on an outpatient basis, and health districts may have one or more
outpatient clinics. Apart from these public drug-treatment services,
there is a growing number of private organisations, which are pre-
dominantly residential or therapeutic communities, although the
number of drop-in centres has increased recently.
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The national drug strategy for Italy is defined by the 1990 legisla-
tion on drugs, and in subsequent acts which have been passed
each year. The legislation deals with demand-reduction strategies,
prevention, treatment and rehabilitation. Supply-reduction strat-
egies are also included in the legislation, but these fall under the
jurisdiction of the police. Great emphasis is placed on prevention
in this legislation, especially for students and young people in
recreational environments.
Harm reduction has only been explicitly mentioned and promoted
in recent years. Both public services and NGOs provide treatment
and rehabilitation. Partnership between public and private ser-
vices is encouraged. The development and organisation of public
and private drug services is carried out at regional level.
Considerable autonomy is afforded to the PTCs and even more to
the private treatment centres.
There were 518 PTCs and 1 348 NGOs in Italy at the end of 1997.
However, the majority of clients are treated by the PTCs. This
varies between regions, from a minimum of 68 % to a maximum
of 98 % of all treated clients.
Substitution
Development of substitution services
The development of the national system of drug services is closely
related to the legal regulations which were in force at different
times. Subsequent to a law passed in 1954 (1041/54), those caught
using illegal drugs were punished regardless of the type and quan-
tity of the substance, and the law permitted their compulsory refer-
ral for detoxification in psychiatric hospitals.
Therefore, during the 1960s and 1970s, when drug use had
became a prevalent problem, the laws against the use of illegal
drugs were quite strict. However, there was a clear change of
direction with a law passed in 1975 (685/75). This law decrimi-
nalised possession of small quantities of drugs, including opiates,
for personal use. It also stated that drug addiction was to be
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managed as a medical condition and that the drug addict had a
right to seek help for his/her condition and his/her social rehabili-
tation, within the appropriate healthcare or other services. Also,
the provision of methadone to opiate addicts became permissible
and specific treatment services were developed. Up to 1993, sub-
stitution treatment was only given in public treatment centres.
However, since 1993, methadone has also been prescribed by
general practitioners (GPs).
The first services for drug treatment were implemented in the
1980s. At the same time, medical doctors were prohibited from
prescribing morphine. PTCs have developed more effectively in
some regions than others, with huge variations in treatment
offered across the country.
The number of PTCs increased from 475 in 1991 to 518 in 1997,
while the number of NGOs increased from 1 249 in 1993 to 1 348
in 1997.
Current situation
Table 1 shows data concerning clients of treatment services
(according to the annual report of the Ministry of Health), the
number of drug-related deaths and the estimated number of drug
users (using the mortality multiplier method — MMM) (14). The
number of drug users was estimated from the mortality rates, cal-
culated on a cohort of drug users enrolled in PTCs and NGOs in
Rome during the period 1980–95.
The rise in the numbers of drug users recorded was probably partly
due to improved monitoring by the Ministry of Health’s surveil-
lance system and to an increase in users attending treatment ser-
vices. Prevalence of drug users (estimated using the MMM) con-
tinued to increase until 1992, stabilising afterwards with a preva-
lence of around 200 000 users.
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(14) The mortality multiplier method for estimating the prevalence of drug use involves deter-
mining the annual number of drug-related deaths in a given setting (e.g. a city) and assum-
ing these represent a proportion (e.g. 2 %) of the total number of active users in that set-
ting. The proportion is usually based on studies of the annual mortality rate amongst groups
of drug users.
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One of the main limitations of these data is that they refer to preva-
lence of heroin use, which still represents 90 % of clients attend-
ing treatment centres. Data on prevalence, spread and risks related
to consumption of other substances are limited. The only available
data come from prevalence studies on selected areas of the popu-
lation and from information on confiscated drugs provided by the
police authority.
In 1994, a survey was carried out on a sample of 35 000 18-year-
old males undergoing an army selection test. Data on drug use
were collected by a self-administered questionnaire and urine
analysis. Fifteen per cent of the sample declared they had used
cannabis, 2.8 % had used amphetamines or ecstasy, 2.7 %
cocaine or crack, 2.5 % heroin or opiates and 1.9 % hallucino-
gens. Four per cent of the sample tested positive in the urine analy-
sis. Of these, 86 % tested positive for cannabis, 4.7 % for opiates,
4 % for cocaine and 2 % for amphetamines (Rezza, 1994). From
1994 to 1996, a harm-reduction integrated programme was car-
ried out in Rome (Verster et al., 1996). One of the outreach units
involved in the programme surveyed a section of the population
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TABLE 1: ESTIMATED PREVALENCE OF DRUG USERS IN ITALY
1990 1991 1992 1993 1994 1995 1996 1997
Drug users in 
treatment 
services (1) 67 500 92 853 103 805 104 742 113 735 123 828 129 884 138 218
Number of 
drug-related 
deaths (police) 1 161 1 383 1 217 888 867 1 195 1 566 1 153
Number of 
drug-related 
deaths (ISTAT, 
ICD-I 304) 1 094 1 180 1 093 760 809 — — —
Mortality rate 
for overdose 
(1 000) (2) 8.9 7.4 6.2 4.3 4.9 5.9 — —
Estimated 
number of 
drug users (3) 130 449 186 891 196 290 206 511 176 938 202 542 — —
(1) Source: Ministero della Sanità, 1996.
(2) Mortality rate among drug users enrolled in PTCs and NGOs, Rome, 1980–95.
(3) Multiplier formula.
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aged, on average, 26 years. Of this sample, 34.6 % reported use
of cocaine in the previous three months, 20 % ecstasy and 14 %
LSD.
In a study evaluating the efficacy of interventions for HIV preven-
tion conducted in Rome in 1997–98 among secondary-school stu-
dents (Bargagli et al., 1999), information was gathered concerning
substance use. Of this sample:
• 35 % reported using cannabis at least once;
• 9.5 % had used sedatives;
• 5.5 % had used ecstasy;
• 3.7 % had used LSD;
• 3.4 % had used stimulants;
• 0.5 % had used heroin; and
• 9 % had used cocaine.
All the available data show a stabilised prevalence of heroin use
from 1990 to date, but it is difficult to evaluate both the trends and
health effects regarding other substances.
Legislation on substitution treatment
In the 1970s, substitution treatment was offered by medical doc-
tors. Morphine and methadone were offered, both in oral and
injectable form. The first regulatory approach to substitution was
initiated by a law passed in 1975 (685/75) which established that
specialised public treatment centres should be developed in each
health district. In 1980, the Ministry of Health pronounced that
GPs would no longer be allowed to prescribe substitution treat-
ment. Since then, substitution treatment has only been offered by
PTCs.
A law passed in 1990 (309/90), which united in one text the exist-
ing Laws 685/75 and 162/90, defined general guidelines for pro-
vision of substitute drugs and criteria for admission to the
methadone programmes. This law was open to a wide range of
interpretations. In practice, some PTCs prescribed no methadone
at all, others gave the minimum required for a detoxification pro-
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gramme lasting three weeks, and others gave it for longer periods
with higher doses. Nonetheless, the official view remained that
methadone maintenance alone was not allowed but that it should
only be provided in conjunction with psychosocial interventions.
Eventually, in June 1993, parts of Law 162/90 were abolished by
a national referendum. A clarification was provided by specific
guidelines produced by the Ministry of Health in September 1994:
• methadone prescription should be personalised according to the
needs of the client;
• methadone can be prescribed over a protracted period of time,
in order to avoid relapse and to help reduce the rate of HIV
infection; and
• medical doctors can prescribe methadone, but always in col-
laboration with the local PTC (and after the PTC has established
a diagnosis).
Substitution clients
The number of drug users treated increased from 93 000 in 1991
to about 140 000 in 1997 (Ministero della Sanità, 1999), corre-
sponding to a prevalence of 24.1 per 10 000 inhabitants in 1997.
The male/female ratio is 6:1. The average age increased progres-
sively from about 28 years to 31 for prevalent cases and from 26
to 28 for new users.
In 1997, the majority of clients in treatment (87.5 %) used heroin
as the primary drug, whereas, in 1992, heroin was used by
91.2 %. This negative trend is completely different for cocaine,
which was used by 1.3 % of clients in 1991 and by 2.3 % in 1997.
Other common features of heroin users are:
• they usually inject;
• they also use other drugs (cannabis and benzodiazepines); and
• they are older than new clients.
Clients in the care of public treatment centres were generally
treated pharmacologically (62 %), as shown in Figure 1.
42d930_insights_brochure  09-11-2000  14:53  Pagina 151
In 1997, about 50 % of clients of PTCs were offered methadone
treatment, half of them on a maintenance schedule. The propor-
tion of clients on methadone progressively increased from 30.3 %
in 1991 to 47.2 % in 1997 (Figure 2).
Data from the Ministry of Health do not provide information on
methadone dosage. Since 1995, the drug-addiction surveillance
system in the Lazio region has collected individual data on
methadone dosage (D’Ippoliti et al., 1998). In 1997, the average
dose of methadone prescribed to people on maintenance was 
44 mg.
As far as prevalence of HIV infection among treated drug users is
concerned, in the period 1991–97 the percentage of HIV-positive
clients was continually decreasing: in 1991, of 51 256 clients
tested, 28.8 % were positive, while in 1997 this figure was 15.7 %
of 76 096 people tested. If we classify clients according to gender
and time spent in the care of PTCs, it is clear that, even if the trend
is decreasing, new male clients are less likely to be infected,
whereas ‘old’ (or longer-term) female clients represent the greater
proportion of people infected.
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Psychosocial
38 %
Methadone for
period < 30 days
12 % 
Methadone for
> 30 days and
< 6 months
11 % 
 
Methadone
for > 6 months 
24 %
 
Naltrexone
6 %
Clonidine
3 %
Other drugs
6 %
 
Source: Ministero della Sanità (1999).
FIGURE 1: TYPE OF TREATMENT OFFERED BY PTCs IN ITALY (1997)
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Hepatitis B is widespread among PTC clients: in 1997, of 68 062
people tested, 43.6 % were positive, while in 1991 this figure was
50.9 %. Data regarding hepatitis C have been collected since
1997, when 67.3 % of patients tested positive in a sample of 
66 467. There were no obvious differences between men and
women.
Pharmacy activity
In Italy, pharmacies only have limited involvement in the provi-
sion of services for drug users. They mainly sell injection equip-
ment. Some pharmacies keep a syringe-exchange machine on the
wall outside the pharmacy. In Rome, a special programme on
overdose prevention started in 1999, one element of which is that
pharmacies sell syringes together with an information leaflet. Also,
the pharmacies will be encouraged to sell naloxone to heroin
users without medical prescription.
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Source: Ministero della Sanità (1999).
FIGURE 2: PREVALENCE OF CLIENTS OF PTCs
ON METHADONE TREATMENT IN ITALY (1991–97)
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Primary-care involvement
There is only occasional medical involvement in primary care and
no specific training has been proposed.
Substances prescribed
Oral methadone has been the only substance authorised for drug
treatment, but, in 1999, new legislation allowed prescription of
sublingual buprenorphine.
Figure 3 shows the trends in methadone consumption in drug
dependency during the period 1993–97. These data confirm the
increased consumption of methadone which has been observed in
PTC clients.
Injectable prescribing
No injectable substitution treatment has been authorised.
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Source: International Narcotics Control Board (INCB).
FIGURE 3: CONSUMPTION OF METHADONE IN ITALY (1993–97)
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Prisons
The problem of drug users in prison has been evident since 1990:
drug users represent about 30 % of all prisoners. More than half
the drug users in prison are there for violating laws regarding drugs
(mainly dealing and trafficking).
Provision of substitution treatment is virtually non-existent (as of
December 1997, only 500 drug users out of the total 14 000 in
prison were on methadone treatment).
Surveillance
Since the second half of the 1980s, two surveillance systems have
been collecting data on drug users attending treatment centres:
one is run by the Ministry of Internal Affairs and the other by the
Ministry of Health.
Every three months, the Ministry of Internal Affairs collects data on
the number of drug users registered at public treatment centres
and therapeutic communities on a specific day (point prevalence).
The Servizio Centrale Antidroga del Ministero degli Interni
(Central Anti-Drug Office of the Ministry of Internal Affairs) keeps
regular records of the number and characteristics of those people
who have died of drug-related causes. This source also provides
data on the following:
• the quantity and kinds of drugs seized;
• the number of criminal charges brought for drug dealing and
trafficking and for drug-related theft; and
• the number of people reported to the authorities for possession
of drugs.
The Ufficio Centrale per le Dipendenze da Alcool e Droga del
Ministero della Sanità (Central Office for Alcohol and Drug
Dependence of the Ministry of Health) gathers data about the
following:
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• the number of drug users attending public treatment centres;
• their demographic characteristics;
• type of drug used; and
• treatments followed.
Other sources of information on drug addiction are the Ministry of
Justice, which provides data on drug users in prison, and the
Ministry of Defence, which collects data on the number of drug
users identified when called up for military service or while 
serving.
All these surveillance systems are based on aggregated data. One
of the major problems is double counting, as some regions have
their own surveillance systems based on individual data. A national
system based on individual data is currently being developed.
Problems
The most critical problems of community-based services is the
shortage of personnel and poor structural organisation. Italy is now
reorganising its health system and minimum quality criteria will be
established for both private and public services.
Another critical problem of these services is the heterogeneity of
treatment offered, with the consequent inequalities across the
country. A lack of continuity of treatment between the healthcare
system and prison is also a major problem.
Finally, most services still have an abstinence-oriented ethos, with
consequent resistance to substitution-treatment programmes,
especially on a maintenance basis.
Evaluation
The first large-scale study of treatment outcome for heroin users
ever conducted in Italy is the ‘Valutazione efficacia dei trattamenti
per la tossicodipendenza da eroina’ (VEdeTTE — ‘Evaluation of
effectiveness of treatments for heroin dependence’). It was
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commissioned and funded by the Ministry of Health and coordi-
nated by the Osservatorio Epidemiologico Regione Lazio (OERL
— Department of Epidemiology of the Lazio Region), the Health
Authority and the Department of Public Health of Torino
University.
Special efforts were made to inform workers in the drug services,
policy-makers and researchers of the objectives and methodology
of the study and its relevance to the planning and implementation
of effective treatment programmes at national level.
VEdeTTE is a prospective, longitudinal, cohort study on a multi-
centre cohort of heroin users entering 130 public treatment centres
for drug addiction in 13 Italian regions. Local and national coordi-
nating groups have been identified for the management of the study.
The objective of the study is to evaluate the effectiveness of differ-
ent treatments for heroin dependence offered in PTCs in order to:
• prevent mortality from overdose, injury and poisoning; and
• retain clients in treatment.
Enrolment of patients in the study, which began between
September 1998 and March 1999 in all participating PTCs, will
continue for 18 months. Two years after the beginning of the study,
checks will be made to ascertain whether the patients are still
alive. A questionnaire and a form for collecting data on treatments
were specifically designed for the purposes of the study. The ques-
tionnaire, to be administered on enrolment, gathers information
on potential confounders, such as:
• socio-demographic characteristics;
• severity of dependence;
• previous overdoses and treatments; and
• physical and psychiatric health status.
All therapeutic interventions are recorded using a standardised
form.
A pilot study involving 1 000 heroin users enrolled in 20 PTCs
across 13 different regions was carried out between November
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1997 and January 1998. The protocol and instruments for collect-
ing data for the VEdeTTE study have been prepared on the basis of
the results of this pilot study. The estimated number of people that
will be enrolled is more than 10 000.
An Italian project, which is part of the COST A6 programme (15),
aims at producing guidelines for treatment evaluation in the field
of drug abuse.
In 1998, the Cochrane collaborative review group on drug and
alcohol was implemented. Its editorial base is in Rome at the
Department of Epidemiology of the Lazio Region. The other edi-
tors collaborating in the review are based in the following:
• the National Addiction Centre, London, UK;
• the Department of Public Health, Torino University, Italy;
• the National Drug and Alcohol Research Centre, Sydney,
Australia;
• the Drug and Alcohol Services Council, Adelaide, Australia; and
• the University Victor Segalen, Bordeaux II, France.
The main objective of the group is to produce, disseminate and
update systematic reviews on the effectiveness of interventions in
drug and alcohol abuse.
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LUXEMBOURG
Simone Dietz, Jugend–An Drogenhëllef, Luxembourg
Introduction
Luxembourg is a constitutional monarchy with a population of
429 000 (as of 1 January 1999). The country’s main characteristics
are as folllows:
• economic prosperity:
• low unemployment;
• 13 % of the population are non-natives (mainly of Portuguese
origin); and
• 25 % of the working population do not live in Luxembourg.
Medical care in Luxembourg is very accessible. Payments from
health insurance are very high. Only a few people have no health
insurance, and they are covered by the well-developed social
services. However, there is no systematic and organised collabor-
ation between health and social services. Health services are
based on a liberal system and social services are private or
financed by the government via NGOs. Collaboration between the
two remains difficult.
Strategy
The first specialised services for those with drug-related problems
were created at the end of the 1970s. Private initiatives at that time
prepared the ground for current drug-treatment structures. During
the 1980s, the drug problem increased and, in parallel, so did
social pressure. The Jugend–An Drogenhëllef (JDH — Youth and
Drug Assistance), a counselling service for young people and drug
users initially financed by the Ministry of Family, was the first spe-
cialist outpatient institution for those with drug-related problems.
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At the end of the 1980s, hepatitis and AIDS prevention became
prevalent and outreach work, a methadone programme and
needle-exchange activities were initiated in 1989 with the help of
the Ministry of Health. In the mid-1990s, the Centre de prévention
des toxicomanies (Centre for the Prevention of Drug Addiction)
was established and the methadone programme extended.
The low-threshold service known as ‘Camionnette–Szene Contact’
(a specially equipped van near the central railway station offering
hot drinks, needle exchange, human contact and counselling) was
created at the beginning of the 1990s.
In 1997, a new agency was developed in collaboration with
Médecins sans frontières which works with minors experiencing
drug problems and conflicts with the law.
A counselling service has been operating in the north of the
country since February 1999. This project was developed with
advice from local institutions and in close collaboration with the
municipality.
There is a distinct trend towards developing low-threshold services
(rooms in which to take drugs under medical supervision,
emergency lodgings, heroin programmes, etc.).
It is current policy to develop an integrated approach, by which
low-, middle- and high-level services are parts of a general strat-
egy, with a complementary perspective. Strategies of harm reduc-
tion and health prevention for drug users, on the one hand, and a
therapeutic approach, on the other, are not seen as mutually
exclusive.
Several ministries are responsible for drug policy: the Ministries of
Justice and Health are responsible at one level and the Ministries
of Family, National Education and Youth at a second level. An
interministerial working group coordinates the activities of these
different ministries.
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The small geographical size of Luxembourg facilitates reciprocal
contacts between citizens and policy-makers. The relevant
schemes rely more on cooperation than confrontation.
Substitution
Development of substitution services
The pilot phase of the methadone programme began in April
1989, evolving from a project entitled ‘SIDA et toxicomanie’
(‘AIDS and drug addiction’), offering a total of 15 places. The ini-
tial results of the pilot project were encouraging and, in 1992, the
capacity of the programme was extended to 25 places. This small
project had a long waiting list (up to one year in 1994) and high
admission criteria. Also, the death rate among drug users peaked
in 1994. This situation induced the Ministry of Health to extend
the programme to 100 places in 1995 and to 160 places in 1996.
At the beginning of the programme, only one doctor (a psych-
iatrist) was prescribing methadone at the JDH. The expansion of
the programme required services to be decentralised. Pharmacies
became involved in the preparation and distribution of
methadone, and general practitioners (GPs) became responsible
for monitoring drug users and for prescribing, in their own con-
sultation room. This rationalisation phase was an important transi-
tion period in the programme’s development. A disagreement
between the doctors’ association and the Ministry of Health ham-
pered this process but, fortunately, these difficulties have been
resolved. There is currently a network of over 40 physicians pre-
scribing methadone in Luxembourg. These doctors have to agree
to the prescribing guidelines.
At first, substitution treatment was firmly structured by the fact that
the national methadone programme had the monopoly of pre-
scription. The methadone programme now constitutes a network
composed of the following:
• staff (psychologist, social workers, male nurse, educator,
secretary);
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• prescribing doctors (general practitioners and psychiatrists who
signed a ‘work convention’ with the Ministry of Health);
• pharmacists; and
• the Commission méthadone (Methadone Commission).
The Methadone Commission is composed of representatives of
GPs, pharmacists, the Ministry of Health and the staff of the
methadone programme. The commission meets regularly to make
decisions in the following areas:
• applications for admission;
• staff proposals for changes to the programme; and
• solutions to problems that cannot be resolved by the staff alone.
Since the pilot project was established in 1989, substitution treat-
ment with methadone has gradually evolved and developed.
Current situation
In 1999, 186 drug users participated in the national methadone
programme (Table 1).
The staff of the methadone programme is composed of one psy-
chologist (responsible for the methadone programme) working
half-time, three and a half social workers, a nurse, an educator and
a half-time secretary. The psychologist and one and a half social
workers provide the therapeutic framework. The programme’s
centre is open between 6 a.m. and 5 p.m. from Monday to Friday.
Two members of staff supervise the distribution of methadone in
the morning to about 40 clients. The rest of the staff work from 
9 a.m. to 5 p.m. In 1998, 186 clients participated in the
methadone programme. Many of them had their key worker,
social assistant or therapist and one of the two other staff in the
JDH counselling centres for drug users in Luxembourg.
A GP visits the centre weekly and prescribes treatment for about
35 clients. However, some of these 35 clients do not have to be
seen by the doctor every week because they have been stabilised
for several years.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
163
42d930_insights_brochure  09-11-2000  14:53  Pagina 163
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
164
TABLE 1: METHADONE PROGRAMME DATA FOR LUXEMBOURG (1999)
GENDER
Male 131 70.5 %
Female 55 29.5 %
Total 186 100 %
SOCIAL SITUATION
Employed 75 40 %
RMG (1) 36 19.5 %
Paying rent 18 10 %
Receiving unemployment benefit 9 5 %
Receiving social aid 2 1 %
Student 1 0.5 %
Without any revenue 45 24 %
Total 186 100 %
NATIONALITIES
Luxembourgish 137 75 %
Portuguese 24 13 %
Italian 10 5 %
French 5 3 %
Belgian 3 1.5 %
Cape-Verdian 3 1.5 %
Spanish 2 1 %
German 2 1 %
Total 186 100 %
AGE
< 20 years 1 0.5 %
20–24 years 20 10.5 %
25–29 years 54 29 %
30–34 years 61 33 %
35–39 years 34 18 %
> 40 years 16 9 %
Total 186 100 %
DURATION OF DRUG DEPENDENCY
< 3 years 4 2 %
3–5 years 30 16 %
6–10 years 85 46 %
11–15 years 44 24 %
> 15 years 23 12 %
Total 186 100 %
GEOGRAPHICAL ORIGIN
North 41 22 %
South 83 44.5 %
East 7 4 %
West 1 0.5 %
Centre 54 29 %
Total 186 100 %
(1) Guaranteed minimum revenue.
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The centre for the methadone programme (in two locations) is sit-
uated near the railway station opposite the counselling centre.
This geographical position has the advantage of being close to the
station and the disadvantage of being close to the ‘drug scene’.
The fact that it is opposite the counselling centre and that the
methadone programme is run by the whole organisation, the JDH,
facilitates collaboration between the two services. Useful collabor-
ation with a general hospital has also been set up in order to be
able to admit pregnant women to the programme. Additionally,
meetings are organised to facilitate collaboration with other spe-
cialist institutions. Staff members have to be mobile in order to be
able to:
• visit clients who are hospitalised;
• visit clients who are in prison; or
• organise meetings with the other services to ensure follow-up.
This collaboration may not be perfect, but much effort has been
expended on improving it.
The development and maintenance of an effective collaboration
network benefit both the centre and the clients. There have been
difficulties regarding collaboration with GPs (partly due to the fact
that the centre does not have a doctor on the staff), although the
GP who counsels in the centre does a lot of networking: for
instance, collecting the medical data of drug users who are in
treatment with other doctors in the methadone programme. These
data will be included in the JDH’s next evaluation, which will be
completed in 2001.
Staff have already collected medical data from 92 patients out of
a total of 186. Of these 92 patients, 5 (18 %) are HIV positive, 44
(48 %) are hepatitis B positive and 55 (60 %) are hepatitis C posi-
tive. Two suicides occurred during 1998. Also, 124 of the 186
patients who participated in the methadone programme in 1998
have been convicted of drug offences at least once in their
lifetime.
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Legislation on substitution treatment
To date, the methadone programme does not have a legal frame-
work. Officially, it is tolerated and relies on verbal commitment. In
fact, the law actually prohibits contributing to the maintenance of
addiction, and substitution could be considered just that. In
August 1997, the Ministers for Health and Justice introduced a bill
which would provide a legal framework for the methadone pro-
gramme. Since then, the two ministers involved have retired and
a new legislative period has begun under which no changes have
occurred. The current situation obviously makes it difficult to
enforce guidelines for treatment.
Those doctors who have signed a convention with the Ministry of
Health benefit from a verbal contract. This convention determines
the conditions of prescribing:
• the rules of the methadone programme have to be respected;
• collaboration with the methadone programme has to be
ensured;
• special training has to be undertaken; and
• meetings organised by the methadone programme have to be
attended.
The Ministry of Health controls prescribing by demanding that
doctors use a special prescription form. In serious cases of abuse
of prescribing practices, the Ministry of Health can withdraw the
prescription forms and make a complaint to the medical commit-
tee. The doctors’ association and the Ministry of Health have
signed an agreement which regulates the prescription of narcotic
substances.
Luxembourg has two kinds of substitution treatment: one in the
official programme (for maintenance treatment) and one outside
the programme. The latter is used for short substitution treatments,
such as detoxification. In Luxembourg, about one third of substi-
tution patients are in the methadone programme and the remain-
ing two thirds are out of the programme. Another function of the
agreement between the doctors’ association and the Ministry of
Health is to structure these treatments. The three JDH services, the
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two counselling services and the methadone programme, can opt
to support and work with the prescribing doctors if they wish.
Luxembourg’s Reitox focal point (the Directorate of Health at the
Ministry of Health) has conducted a study on the attitudes and
practices of GPs treating drug-addicted patients. The results, pub-
lished in the 1998 report by the Réseau luxembourgeois d’infor-
mations sur les stupéfiants (RELIS — Luxembourg information net-
work on drugs and drug addiction), show that 29 % of the doctors
received special training of between 1 and 15 days maximum;
71 % of doctors felt that they were insufficiently prepared.
The methadone programme normally organises training, but only
a few doctors are interested. All the doctors are invited to collab-
orate with JDH staff, since it is generally felt to be more construc-
tive to work in a medical psychosocial team and to have its sup-
port. However, it seems that this collaboration is not necessarily
desirable for some of them. Collaboration with doctors is useful for
an efficient follow-up of the client, and it is also useful for the
good working of the methadone programme. Guidelines which
are developed by JDH staff are often the result of suggestions made
by the clients themselves and our collaborators.
New concepts are discussed by the Methadone Commission and
are then disseminated to all JDH collaborators. Meetings are
organised for the clients and collaborators to facilitate debate and
exchange of opinions.
Substitution clients
A drug user who wants to be admitted to the national methadone
programme must be interviewed by a social worker or a therapist
from the counselling service for assessment (for instance, to ascer-
tain if substitution is really the best solution in the light of his/her
specific social situation and past treatment). After this, an admis-
sion questionnaire is passed on to the Methadone Commission,
where his/her possible admission is debated. The two main entry
criteria are:
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• confirmed opiate addiction; and
• minimum age of 18 years.
An earlier entry criterion of having undergone two trials of
abstinence-oriented therapies has now been discontinued.
Once admitted to the methadone programme, the applicant is reg-
istered and receives an anonymous M-number. He/she is also reg-
istered with the Ministry of Health via the special prescription
form. A treatment contract has to be signed by a representative of
the methadone programme, by the prescribing doctor and the
client himself/herself. This contract sets out the obligations of the
applicant and details of the services provided by the centre. In the
first four months of treatment, weekly urine controls and visits to
the doctor are mandatory. When a client can prove abstinence for
at least four months, he/she is rewarded (for instance, instead of
having to attend every day for his/her prescription he/she can do
so only three times a week). After the first four months, the client
is allowed to decide for himself/herself whether or not to undergo
urine controls. If the doctor or a member of staff believes a urine
control will be useful, it will be carried out. For young parents,
urine controls remain mandatory.
A client decides with his/her doctor how long he/she will stay in
the programme; there is no time limit whatsoever. There are three
situations where treatment will stop:
• if the client is violent;
• when a deterioration of the client’s situation since the beginning
of treatment shows that substitution is not an adequate solution;
and
• when it is estimated that methadone is only one substance in a
panoply of substances consumed by the client.
One of the biggest problems is the polydrug user, a problem to
which an adequate solution has not yet been found. In such cases,
two substitutions are offered; one for opiate addiction and one for
benzodiazepine addiction. In the latter, periodical qualitative
urine controls are carried out. Nevertheless, when the polydrug
use is too compelling, the treatment is stopped.
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The JDH offers many services, ranging from support with tradi-
tional therapies to social aid such as help for urgent problems and
assistance in searching for employment or accommodation. Even
clothing is supplied, if needed. The JDH also has the facility to
organise groups to discuss specific problems. Whenever a patient
is a parent, psychosocial care is obligatory.
Twice a year, the clients are invited to complete a questionnaire
for the organisation’s statistics and evaluation programme. At the
same time, the client is interviewed to evaluate his/her current
situation.
Pharmacy activity
Since decentralisation in 1994, about 35 pharmacists have par-
ticipated in the distribution of methadone. They are involved in
the treatment and can benefit from psychosocial support if they
wish. They are invited to participate in training programmes
organised by the methadone programme.
The pharmacists who participate in the distribution of methadone
also sell needles, and thus sometimes have a dual role. Harm
reduction is often the major aim (AIDS and hepatitis prevention),
making the distribution of sterile needles vital.
Primary-care involvement
Currently, of the prescribing doctors who participate in the
methadone programme, 90 % are GPs (40 out of a total of 225),
5 % are medical physicians and 5 % are psychiatrists. As can be
seen, GPs are very involved in substitution treatment. As stated
above, an agreement between the doctors’ association (a group of
doctors who created a working group to debate substitution treat-
ment) and the Ministry of Health outlining guidelines for substitu-
tion treatment is in preparation.
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Prior to the expansion of the methadone programme in 1994, only
a few doctors were involved in the treatment of drug users. At that
time, doctors could prescribe substances such as dihydrocodeine
without being monitored through the use of the special
prescriptions.
In 1994, there were no professional bodies offering advice
because few doctors were interested in drug-related medical prob-
lems. However, a working group of about 12 doctors has now
been created. An important point is that specialised training and
supervision are paid for by the Ministry of Health to encourage
doctors to participate in substitution treatment.
For most doctors in Luxembourg, the practice of working in a net-
work is new, because of the country’s tradition of a liberal medical
system. Organising meetings to discuss clients (for pooling infor-
mation or case management) is not usual practice, because these
meetings are not paid for. Nevertheless, such practices could be of
considerable benefit to many patients. Unfortunately, this defi-
ciency shows that social medicine does not exist in Luxembourg.
Substances prescribed
The substitution substance most often prescribed for opiate addic-
tion is methadone (95 %). It is prescribed in syrup form for the
clients who are in the national methadone programme. All other
drug users receiving substitution treatment receive their
methadone in tablets. The dosage for long-term substitution is
between 40 and 80 mg, with a maximum of 150 mg.
The situation regarding other substitution substances is as follows.
• Dihydrocodeine was often prescribed before the expansion of
the methadone programme in 1995. Now it is only prescribed
in very few cases.
• LAAM and palfium are not prescribed in Luxembourg.
• Buprenorphine is sometimes prescribed and this will probably
increase in the future (dosage 8–16 mg).
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• Dezitramide (20–40 mg) is sometimes prescribed to clients who
cannot tolerate methadone.
• Mephenon (methadone in pill form) is often prescribed in
Luxembourg. Its pharmacological action is equal to that of
methadone.
• Clonazepam (6 mg/day), bromazepam (up to 36 mg/day) or
lorazepam (up to 7.5 mg/day) are the substitution benzo-
diazepines most often prescribed for benzodiazepine addiction.
• Frazodone chlorhydrate (50–200 mg/day), fluoxetine (20–40
mg/day) or any other antidepressant drugs are prescribed for
amphetamine addiction.
Usually detoxification proceeds gradually and might take several
years. If a client desires a more rapid withdrawal, his/her dosage
will be reduced by about 10 % every 14 days. More rapid detox-
ification is possible but remains difficult.
Injectable prescribing
Luxembourg does not have any injectable prescribing. The August
1997 bill proposed a heroin programme, but the retirement of the
Ministers for Health and Justice involved (see above) engendered
a blocked situation.
Surveillance (16)
Established in 1994, RELIS is based on a standardised data proto-
col which includes 24 core items and over 60 sub-items. Ninety-
five per cent of the items in the Pompidou Group Protocol (a list
of treatment-demand indicators) are integrated into the standard
protocol. A second protocol, namely the ‘actualisation protocol’,
is completed each time a previously known drug addict is re-reg-
istered after a period of one year following the previous registra-
tion. This registration system allows for updated quality data and
efficient follow-up of the institutional careers of drug addicts.
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(16) The surveillance section was compiled from selected writings of Alain Origer, Head of the
Luxembourg national focal point of the EMCDDA’s Reitox network.
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RELIS relies on a mechanism known as the ‘institutional contact
indicator’, a data-providing network which includes all spe-
cialised drug-treatment institutions, law-enforcement agencies and
custodial institutions. Efforts are currently under way to encourage
the participation of GPs and emergency services in the information
network.
In terms of prevalence estimation and assessment of the impact of
specific demand-reduction or law-enforcement interventions, as
well as in terms of planning new institutions or addressing gaps in
drug care, RELIS is a reliable monitoring tool which operates on a
national basis and is regularly updated.
RELIS became operational in 1994 and currently relies on a multi-
sectoral network which includes:
• specialised treatment centres;
• general hospitals;
• counselling centres;
• legal bodies; and
• penal institutions.
In order to avoid duplication and to allow for follow-up of drug
users’ careers, RELIS operates on a nine-digit numerical code
which is obtained by combining the three variables (attributors),
namely:
• gender;
• date of birth (e.g. 10051967); and
• country of birth.
This results in a Luxembourg Reitox focal point proper code (cal-
culator). This technical device was developed by the focal point
itself. The method is very time- and cost-effective, because it relies
on a simple Hewlett Packard calculator that runs an attributor-to-
code transcription programme on a 27-step algorithm.
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It is not possible to extract information on the person to whom the
code relates and the transformation key is unknown to participat-
ing field institutions and to all members of the focal point. Even if
the calculation algorithm were to be discovered, he/she would be
unable to do a backward calculation. Each contact person in the
participating field institutions disposes of the calculator and pro-
duces the code himself/herself. The reliability of this system, in
terms of data protection, has recently been acknowledged by the
Commission nationale d’informatiques et de liberté (National
Commission for Informatics and Liberties) of France.
One of the main assets of RELIS is that no personal data can be
inferred directly from the identification code. The inputting and
encoding procedures are carried out at the level of the field insti-
tutions. In this way, the focal point receives individualised data
(reporting protocols) without nominative information or attributors
on the persons thus registered, which is undoubtedly one the
major preoccupations of field institutions.
The information gathered by this system and the results of research
coordinated by the national focal point contribute to the political
decision-making processes in Luxembourg as well as to the draft-
ing of new action plans in the area of drug abuse. At the European
level, Luxembourg’s national focal point collaborates with the
other national centres of the Reitox network. This collaboration
focuses, among others things, on:
• implementation of an interregional drug-treatment reporting sys-
tem (TRANS-RELIS), which includes border regions of Belgium,
Germany and France;
• active collaboration in establishing the Reitox network’s
IDA/EMCDDA project; and
• analysis of procedures to improve national drug monitoring sys-
tems within the European Union.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
173
42d930_insights_brochure  09-11-2000  14:53  Pagina 173
Comments and remarks
The numbers of counselling clients have varied only slightly over
the years. Low-threshold services are being increasingly solicited.
The residential community had 39 admissions in 1998 and it ran
a full house with a waiting list during some periods. Over the pe-
riod 1998–99, the work concept of the residential community has
been usefully modified.
Many drug users go to other countries (Belgium, Germany, France
and Italy) for residential treatment, because of the limited number
of places offered in Luxembourg.
Problems
A number of the residents in the neighbourhood of the treatment
centres encounter considerable problems with the services, mostly
due to the following factors:
• the centres are situated near the railway station;
• prostitution is practised in this area; and
• the area is still a residential one.
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TABLE 2: SOME DATA FROM THE RELIS STUDY AND THE ANNUAL
REPORTS OF THE SPECIALIST SERVICES IN LUXEMBOURG (1996–98)
SPECIALIST INSTITUTIONS 1996 1997 1998
Counselling JDH-Lux 
(ambulatory service) 308 persons 244 persons 270 persons
Counselling JDH-Esch 
(ambulatory service) 175 persons 166 persons 183 persons
Methadone programme 128 persons 158 persons 186 persons
Camionnette 
(low-threshold specialist 
service) 6 456 contacts 8 734 contacts 8 525 contacts
Neuro-psy hospital 
(specialised service 
for inpatient detoxification) 250 admissions 226 admissions 251 admissions
Residential community 
(Manternach) 58 admissions 62 admissions 39 admissions
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Unfortunately, the residents no longer feel safe. They have formed
a local organisation but this is unlikely to bring about the closure
of the centres. Staff hold regular meetings to discuss strategies for
dealing with these problems.
As regards the situation in Luxembourg’s prisons, 36 % of prison-
ers in 1997 were imprisoned for drug-related offences. Clients
who are in methadone treatment before their detention continue
their treatment during remand and, in cases of a long prison sen-
tence, undergo slow detoxification. A prisoner is allowed
methadone before his/her release.
Evaluation
An evaluation of the methadone programme will be undertaken in
late 2000.
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THE NETHERLANDS
Han Kuipers, Trimbos-Instituut, Utrecht (17)
Introduction
The Netherlands is one of the smaller countries of Europe, yet it is
also one of the most densely populated and urbanised countries in
the world. For almost two centuries, the political system has been
a democratic one. The members of the Houses of Parliament of the
national government represent the people, while the judiciary
oversees the implementation of the laws.
In the Netherlands, there is an extensive and comprehensive
healthcare system. In practice, the system has two pillars:
• a considerable network of facilities for general healthcare; and
• a more extended network of facilities dedicated to specific
health tasks and social work (for instance, mental healthcare
and addiction care).
These facilities are funded by the Ministry of Health, health insur-
ance companies and funds controlled by private organisations
(foundations and associations) founded for this specific purpose.
Strategy
Drug laws
The first Opium Act of 1919 was a direct result of the Netherlands
attending the first International Drug Conference in The Hague
(1912). Opiates were strongly forbidden, except for registered use
for medical and scientific purposes. In 1928, the Opium Act was
amended for the first time (cannabis was included in this revision)
(17) The Trimbos-Instituut is the Dutch national focal point in the EMCDDA’s Reitox network.
42d930_insights_brochure  09-11-2000  14:53  Pagina 176
and for the second time in 1953. In 1976, the act was fundamen-
tally changed:
• a distinction was made between hard and soft drugs (unaccept-
able versus acceptable health risks); and
• the philosophy of reducing the health risks of users (harm reduc-
tion) was formally accepted.
Since 1976, the Netherlands has had its own drug policy. Prior to
that, the country was committed to a number of international
treaties, such as the 1961 UN Single Convention on Narcotic
Drugs.
The Opium Act is a penal law, and Dutch penal law recognises
two kinds of criminal act: criminal offences (crimes) and minor
offences (misdemeanours). In relation to drugs, processing, pro-
duction and trade other than for medical and scientific reasons are
major offences. The only minor offence in the area of drugs is pos-
session of small quantities of cannabis (up to 30 mg) other than for
personal use. Dutch penal law is strongly influenced by a prin-
ciple of expediency, which means that the public prosecutor
decides whether or not prosecution is necessary. The public pros-
ecutor is bound by a comprehensive set of guidelines.
The Netherlands is still party to a number of international treaties.
All three United Nations conventions in the area of drugs have
been ratified by the Dutch Parliament and some elements have
been integrated into Dutch law. Besides these UN conventions,
the country is also committed to a number of European treaties,
the most important of which is the Treaty on European Union
(Maastricht Treaty), and other treaties where EU Member States
cooperate on issues such as police activity and money laundering.
Since the 1980s, and particularly in 1995, when a government
paper entitled ‘Continuity and change’ was introduced, a number
of measures to reduce public nuisance caused by drug users and
drug tourists have been implemented to reduce the burden on the
judicial system. These policy changes have aimed at addressing
unwanted outcomes of the drug policy formulated in the 1970s.
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Philosophy and objectives
Availability of drugs is a reality in open western societies.
Recognising that drugs are probably here to stay, the Netherlands
Government acknowledges the importance of prevention, treat-
ment and harm reduction for the individual and his/her environ-
ment, and for society as a whole. The underlying premise is that
the harmful effects of drug use do not depend solely on the prop-
erties of the substance, but also on the characteristics of the user,
the reasons for use and the circumstances under which the drug is
taken. Any policy ignoring such complex interrelations is bound to
fail. The government attaches great value not only to legislation,
but also to social control and social support. It believes that
prevention, treatment and harm reduction are better ways of con-
taining drug use and its associated problems than repression
alone.
The national cannabis policy is based on the assumption that
people do not switch from soft to hard drugs because of the prop-
erties of the substances in question, but rather because of social
and economic factors, such as the availability of both types of
drugs in criminal settings. According to this hypothesis, such a
transition can be prevented by separating the soft and hard drug
markets. At the same time, the government is actively fighting the
wholesale transporting, trafficking and manufacturing of hard
drugs and is also increasingly taking measures against the large-
scale cultivation and sale of cannabis.
Responsibilities
The Minister for Health, Welfare and Sport (HWS) and the Minister
for Justice are jointly responsible for national drug policy. The for-
mer coordinates this policy and is responsible for demand reduc-
tion (health policy in general, drug prevention, drug treatment and
harm reduction). The Minister for the Interior is responsible for
matters related to local administration and the police and the
Minister for Justice for the enforcement of criminal law and partly
for probation and aftercare services.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
178
42d930_insights_brochure  09-11-2000  14:53  Pagina 178
Objectives
Current drug policy in the Netherlands has four objectives:
• prevention (demand reduction) and treatment;
• harm reduction for drug users;
• reduction of the supply of drugs; and
• maintenance of public order.
This policy is carried out in close collaboration with healthcare
services (including addiction care), social-care professionals,
judicial authorities and those responsible for public order and
safety, such as the police. The main policy instruments are:
• separation of markets for soft and hard drugs;
• decriminalisation of the use of soft drugs;
• monitoring of changes in drug use and the consequences of drug
use;
• establishment of a highly diversified and extensive professional
network of healthcare and social services and institutions offer-
ing treatment and care for drug users;
• prevention of problem drug use through information and edu-
cation targeted at both the general public and specific groups;
• rehabilitation of (former) drug users;
• prevention of marginalisation and criminalisation of drug users,
to prevent them becoming outcasts or sources of infection;
• reconciling the interests of crime control with those of public
order, public health and public welfare;
• implementing severe penalties for the trafficking of hard drugs
and larger quantities of soft drugs; and
• financing research into the effectiveness and efficiency of addic-
tion treatment, care services and prevention programmes.
Nuisance policy
In 1993, the cabinet concluded that the nuisance caused by hard
drug addicts required a separate policy. The integration of various
measures and the cooperation between the municipalities,
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addiction-care facilities, the police and legal systems have been
the core of nuisance policy.
From the wide range of projects and facilities that have been set
up, some appear to function well, although others have been dis-
appointing or have led to unexpected results. The intramurale
motivatie centra (intramural motivation centres), and, in part, the
projects that encourage addicted prisoners to be treated, are
examples of this. An important conclusion is that no policy can 
be truly effective unless there is a degree of coherence and com-
patibility between the facilities. To prevent a situation arising
where a client is not accepted by any of the facilities, continuous
monitoring will be essential, which, in turn, requires a coordinated
approach and supervision of the various facilities.
A review study on the effectiveness of recommending treatment or
of compulsory treatment in cases of addiction-related nuisance
concluded that the benefits of these responses may well turn out
to be small and probably short lived. Little evidence can be found
in the international research literature on the effectiveness of the
large-scale application of recommending treatment (Rigter, 1998,
1999). Small-scale measures stimulating treatment for these
addicts might be considered.
Recent actions
Since 1997, the Unit Synthetische Drugs (Synthetic Drugs Unit)
has been operational in the Netherlands. Its main objectives are:
• to improve the national collation of information on synthetic
drugs and their precursors and to improve the use of this infor-
mation for judicial purposes;
• to provide support to local public prosecutors, police teams and
special investigation teams in their investigations into synthetic
drugs and their precursors; and
• to make national and international inquiries, independently of,
or in cooperation with, others, into synthetic drugs.
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This unit is expected to expand to a staff of about 50 professionals
with statutory power of investigation. Members come from the
Economic Surveillance Department of the Ministry of Economic
Affairs, the Customs Department, the Ministry of Finance’s Fiscal
Intelligence and Investigation Department, the Royal Netherlands
Military Constabulary, the Central Criminal Intelligence Service
and the Public Prosecution Department.
In 1997, the Minister for Health, Welfare and Sport announced
plans to establish a coherent national monitoring system, the
Nationale Drug Monitor (National Drug Monitor), covering exist-
ing projects and a number of new initiatives. The main reason was
the need for sound and comparable information on the effects of
drug policy measures and developments in use, treatment and
care. The general objective of this monitoring system is to improve
the existing, divergent monitoring practices by creating a harmon-
ising and coordinating framework. This will enable policy-makers
and researchers to better compare data from various sources and
to process and interpret such findings. It is aimed at illicit drugs,
but also includes alcohol, tobacco and other addictive substances.
Prevention and harm-reduction activities will be covered. The
main purpose is to yield reliable data at national level, although
local and regional information relevant to national policy should
also be considered. The National Drug Monitor went into effect in
1999 and published its first annual report in October 1999.
In 1998, a government paper was published by GGZ Nederland
(the Netherlands Mental Health Organisation) to stimulate quality
and innovation in addiction care. Core competencies of addiction
care should be enhanced. Recently established development cen-
tres in three areas are intended to stimulate this. These areas are
prevention, care and social addiction care (e.g. nuisance projects,
user rooms, supported living, or harm reduction). A starting con-
ference for the Nederlands Ontwikkelcentrum Preventie
(Development Centre for Prevention) was organised by three
addiction-care organisations that have volunteered to initiate this
quality-enhancement process. Several others are willing to join the
activities. Further initiatives are expected during 2000.
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The addiction-care system
There are 16 instellingen voor ambulante verslavingszorg (IAVs —
institutions for ambulatory addiction treatment and care), formerly
known as consultatiebureaus voor alcohol en drugs (CADs — con-
sultation bureaux for alcohol and drugs). These offer a wide range
of treatment, such as pharmacotherapy, psychotherapy, group
therapy and other forms of counselling. These 16 IAVs have some
130 branches throughout the country. Originally, there were
around 60 low-threshold facilities for social care, such as street-
corner work, shelter, methadone programmes, social and work-
rehabilitation projects, day programmes and crisis interventions.
Most of these facilities have merged with the CADs to form the
present IAVs. One of the historical tasks of these is the aftercare of
discharged prisoners. Police, prosecutors and judges may refer
drug users to one of the institutions. In such cases, the social
worker functions as a probation officer.
Inpatient treatment is provided by 19 addiction clinics (in an intra-
mural setting). Of these 19 institutions, 3 are independent, 8 are
part of a psychiatric hospital and 8 are part of an institution for
integrated (in- and outpatient) care for addicts. The treatments
offered can be short- or long-term interventions. Short-term inter-
ventions are directed at averting a crisis or at detoxifying the
client. A long-term intervention generally comprises a detoxifica-
tion programme (3 to 12 months’ therapy). During the 1990s, a
number of new formats of inpatient treatment were developed:
• living at home;
• living between home and hospital;
• daytime treatment (offered by some institutions); and
• intramural motivation centres.
In 1996, 10 addiction clinics were granted funding by the national
government to establish these intramural motivation centres with
a total of 136 places. These facilities are time-out centres for prob-
lem drug users for whom regular clinical treatment is not yet
appropriate.
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In 1997, there were 20 verslavingsbegeleidingsafdelingen (addic-
tion guidance departments), formerly the drugsvrije afdelingen
(drug-free departments), with a total of 446 places. More than half
of these facilities are located in detention centres and the rest are
in prisons.
Funding and budget
Implementation of the national drug policy and the addiction-care
system is financed by income from the social security acts, taxes
and health insurance companies. Relevant social security acts are
the Algemene Wet Bijzondere Ziektekosten (General Law for
Special Disease Management) and the health insurance funds. In
1997, the Ministry of Health’s overall budget for addiction issues
(including alcohol) was over NLG 66 million (EUR 30 million).
The municipalities fund the IAVs. The total budget available for
local and regional ambulatory treatment and care, and also for
preventive and harm-reduction activities, was more than NLG 110
million (EUR 50 million) in 1997. Also, the Ministry of Justice allo-
cated NLG 33 million (EUR 15 million) to the institutions for pro-
bation and aftercare services. Local methadone-maintenance pro-
grammes and low-threshold facilities received NLG 70.5 million
(EUR 32 million). The maximum budget for supplying methadone
was fixed at NLG 5 million (EUR 2.3 million) in 1998. In 1997,
NLG 4.21 million (EUR 1.91 million) was spent on methadone
supplies, and the actual costs in 1998 came to NLG 4.6 million
(EUR 2.1 million). In 1999, the budget for supplies was again fixed
at NLG 5 million (EUR 2.3 million).
The institutions that offer inpatient treatment are financed on the
basis of the General Law for Special Disease Management. In
1997, the budget for specialised addiction clinics was NLG 147
million (EUR 67 million). Most treatment costs for addicted clients
are mandatorily covered by public health insurance.
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Substitution
Development of substitution services
The history of substitution services has been well documented by
a number of authors (Driessen, 1990; van de Wijngaart, 1991).
According to some sources, substitution treatment started in 1968
in Amsterdam. The objective of this first methadone programme
was abstinence for heroin addicts. The format of the programme
was derived from Dole and Nyswander’s (1966) experiment in the
United States. Only a few addicts attended this first programme,
due to the fact that there were relatively few heroin users at that
time. This situation rapidly changed during the 1970s and, from
1972, a number of institutions offered methadone programmes to
clients.
From the beginning, the consultation bureaux for alcohol and
drugs were involved in substitution. In 1976, the Health Council
advised general practitioners (GPs) to stop prescribing methadone
to drug addicts because of the risks involved, such as manipula-
tion by the clients and improper use of prescriptions. In
Amsterdam, many GPs ignored this advice.
Surveys of methadone prescription and the availability of substitu-
tion programmes at a national level were conducted in 1978,
1982 and from 1989 to 1990. Local data are available in the big
cities, such as Amsterdam and Rotterdam, which have their own
registration system.
During the 1970s, the IAVs were relatively independent. One of
the consequences of this was that there was considerable variation
in the way methadone was provided, depending on healthcare
workers’ attitude towards methadone. The main treatment meth-
ods were the short-reduction, or detoxification, model, or a
longer-reduction model. Intake criteria hardly existed and there
were no general guidelines for determining dosage.
In 1977, the Ministry of Health published a paper as an attempt to
formulate policy principles and to provide some points of refer-
ence for everyday practice for those working in the field. As a
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result, new methadone programmes were set up whose main
objective was to improve the social functioning of a client. Thus,
reduction of heroin by means of methadone in order to achieve
abstinence had been replaced by the goal of maintenance. A study
carried out in 1982 (Buisman, 1983) confirmed this: 87 % of the
institutions reported that improving social functioning was their
main goal. Furthermore, they invested much energy into keeping
clients in the programme.
The admission criteria for methadone programmes were never
very specific during the 1980s and 1990s: being addicted to her-
oin for more than six months was (and still is) qualification enough
to enter a programme.
The present situation is not very different to that in the 1980s.
Methadone programmes are offered by all IAVs, which means that
every region has its own programme. Big cities such as Amsterdam
and Rotterdam, and also The Hague, have their own approach,
which is quite similar to the other regions. Almost all programmes
are to be considered as maintenance programmes. The structure of
the programme is clear to the client, and it is quite easy for an opi-
ate addict to enter a programme. To reach specific categories of
clients, the methadone mobile bus has been introduced in a num-
ber of cities.
Substances prescribed
In the Netherlands, a few experiments have been conducted to
look for alternatives to methadone. At the beginning of the 1990s,
an experiment with morphine was conducted in Amsterdam with
some positive results. This could be considered as an alternative
for a very small category of clients. LAAM substitution was not a
success, as drug addicts simply refused to participate in the proj-
ect. The same goes for clonidine: clients were not interested in this
alternative, so the experiment failed.
In a recent experiment, palfium was offered in combination with
methadone to 53 chronic opioid addicts (mean age of 43 years
and a mean maintenance use of methadone of 21 years). Heroin
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use was reduced for 60 % of the clients and most of the others
stopped using palfium. Using palfium for a longer period (in a
maintenance programme) is mainly effective when clients have a
more or less normal social situation (housing, partner, family
contacts).
Heroin supply
After a long period of preparation, the government, in 1997,
approved to start an experiment with heroin on strictly medical
grounds. The structure of the experiment is quite similar to the
Zurich experiment. The selection criteria the drug addicts have to
meet before entering the programme are very strict, and only seri-
ous problem drug users with a long history of unsuccessful treat-
ment are allowed to enter it. The first report on the experiment
describes the problems experienced during the first six months.
The results show that, despite many negative perceptions, it is pos-
sible to organise and carry out such a complex experiment.
Current situation
The current situation is much the same as it was at the beginning
of the 1990s. The 16 IAVs (see ‘The addiction-care system’ above)
and the Municipal Health Service in Amsterdam and Groningen
are the main providers of methadone treatment. A very few GPs
prescribe methadone to a small number of clients.
Almost all IAVs offer a maintenance and a reduction programme.
Over two thirds of the clients attend maintenance programmes.
One exception relates to programmes in detention centres, where
addicted prisoners who will spend more than a few weeks in
detention are obliged to follow a reduction programme.
According to the national registration data, in 1999 more than 
11 000 addicts were attending methadone programmes provided
by the IAVs, compared with 8 000 clients registered in 1988. More
than 75 % of all methadone clients live in the four big cities of the
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Netherlands: Amsterdam, Rotterdam, The Hague and Utrecht. The
number of prescriptions supplied per month is about 16, which
means that clients visit the institution four times a week for their
supplies. The average dose of methadone supplied is 35 mg. This
figure has been fairly stable over the years.
A large majority of the population using methadone is male (over
80 %), with an average age of over 30 years in 1997 and just
under 30 years in 1988. This figure is still rising: in Amsterdam the
average age was 37.8 years in 1997. This means that there are less
‘new’ heroin addicts and it could also mean that maintenance pro-
grammes do maintain the addiction: a considerable number of
clients have been in the programme since the mid-1980s.
More than a quarter of all clients using methadone are members
of ethnic minorities. This figure has remained stable for the last 10
years. A majority of these are from the former Dutch colonies of
Suriname and the Dutch Antilles. A minority were originally
Moroccan or Turkish but have lived in the Netherlands for many
years. These minorities, in total, constitute around 5 % of the pop-
ulation. This means ethnic minorities are over-represented in the
drug-using population in the Netherlands.
Legislation on substitution treatment
The Opium Act prohibits the use of methadone and other opiate
substitutes such as clonidine and palfium. The first Opium Act of
1919 (see ‘Drug laws’ above) regulated the production, transport,
trade and application of opium and its derivatives. This act was
amended in 1928 and 1953 in response to prevailing international
attitudes to drugs, dominated by the United States. The 1953
amendment meant that drug use became a criminal offence. The
1976 amendment was a political response to the actual situation
in the Netherlands at that time with regard to the use of cannabis
and opiates: production, transport and trade in opiates are still for-
bidden. Production and use of cannabis for private (recreational)
purposes were classified as a misdemeanour and were no longer
a criminal offence. Heroin and cocaine are not classified as med-
ical drugs, so only formal use within a scientific setting is allowed,
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whereas methadone is classified as a medical drug and can there-
fore be prescribed by any doctor. The rules of prescribing are cov-
ered by the Wet op de Geneesmiddelenvoorziening (Law on the
Provision of Medicines), and this is controlled by the Ministry of
Health. Clients in the substitution programmes are registered at
national level (see National Alcohol and Drugs Information
System under ‘Surveillance’ below).
A number of studies have been carried out, but these are almost
always statistical surveys. Only Driessen’s (1990) study can be
considered as an evaluation of methadone programmes in the
Netherlands. The conclusions of this study are rather disappoint-
ing: there is still much variation in the way different institutions
run their methadone programmes. There are no clear guidelines
for determining dosage. The differences identified seem to bear no
relation to any particular philosophy or treatment objective. The
majority of methadone programmes are well organised, but a con-
siderable number of institutions do not have any serious intake cri-
teria or medical examination requirement.
Related to this evaluation of methadone programmes, Driessen
(1992) also carried out a study on clients of the programmes. The
main results of this study are:
• the majority used methadone for a long period (on average eight
years);
• most clients used other substances in addition to methadone;
• morbidity is two times higher than in the same age group in the
general population; and
• many clients suffer infectious diseases related to drug use and
report more psychological problems than the same age group in
the general population.
Most of these results are applicable to general drug use rather than
to the specific use of methadone.
The first results of methadone maintenance in the Netherlands
were recently published by Driessen et al. (1999). Two and a half
years after the first tests, 8 % of the methadone users were found
to be abstinent. For more than half of the clients (57 %), a less-
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ambitious goal had been achieved: prevention of further deterior-
ation of the physical, psychological and social situation of the
addict; in other words, their situation had remained stable. For
26 % of clients, their situation had improved and for 17 % it had
worsened. The authors conclude that methadone maintenance is
successful when abstinence is not the primary goal. However, the
optimal dose has still not been determined in the Netherlands, and
a combination with counselling might be more effective.
Surveillance
The Netherlands has a system of national registration of clients of
the IAVs called Landelijk Alcohol en Drugs Informatie Systeem
(National Alcohol and Drugs Information System) which accumu-
lates considerable data on clients. Most clients of methadone pro-
grammes are registered with this system, and there are other
national registration systems which cover clients of the gemeen-
telijke geneeskundige en gezondheidsdienst (GGD — municipal
health services). Clients receiving inpatient treatment at intramural
institutions for addiction care are registered with an inpatient
register of the Patiëntenregister Intramurale Geestelijke
Gezondheidszorg (PIGGZ — Netherlands Mental Healthcare
Organisation).
Duplicating the records of those who attended an IAV as well as a
municipal health service used to be a problem, but in the 1980s
the registration systems were modified to overcome this.
Problems
There are two main problems relating to substitution treatment.
• A maintenance programme cannot exactly be seen as treatment.
The client is still addicted and, more problematically, he/she is
dependent on his/her methadone supplier. The original objec-
tive of maintenance was to improve the social functioning of
addicts, so that they could be stimulated to make changes in
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their lives, such as finishing school, starting vocational training
or applying for a job.
• Another problem is the lack of longitudinal studies on the effects
and effectiveness of substitution programmes. As stated before,
one study of this started recently and the results are not yet 
available.
Evaluation
Some studies have already been mentioned in the text, and an
extended list of references is given below under the heading
‘Further reading’.
Information in this chapter was updated by the EMCDDA and by
André van Gageldonk of the Trimbos-Instituut.
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AUSTRIA
Gabriele Fischer, University of Vienna, Vienna
Introduction
Although the increasing illicit drug consumption in the 1970s was
recognised as a social problem in Austria, abstinence-oriented
therapy was the only legal option in the medical treatment of
addiction until 1987 — the year when the Substitutionserlass
(Narcotics Maintenance Decree) was issued. Withdrawal therapy
was carried out with a variety of neuroleptic drugs, tranquillisers
and antidepressants. In 1998, the principle of providing mainte-
nance therapy for opiate dependence was anchored in the
Suchtmittelgesetz (Narcotic Substances Act).
Strategy
The Austrian ‘drug strategy’ (18) has a number of fundamental
objectives in addressing opiate dependence and provision of
treatment:
• prevention;
• maintenance therapy;
• harm reduction;
• social reintegration;
• abstinence-oriented therapy; and
• repression.
A federal law regulates the therapy options, and the individual
provinces are responsible for the implementation of these options.
This situation leads to significant variations in the implementation
of drug treatment in the various provinces. In some parts of
Austria, an opiate addict must submit a written application to a
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special commission prior to being admitted to one of the main-
tenance programmes, whereas, in Vienna, it is solely the respon-
sibility of the attending physician or care unit to decide who is
suitable for maintenance therapy.
Substitution
Development of substitution services
For a long time, outpatient or inpatient detoxification treatment
was the only legal option in the treatment of opiate dependence.
However, the effectiveness of maintenance therapy in other
European countries, and the increasing awareness of risk factors
such as HIV infection, led to a gradual acceptance of maintenance
therapy.
In 1985, the first treatment trials were carried out with methadone
tablets at the Department of Psychiatry at the University of Vienna.
Since the official Narcotics Maintenance Decree of 1987,
methadone has been available only in liquid form. Initially, treat-
ment of opiate dependence with opioids was offered only in the
specialist departments of hospitals (primarily psychiatric wards),
but, over the years, an increased demand for therapy resulted in
the establishment of a number of facilities with various strategies.
‘Outreach services’ are the first level of care for drug addicts.
Support and harm reduction are important for patients who are not
particularly motivated to change their life circumstances. The
social workers at the Verein der Wiener Sozialprojekte
(Association of Social Projects, Vienna) not only operate a base in
one of the underground stations in Vienna, which has been a
meeting-point for drug addicts for many years, but also a bus that
travels to other parts of Vienna on a fixed schedule. The main
emphasis of the bus is a syringe-exchange programme. In 1997,
438 661 syringes were exchanged for sterile instruments 
(Figure 1).
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So-called ‘street workers’ make contact with addicts at known
meeting-points and offer advice, help and medical care in order to
form a basis of trust. These street workers usually cooperate very
closely with low-level facilities.
The next level of care are the ‘low-level facilities’, such as the
Ganslwirt. The Ganslwirt not only offers patients psychiatric and
medical care for their substance dependence and consequent
physical problems, but also provides facilities for washing clothes,
receiving cheap meals and participating in leisure activities; there
are also a few beds available. Social workers offer help with finan-
cial problems and official matters.
The next stage, the so-called ‘high-level facilities’, requires that
patients understand the nature of their condition, since their visits
are scheduled by appointment only. Only patients with strong
motivation to undergo treatment are allowed to follow the therapy
regime. Multiprofessional teams, consisting of physicians, social
workers, psychotherapists and nursing staff, provide patients with
medical treatment and also try to improve patients’ whole life sit-
uation where possible.
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FIGURE 1: NEEDLE EXCHANGE IN VIENNA, AUSTRIA (1993–97)
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One example of such a facility is the Drogenambulanz Klinische
Abteilung für Allgemeine Psychiatrie (drug-addiction outpatient
clinic at the Department of General Psychiatry), University of
Vienna (http://www.akh-wien.ac.at/drogenambulanz; e-mail:
drogenambulanz@akh-wien.ac.at). This clinic was established in
1967 and was originally only open for a few hours each week. In
1995, Gabriele Fischer became medical director of the drug-
addiction outpatient clinic and expanded it. Currently, three psy-
chiatrists, two social workers and two psychologists are employed
there, in collaboration with nurses (who also work in other out-
patient clinics of the Department of General Psychiatry) and
interns. 
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195TABLE 1: DRUG-ADDICTION OUTPATIENT CLINIC: 
TREATMENT DOSES OF SYNTHETIC OPIOIDS 
USED FOR MAINTENANCE THERAPY, AUSTRIA (1998)
MEAN/DAY STANDARD RANGE
DEVIATION
Methadone
Total (n = 436) 60.96 29.34 16–150
Females 58.68 33.60 15–200
Males 61.18 23.76 15–200
Mundidol retard® (1)
Total (n = 17) 470.00 210.27 300–700
Females 240.00 207.85 120–600
Males 670.59 95.58 120–700
Vendal retard® (2)
Total (n = 255) 651.34 234.38 300–1 200
Females 635.52 237.75 300–1 200
Males 666.67 230.04 300–1 200
Kapanol retard® (1)
Total (n = 225) 452.63 186.80 100–900
Females 443.41 192.65 150–900
Males 459.46 182.04 100–900
Subutex® (3)
Total (n = 102) 9.12 3.40 2–16
Females 8.46 3.52 2–16
Males 9.83 3.10 2–16
(1) Morphine sulphate.
(2) Morphine hydrochloride.
(3) Buprenorphine.
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In 1998, 448 male and 307 female patients received medical and
sociotherapeutic care at the clinic (Table 1; Figures 2 and 3). In
addition, a number of physicians involved in research trials also
work there.
The relatively high percentage of women patients is explained by
the fact that a special programme for pregnant women with sub-
stance dependence was established in 1995. In close cooperation
with the Department of Gynaecology and Obstetrics and the
University Children’s Department, the women receive multi-
professional care during pregnancy and after delivery. Neonates
suffering from neonatal withdrawal can be treated in the collab-
orating children’s clinic.
Since 1991, all prisons in Austria have been offering maintenance
therapy with synthetic opioids during a prison sentence. The
prison in Favoriten (Vienna) has specialised in the treatment of
addicts, and patients can also acquire job qualifications in the
form of an apprenticeship there. Social and psychotherapeutic
approaches are offered in addition to medical treatment.
‘Abstinence-oriented facilities’ can only be used by patients after
successful physical detoxification, which is usually performed in
psychiatric departments. Subsequently, a long-term therapy pro-
gramme tries to facilitate the social and vocational rehabilitation
of patients. This therapy usually lasts for between six months and
two years, and is offered in therapeutic housing communities.
Most of these facilities are within an hour’s drive of Vienna (such
as the Grÿner Kreis, Anton Proksch Institute), but there are also a
few in the western parts of Austria (such as the Stiftung Maria
Ebene). Group-therapy sessions, individual therapy, sports and
regular work are all part of the programme.
Current situation
Austria has tried to prevent open drug scenes developing (such as
existed in Switzerland some years ago) by increasing deployment
of police. A further focus of police work is to attempt to stop drug
dealing and smuggling. Possession of even small quantities of 
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illegal drugs is a criminal offence, although criminal proceedings
can be avoided if the offender agrees to undergo counselling or
treatment. This aims at avoiding criminalisation of those patients
who buy or possess drugs solely for their own use. However, the
distinction between persons who only use drugs themselves and
those who smuggle and deal in drugs is quite limited when it
comes to addicts becoming minor dealers or drug couriers in order
to finance their own addiction. This can be seen from the fact that
convictions for dealing or possessing small quantities of illegal
drugs (paragraph 16 of the Suchgiftgesetz (SGG — Narcotic Drugs
Act)) were twice as high as those for larger quantities (paragraph
12) (Table 2). (The Narcotic Drugs Act of 1971 — revised in 1980
and 1985 — was the predecessor of the 1998 Narcotic Substances
Act.)
As in most countries, the drug problem is concentrated in the
major cities. Also, the opening of the borders in the east of Austria
to the countries of the former Warsaw Pact has led to increased
smuggling and thus to cheaper drugs. In 1987, 33 kg of heroin
were confiscated, but by 1997 this figure had risen to 102 kg.
During the same period, the amount of cocaine confiscated rose
from 72 to 87 kg. Cannabis is the most frequently confiscated drug
and is also the most common reason for criminal charges under
the 1998 Narcotic Substances Act. Confiscation of amphetamines
and ecstasy is also on the increase. Ecstasy was first discovered in
TABLE 2: DRUG-RELATED CONVICTIONS IN AUSTRIA (1997)
DRUG-RELATED CONVICTIONS
14–19 20–24 25–30 31–35 > 35 
YEARS YEARS YEARS YEARS YEARS
TOTAL
Total Male 453 1 166 712 469 479 3 279
Female 68 190 113 81 66 518
Narcotic Drugs Act, Male 84 275 217 152 175 913
paragraph 12 (1) Female 14 41 27 17 24 123
Narcotic Drugs Act, Male 380 888 480 300 279 2 327
paragraph 16 (2) Female 54 148 85 63 40 390
(1) Suchgiftgesetz (SGG), paragraph 12: Professional possession and dealing. 
(2) Suchgiftgesetz (SGG), paragraph 16: Possession and dealing of small amounts.
Source: Österreichisches Statistisches Zentralamt (ÖSTAT) — Austrian criminal court statistics from the
Austrian statistical office. 
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Austria in 1994, and, since then, the number of tablets confiscated
has increased eightfold (Table 3). Most of those convicted are aged
20–24, followed by people aged 25–30, with a strong male dom-
inance (Table 2 above).
As a result of greater freedom in travelling and the varying eco-
nomic situations in Europe, immigration to Austria has consider-
ably increased, primarily from the former eastern bloc countries,
as well as the former Yugoslavia and Turkey. Refugees (and their
children) who have fled their home countries for political or eco-
nomic reasons represent a steadily growing section of the patients
in drug-counselling facilities.
Legislation on substitution treatment
From 1987, the Narcotics Maintenance Decree regulated the
treatment of opiate addiction with synthetic opioids. Until this
decree was revised in 1998, physicians were entitled to use any
oral opioid licensed in Austria for the treatment of severe pain.
Unfortunately, there are no standardised qualification require-
ments for physicians treating drug addicts with opioids. Since spe-
cial qualifications are not required, the quality of therapy depends
greatly on the commitment and motivation of individual physi-
cians to undergo further training. There are no regulations as to
how often urine samples should be analysed for drug toxicology,
and, although concurrent psychosocial care is recommended, it is
only mandatory in the case of young patients. At present, there 
is a strong emphasis on concurrent psychotherapy, whereas 
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TABLE 3: SUBSTANCES CONFISCATED IN AUSTRIA (1988–97)
SUBSTANCE 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997
Cannabis (kg) 205 192 320 12 166 248 546 394 697 517 915
Heroin (kg) 50.5 100.5 72.3 102.8 78.2 104.8 80.2 47 81.3 102
Cocaine (kg) 14.4 20.9 41.2 84.4 58.1 83.9 52.6 55.3 72.7 87
Amphetamines (kg) 0.1 0.1 0.2 0.3 0.4 0.3 0.7 1.6 3.7 7.9
LSD (tablets) 1 092 3 237 418 906 3 847 28 201 1 543 2 602 4 166 5 243
Ecstasy (tablets) — — — — — — 3 003 31 338 25 118 23 522
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psychosocial care, combined with medical care, has been proven
to be more relevant for patients in rehabilitation.
Since the decree was revised, it is still possible for any general
practitioner to prescribe methadone, but prescription of oral slow-
release morphine for maintenance is now reserved for specialist
clinics.
The law defines methadone as the substance of choice in substi-
tution treatment. From a medical point of view, this must be
regarded critically, as it shows that treatment of substance
dependence is still strongly governed by social attitudes and polit-
ical views. Therapy guidelines should be based purely on medical
considerations, as with other diseases. In the event of strong side
effects, such as depressive symptoms or extreme weight gain, or in
the case of pregnancy or patients with HIV infection, slow-release
morphine should be the substance of choice.
Most patients are prescribed their opioid with a so-called ‘narcotic
long-term prescription’. This allows them to obtain a fixed daily
dose of the maintenance substance for 30 days. Once the pre-
scription has been issued by a physician, it must be endorsed by a
medical officer from the health authority. He/she checks that the
prescription is formally correct and that the patient is a resident of
the relevant district. This is to prevent a patient from obtaining
more than one long-term prescription.
Daily opioid issue at the pharmacy is a legal requirement,
although exceptions can be made for those patients who are
unable to go to the pharmacy every day because of their working
hours or because of physical problems. At weekends, the syn-
thetic opioids are usually issued on Fridays. However, in the case
of well-stabilised patients without relapse, it could be argued that
issuing opioids for several days can and should be used
therapeutically. This could enhance patients’ self-confidence and
help develop responsibility for handling their own problem.
The attending physician must report all patients undergoing main-
tenance therapy to the Suchtgiftüberwachungsstelle (Substance
Monitoring Authority). In 1998, 3 082 such cases were reported
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(Figure 4). However, it should be mentioned that this figure is
incomplete, since not every physician reports his/her patients.
Substitution clients
Patients who meet the criteria of the 10th edition of the
International Classification of Diseases (ICD-10) for opiate
dependence can be included in a maintenance therapy pro-
gramme. Adolescents must prove that detoxification has been
attempted before being accepted on a maintenance programme.
In 1998, 3 082 patients were enrolled in maintenance therapy,
most of them (2 121) in Vienna (Figure 4). This is due not only to
the fact that major cities have more drug addicts, but also because
the criteria for inclusion in a therapy programme can be very strict
in some provinces. Therefore, many drug addicts outside the cities
either do not undergo therapy or they try to access it in Vienna.
One remarkable phenomenon is that the age of patients in main-
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FIGURE 4: NUMBER OF OPIOID-MAINTAINED PATIENTS 
IN AUSTRIA (1998) (PAIN TREATMENT NOT INCLUDED)
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tenance therapy is fairly high. The majority of patients of both
sexes are aged over 34 years (Figure 5).
In order to make comprehensive rehabilitation possible, the
Arbeitsmarktservice (Labour Market Service) has for some years
offered special services for drug addicts. In addition, there are a
number of private and public associations that offer vocational
training and further education.
Virus infections
In Austria, the number of individuals who are HIV positive can
only be estimated, since only those who are actually suffering
from AIDS are registered. Unlike hepatitis C, HIV infection does
not have to be reported. In 1997, 76 persons were reported with
AIDS, 17 of whom were injecting drug users.
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In total, the HIV infection rate in Austria is fairly low compared
with other European countries. However, since only estimates are
available, figures are not provided here.
The situation with regard to hepatitis C infection is quite different.
In a study at the drug-addiction outpatient clinic at the Vienna
General Hospital, hepatitis C antibodies were found in 80 % of a
random sample of 197 patients. Since, according to estimates, up
to 40 % of patients with hepatitis C infection develop liver cirrho-
sis, this disease is likely to become a major challenge for the
health system.
Pharmacy activity
Pharmacies play an important role in maintenance therapy. The
prescription must be deposited with the pharmacy, and the patient
takes his/her opioid under supervision at the pharmacy. The phar-
macist records whether the patient has received his/her drug on
the prescription every day. Since the pharmacist is in contact with
the patient every day, he/she is often the first to notice any worry-
ing changes in behaviour. The pharmacist, therefore, can be an
important link between the physician and the patient. In future,
pharmacists should be integrated more actively into the treatment
programme. Education events organised by the Österreichische
Apothekervereinigung (Austrian Pharmacists’ Council) have led to
a clear increase in understanding and a decrease in bias with
regard to maintenance patients.
Primary-care involvement
The involvement of general practitioners in maintenance therapy
varies considerably from one province to another.
The national health insurance and the Ärztekammer (Medical
Council) run a joint scheme which acknowledges that the treat-
ment of drug addicts is a special service. If proof of participation
in an education event is furnished by a general practitioner, an
42d930_insights_brochure  09-11-2000  14:53  Pagina 203
appropriate fee is paid for the treatment of drug addicts.
Unfortunately, these education events do not follow standardised
treatment procedures. The aim of this scheme is to encourage
greater involvement of general practitioners in maintenance ther-
apy. Many general practitioners are overtaxed by the demands of
the psychiatric disorders which can accompany drug addiction;
addicts are sometimes difficult patients. It is often feared that other
patients might be deterred from attending a general practitioner
who treats addicts. Some doctors accept a small number of substi-
tution patients, or only patients that they know well, while others
treat too many and find it difficult to cope, which can lead to pre-
scribing benzodiazepines. Only estimates and no conclusive data
are available about how many maintenance patients are treated by
general practitioners.
Substances prescribed
Methadone: Racemic methadone is used exclusively in liquid
form. The recommended daily dose is 60–100 mg. In exceptional
cases, more than 100 mg a day may be prescribed, especially for
patients with a physical disorder where additional drug therapy
leads to enzyme induction in the liver. Methadone is administered
with syrup, partly in order to prevent intravenous consumption
and partly to improve the taste.
Oral slow-release morphine: Morphine sulphate and morphine
hydrochloride, with an action of 12–24 hours, are used.
Recommended daily doses range from 200–600 mg. HIV-positive
patients, especially those on combination therapy, often require a
higher dose. Until recently, slow-release morphine was licensed
only as a drug for treating severe pain, but a preparation has now
been licensed specifically for maintenance therapy. Further such
opioids will be submitted for licensing in the near future.
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Buprenorphine: This partial morphine agonist has been used in
low doses for pain therapy for some time. At the drug-addiction
outpatient clinic, tablets of 2 and 8 mg (Subutex®) are being used
for maintenance therapy in clinical trials. The average recom-
mended daily dose is 8–12 mg. Buprenorphine has been licensed
in Austria since 1999.
LAAM: This is already licensed but hardly used in Austria.
Injectable prescribing
Under the 1998 Narcotic Substances Act, opioids for injection are
not permitted. Oral maintenance therapy is used in order to avoid
the health risks associated with unsupervised injecting. It also
avoids promoting the mystique and seduction associated with the
ritual of preparing and administering the injections.
Surveillance
In Austria, no special surveillance system for substitution treatment
has been defined.
Problems
A significant problem in the treatment of drug addicts results from
the fact that substance dependence is still regarded by the public
as a vice and not as a disease. Treatment is still not possible on a
purely medical-scientific basis, as it is too strongly associated with
public opinion and political views.
The Austrian media present the statistics on drug-related deaths as
a measure of the success or failure of political policy (Table 4).
Although, since 1995, there have been efforts to differentiate
between overdose and other causes of death, these statistics
remain a problem. The high degree of co-morbidity in addicts with
depression, anxiety and other psychiatric disorders is ignored. 
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A correlation between death and efficacy of treatment is not made
in any other disease.
Another problem is the lack of scientifically obtained epidemio-
logical data. Very few studies have been conducted investigating
the prevalence of addiction (of legal and illegal substances) in
Austria. The data provided by the Ministry of Health (currently part
of the Federal Ministry of Social Security and Generations) must be
considered incomplete, and the World Health Organisation
(WHO) gives estimates based on ‘official’ data.
Differences in how the 1987 Narcotics Maintenance Decree is
interpreted make the development of an adequate nationwide care
network difficult. Patients in all the federal provinces should 
have equal access to maintenance therapy.
Physicians who are permitted to prescribe opioids for the treat-
ment of opiate addicts should have to prove that they are suitably
qualified. General practitioners can only cope with a limited num-
ber of patients in an oral maintenance programme, depending on
the severity of the disease.
TABLE 4: DRUG-RELATED DEATHS IN AUSTRIA (1989–97)
AGE 1989 1990 1991 1992 1993 1994 1995 1996 1997
ABS. % ABS. % ABS. % ABS. % ABS. % ABS. % ABS. % ABS. % ABS. %
Up to 
19 6 7 4 5 2 2 22 12 32 14 34 13 33 14 24 10 20 12
20–24 14 17 13 16 22 19 40 21 63 28 55 22 40 16 47 20 38 22
25–29 29 35 21 25 36 31 42 23 38 17 42 17 46 19 36 16 26 15
30–34 22 27 27 33 39 34 47 25 56 25 65 26 62 26 54 24 33 19
35–39 8 10 16 19 13 11 25 13 32 14 42 17 41 17 45 20 30 17
40 or 
over 3 4 2 2 4 3 11 6 5 2 12 5 19 8 24 10 25 15
Total 82 100 83 100 116 100 187 100 226 100 250 100 241 100 230 100 172 100
Female n.a. n.a. 14 17 24 21 33 18 39 17 40 16 45 19 36 16 29 17
Male n.a. n.a. 69 83 92 79 154 82 187 83 210 84 196 81 194 84 143 83
Source: Department VIII, Ministry of Health.
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Currently, a strong emphasis on psychotherapeutic care can be
observed. However, psychotherapy is only helpful once a patient
is medically and socially stable, and once there is evidence of
strong motivation for change (only about 10 % of patients are suit-
able for psychotherapy). Thus, a phased therapy plan is more use-
ful than the concurrent therapy approach which frequently leads
to years of ‘wrong’ treatment being provided. The national health
insurance pays for medical and psychotherapeutical care, but not
for psychosocial care, which constitutes a very important part of
treatment for stabilising patients. A disease that leads to discrimi-
nation must not be subject to discriminatory treatment.
Evaluation
In Austria, there is no public funding for the evaluation of patients
enrolled in substitution programmes.
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PORTUGAL
Rodrigo Coutinho and José Godinho, Serviço de Prevenção e
Tratamento da Toxicodependência, Lisbon
Introduction
Portugal became a parliamentary and democratic republic on 
25 April 1974. It is one of the most socioeconomically disadvan-
taged countries in the EU, with considerable deficiencies in edu-
cational and professional training and significant asymmetries of
development between the coastal and inner areas. The main cities
are densely populated, and a high proportion of the population is
very deprived, with living standards far below the European aver-
age. This situation generates serious social problems, such as
increased trafficking in, and consumption of, illicit drugs.
The number of heroin users in Portugal is unknown, although
some empirical estimates suggest that there are around 50 000
(approximately 5 in every 1 000 of the overall population).
However, recent research of local prevalence suggests this number
may be much higher (around 100 000).
Recent years have witnessed the development of social policies
which have brought about some improvement in the situation,
either through the social security system, of which the most
recently implemented measure was the minimum guaranteed
income, or through incentives by non-governmental organisations
(NGOs).
In 1979, the Serviço Nacional de Saúde (SNS — National Health
Service) was created, whose aims were:
• to provide universal and free access to integrated healthcare
(primary and specialised);
• to promote good health; and
• to monitor and prevent disease.
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In 1990, the Lei de Bases da Saúde (Basic Health Law) was passed,
which aimed at promoting a universal healthcare system consist-
ing of the SNS, private entities and independent professionals. This
system would, in principle, offer free healthcare to everyone.
The healthcare centres and hospitals are the local and regional
bodies responsible for providing healthcare to the population.
These are administered by the Ministry of Health.
The Ministries of Health and Social Solidarity collaborate on
health and social security, both at a regional level (through the
regional health administrations and the social security) and at a
local level (through the provision of social service workers in the
healthcare units).
Strategy
In Portugal, the coordination structure for addressing the drugs
problem is ensured at the highest political level by the Conselho
Coordenador da Estratégia Nacional de Luta contra a Droga
(Council for the Coordination of the National Drug Strategy). This
interdepartmental political body, chaired by the Prime Minister,
includes all Portuguese ministers working on drugs. It determines
the national drug policy and the plans for its implementation.
The Secretary of State of the Presidency of the Council of Ministers
is the member of government appointed to oversee the imple-
mentation of all drug-related political decisions, in particular the
Estratégia Nacional de Luta contra a Droga (National Drug
Strategy) adopted on 26 May 1999.
The execution of the national policy on drug addiction is guar-
anteed by the Instituto Português das Drogas e das Toxico-
dependências (IPDT — Portuguese Institute for Drugs and Drug
Addictions), which was restructured on 18 May 2000. The IPDT
replaced the former national drug-prevention programme —
‘Projecto VIDA’ — on 18 August 2000. The president of the IPDT
also took over the coordinating functions previously performed by
the coordinator of ‘Projecto VIDA’.
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The Comissão Técnica de Acompanhamento (Technical Support
Committee), one of the IPDT bodies, consisting of directors-general
and heads of department in the various ministries involved in the
field of drug addiction, plays an important coordinating role at
national level. The IPDT also ensures the functioning of a national
information system on drugs and drug addiction and constitutes
the Portuguese focal point in the EMCDDA’s Reitox network.
In addition, the Conselho Nacional da Droga e da
Toxicodependência (National Drug Council) exists as an advisory
body to the Prime Minister. This involves representatives of over
20 social, political and religious organisations and provides expert
opinions on request.
In 1999, PTE 17 billion (EUR 85 million) was allocated to the min-
istries and public services implementing actions against drugs, 
PTE 7 billion (EUR 36 million) of which went to the Ministry of
Health’s Serviço de Prevenção e Tratamento da Toxico-
dependência (SPTT — Service for the Prevention and Treatment of
Drug Addiction) set up in 1990.
Local and regional authorities and NGOs also promote some ser-
vices and intervention measures.
Treatment
The following excerpt from the publication Estratégia nacional de
luta contra a droga (1999) (1999 National strategy against drugs)
outlines key points in Portugal’s treatment activities:
‘Drug-addiction treatment reveals specific features charac-
teristic of each drug in particular and general features
which are common to all addictions.
Heroin is the addiction substance that is responsible for
more than 95 % of requests for specialised help. That is why
the therapeutic structures of this area have been specially
adapted to the treatment of heroin addicts. It is also in the
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heroin-related field that the psychopharmacological thera-
peutics are most developed.
The treatment of drug addicts in Portugal is carried out by
public services and by a high number of both profit-making
and non-profit-making private organisations, which demon-
strate the engagement of civil society in this sphere. It com-
prehends a set of differentiated or specific interventions,
according to the treatment phase or the problem posed by
each case. The technical, multidisciplinary teams reflect the
diversity of this intervention. They are made up of phy-
sicians, psychologists, social service workers, nurses, 
psychosocial workers, physiotherapists, occupational 
therapists, etc.’
Substitution
Development of substitution services
The Portuguese substitution programme started in 1977 in Oporto.
The Centro de Estudos e Profilaxia da Droga/Norte (CEPD/Norte
— Study Centre on Drug Prevention/North), which ran the pro-
gramme, was the responsibility of the Ministry of Justice, and this
centre along with the CEPD/Centro (CEPD/Central), in Coimbra,
and the CEPD/Sul (CEPD/South), in Lisbon, were the only
institutions exclusively engaged in the drug-addiction field. The
CEPD/North, using methadone as the substituting substance, was
the only unit using opioid substitution until 1992. While primarily
meant for users living in the Greater Oporto area, this programme
also served a limited number of patients in the central and south-
ern regions.
In 1987, the Centro das Taipas in Lisbon was created, an institu-
tion specialising in the treatment of drug addicts. This centre con-
sisted of a consultation service, a day centre and an inpatient
detoxification unit. This facility, which was the responsibility of
the Ministry of Health, was the first in the network of centres spe-
cialising in treating drug addiction which now covers the whole
country. These units, called centros de atendimento a toxico-
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dependentes (CATs — centres of assistance to drug addicts), are
administered by the SPTT and, since 1990, have included the for-
mer study centres on drug prevention. With the exception of the
Boavista CAT (the former CEPD/North — Boavista is an area of
Oporto), the CATs developed a drug-free therapy strategy, as they
had not adopted a substance-substitution approach from the start.
However, the increase in numbers of drug addicts (including an
‘explosion’ at the beginning of the 1990s), together with the
growth of AIDS and hepatitis C among this population, has led to
a change in attitude. Since 1992, methadone-substitution pro-
grammes have been extended to several CATs. The Leiria (Centre)
and Olhão (Algarve) CATs were the first to join this therapeutic
model, but now most of the others have substance-substitution
programmes. In 1994, the Taipas CAT started a substitution pro-
gramme with LAAM, becoming the first European centre to use
this substance. LAAM has the advantage of needing to be taken
only three times a week, thus avoiding Saturdays and Sundays,
and is currently prescribed in several centres throughout the coun-
try (Almada, Gaia, Gondomar, Lisbon, Oporto, Setúbal, etc.).
To date, substitution services in Portugal have been the sole
responsibility of the State and dependent on the authorisation of
the SPTT. In 2000, the only substitution services which are not
dependent on the SPTT are the psychiatric services of Santa Maria
Hospital in Lisbon, S. João Hospital in Oporto and the Sines
Health Centre.
The intervention model adopted varies from centre to centre, but,
overall, the programmes are medium or high threshold. With the
exception of occasional activities in a slum area in Lisbon, there
are no true low-threshold programmes (risk and harm reduction).
The main goal of the current drug-addiction intervention policy is
expansion of the substitution programmes in order to meet the
growing demand. The possibility of developing risk- and harm-
reduction programmes in the worst-affected areas is currently
under study. Some of the resulting programmes are likely to be
implemented by non-governmental organisations duly authorised
by the SPTT.
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Current situation
Most areas of Portugal currently run substitution programmes, the
most developed being located in the main urban centres of the
coastal areas (Lisbon and the Tagus Valley, Oporto and the
Algarve). With the exception of the Boavista CAT, which has 20
years of experience in substitution programmes, all the Portuguese
centres (having only recently introduced substitution programmes)
prioritise abstinence, offering the following therapeutic services:
• individual and group psychotherapies;
• family therapy; and
• therapy with an opioid antagonist.
Until 31 December 1998, 74 312 users had been treated by the
CATs. Of this total, 24 164 were treated in 1998. In December
1998, 3 984 users were currently in substitution (3 475 on
methadone and 509 on LAAM). The average age of clients was
30–35 years; 75–80 % were men and 20–25 % were women.
Until 31 December 1999, 102 062 users had been treated by the
CATs. Of this total, 27 750 were treated in 1999. In December
1999, 6 040 users were currently in substitution (5 343 on
methadone and 697 on LAAM).
Until now, the substitution programmes and non-opioid therapies
have mostly been carried out in the CATs (with the exception of
the programmes in Santa Maria Hospital in Lisbon and S. João
Hospital in Oporto). Some CATs assign other institutions, namely
the healthcare centres, to administer their programmes. Currently,
an experimental programme is in progress in which some phar-
macies cooperate in the administration of methadone to fairly sta-
bilised patients who are being treated by the CATs. In all cases,
methadone is always administered under the supervision of qual-
ified staff. Unlike some methadone centres in other countries, the
CATs have a limited number of available places. The number of
patients in each centre varies according to its capacity and the
availability of staff. There are long waiting lists for substitution pro-
grammes in the urban centres, and efforts are being made to
increase the response ability of treatment centres.
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It is not possible to assess the staff/client ratio in substitution pro-
grammes, since the staff are often involved in other therapeutic
interventions and psychosocial staff may not be directly involved
in the administration of the programme.
Some centres are open seven days a week, so that medicine can
always be taken on the premises. Centres which are open on
weekdays and closed at weekends arrange for the substitute to be
administered by a member of the family or by another institution
(either a State institution or an NGO).
Despite some difficulties (partly caused by the fact that services
are currently being computerised), there is collaboration between
all the SPTT services, allowing for patients to move between cen-
tres, provided this is arranged in advance. The centres also treat
clients from other countries who are staying in Portugal for limited
periods, once this is arranged in advance and essential clinical
information is forwarded.
Surveys of drug problems
It has been estimated that approximately 5 in every 1 000 of the
total population are heroin users, but research on local prevalence
suggests this number may be much higher. Two prevalence sur-
veys conducted in 1997 and 1998 in the Setúbal region were
based on the capture–recapture method. Setúbal is situated 50 km
from Lisbon and has a population of 103 534; it is considered to
be one of the worst-affected regions of Portugal.
The first survey, carried out in Setúbal in 1996 as part of a
European project, estimated a prevalence of 1.82 % of heroin
addicts in the 15–54-year-old age group in this city (EMCDDA,
1997). This estimate is probably on the low side, since the authors
only surveyed two medical sources, one of which was quite small.
A second survey conducted in the Setúbal district in 1995–97
aimed at estimating the overall prevalence of heroin consumers in
the city. Three medical sources were used for data gathering, and
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the results point to a prevalence of 4.07 % of heroin addicts in the
overall population (confidence interval (CI) 95 %; 2.56–7.13 %).
Despite the consistency of the survey model and the high number
of consumers surveyed (1.04 % of the overall population), it is
probable that some factors, such as the three-year duration of the
research (1995–97), may have led to an inflated estimate
(Godinho et al., 1998). These two surveys show a very high preva-
lence of heroin addicts in the Setúbal region, and it is probable
that there is also a high number of addicts in other urban areas,
such as Lisbon and Oporto.
In the years 1995–97, the SPTT centres conducted 26 532 first
consultations (7 460 in 1995; 9 889 in 1996; 9 183 in 1997)
(GPCCD, 1998). These figures suggest that the underlying amount
of heroin use is very high, since the centres have a low response
ability (there are long waiting lists in many units). Also, drug
addicts usually only seek help after several years of consumption,
hence the high average age (27) of the patients (Félix da Costa and
Freire, 1998). Research shows that clients have been using for four
years on average when they visit the centres for the first time
(Godinho and Costa, 1997). Injectable drugs are consumed by
50–60 % of the patients that seek help (Godinho and Costa, 1997;
Félix da Costa and Freire, 1998).
A recent study (forming part of an international study) surveyed 
2 033 15–16-year-old youngsters attending the 10th, 11th and
12th grades in public schools. The results suggest that Portuguese
students show a lower consumption than the European average in
all drugs, including alcohol and tobacco (ESPAD, 1997).
Legislation on substitution treatment
The SPTT, operating under the Ministry of Health, is the only ser-
vice authorised to provide substitution substances (methadone or
LAAM), apart from the psychiatric services of Santa Maria
Hospital, S. João Hospital and Sines Health Centre. Most experts
agree that there is a pressing need to increase the response ability
regarding substance substitution, a view shared by the government.
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A serious effort is currently under way to expand the existing pro-
grammes, through the creation of new units and an increase in the
number of places available in the existing units. A study is also
being conducted on risk-reduction programmes and an experi-
mental programme is being carried out in a Lisbon slum area.
Substitution programmes have to be authorised by the direcções
regionais and the Direcção de Acção Médica (regional direc-
torates and Directorate for Medical Action) of the SPTT.
Prescription of the substitutes is the responsibility of clinicians
authorised by the SPTT. Currently, substitution is only authorised
in State services, mostly those belonging to the SPTT. Although
specific training is not compulsory, only clinicians who are ex-
perienced in the treatment of drug addicts are authorised to pre-
scribe substitution substances. The possibility of allowing non-
profit-making private institutions (NGOs) to conduct substitution
programmes is currently being considered.
The substitution programmes must comply with a set of proced-
ures laid down by the regional directorates and the Directorate for
Medical Action. Programmes must specify the following:
• the narcotic to be used;
• the population to be addressed;
• the mode of administration and treatment (residential or ambu-
latory);
• the duration of the programme;
• admission criteria;
• criteria for exclusion and discharge of patients;
• the psychotherapeutic model to be used; and
• the people in charge of the programme, including the prescrib-
ing doctors.
There are no compulsory guidelines for treatment. However,
patients are not encouraged to take the substitution substance for
administration home, although some programmes can make spe-
cial arrangements for this to occur. Most of the programmes are of
medium or high threshold, and there are periodical controls on
illicit drug consumption, with accompanying psychosocial sup-
port. The frequency of these controls and of the psychosocial sup-
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port, as well as the sanctions, depends on the type of programme
being followed. In most cases, good compliance with intake of the
prescribed substitute, an absence of aggression and availing of
improved psychosocial support are sufficient conditions for the
patient to be retained on the programme, despite evidence of
some consumption of illicit drugs. The duration of the programme
and size of dose administered vary according to the needs of the
patient; there are no restrictions regarding the maximum pre-
scribed dose or duration of the programme. The patients under-
taking this programme must be registered, and treatment records
are kept. Most of the programmes are not yet computerised, so
there is as yet no exchange of information between the institu-
tions.
Substitution clients
There are no compulsory admission criteria. However, the follow-
ing criteria are generally a basis for admission:
• age over 18 (except if HIV positive);
• HIV positive;
• pregnancy;
• long years of addiction and several failed treatment attempts;
• psychiatric morbidity;
• evidence of severe medical disease; and
• lack of social and family support leading to a bad prognosis for
therapy (the goal of which is abstinence).
Clients are generally agreeable to treatment, as it is usually pro-
vided when other attempts have failed. However, as is often the
case in other countries, dependence on a substance and, in a way,
on an institution, can lead to the client wanting to stop treatment
early or disregard the rules of the programme.
Most programmes include relevant psychosocial support (pro-
vided by a social worker) and psychotherapy. Although the social
support is limited, social workers play an active role in liaising
with the families, securing lodgings and food subsidies and seek-
ing employment. This support is generally well received. After
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some time has been spent in treatment, patients are often less
receptive to psychotherapy, probably because the treatment leads
to a greater degree of calmness and a consequent desire to avoid
confrontation with the therapist concerning changes in lifestyle.
Considerable efforts are made to maintain patients in regular psy-
chological care, particularly during the process of change. Some
programmes exercise sanctions if the patient does not comply with
the psychotherapeutic support. However, these sanctions are sel-
dom applied in cases where there is an overall improvement in the
patient.
Some programmes prefer to take heroin users who are not signifi-
cantly dependent on other drugs, but the majority accept patients
who regularly consume other substances. Although heroin is the
main illicit drug in Portugal (apart from cannabis), there are cur-
rently a significant number of heroin addicts who use cocaine as
a secondary drug (30–50 %). Regular consumption of cocaine, as
revealed by many patients, generates problems, since it frequently
occurs during the substitution treatment. Abuse of alcohol and
benzodiazepines is also a frequent problem with these patients.
Substitution programmes in Portugal do not have a restricted time
limit but operate on a case-by-case basis.
Pharmacy activity
A national network of pharmacies covers the whole of Portugal,
and pharmacists play an important role in drug-addiction inter-
ventions. Pharmacies are private institutions, owned and run by
pharmacists. From 1993 onwards, through a protocol between the
Associação Nacional de Farmácias (ANF — National Association
of Pharmacies) and the Commissão Nacional de Luta contra a
SIDA (CNLCS — National Commission for the Fight against AIDS),
all pharmacies and some mobile outlets located in high-drug-use
areas have started a needle-exchange programme. The pro-
gramme consists of free provision (in exchange for a used syringe)
of a kit containing a syringe and a needle, a sterilised towel, a con-
dom and a leaflet entreating the addict to give up drugs.
Apparently, this programme was well received by drug addicts and
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led to a decrease in syringe sharing (Félix da Costa and Ferraz de
Oliveira, 1997). There are currently 2 000 pharmacies involved in
this needle-exchange programme. The number of syringes
exchanged in the pharmacies increased between 1994 and 1997,
as the following figures show:
• 2 440 705 in 1994;
• 2 853 005 in 1995;
• 2 913 915 in 1996;
• 3 250 185 in 1997;
• 3 049 065 in 1998; and
• 2 992 165 in 1999.
The pharmacists’ willingness to cooperate in the needle-exchange
programme and treatment of drug addicts has made it possible to
establish, through an agreement between the SPTT and ANF, an
experimental programme of methadone provision by pharmacists
to patients who are undertaking substitution treatment in a CAT,
provided they are stabilised and are not too problematic. This
measure aims at lessening the overload of the CATs and allows
patients to take their medication close to home. This experimental
programme involves a small number of pharmacies, and allows
each pharmacy a maximum of five patients in treatment. As this
programme only started in 1998, no assessment has yet been
made. The pharmacists involved in the programme were given
specific training by SPTT workers and they receive continual sup-
port from the CATs’ technical staff.
Primary-care involvement
The SPTT, created in 1990, is a specific drug-addiction service.
This service is a vertical structure operating under the jurisdiction
of the Ministry of Health, on a par with the primary-healthcare
services, and is not part of the National Health Service. The SPTT
guarantees free treatment and anonymity.
The decision to create a vertical structure stemmed from the need
to respond quickly and efficiently (which the existing structures of
the SNS were unable to do), taking into account the seriousness of
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the problem at hand. After some initial problems, links were estab-
lished between the various services, allowing for a complemen-
tarity of tasks that was extremely necessary to tackle this problem.
This collaboration can take a variety of forms, including the
following:
• staff from the CATs provide support and consulting to the health
centres;
• some general practitioners (GPs) work part-time in the CATs or
in the health centres in the field of drug addiction; and
• training is regularly provided by CAT staff members to the
healthcare service personnel.
Substances prescribed
The only substitution substances prescribed in Portugal are
methadone and LAAM. There are no restrictions regarding dose or
duration of treatment. These substances are usually used in substi-
tution programmes, and in detoxification programmes for preg-
nant women, either as part of an inpatient or ambulatory regime.
Some detoxification units use low doses of methadone in the first
three or four days of treatment, so as to reduce the withdrawal
symptoms. However, it is not usual practice to use methadone in
detoxification programmes; alpha 2 agonists, sedatives and anal-
gesics are the preferred medications. Tramadol, a strong analgesic
which acts on the opioid receptors, is currently very much in use
in abstinence treatment, apparently with good results.
In Portugal, there are no substitution therapies for abuse of other
substances.
In 1998, 63 177 kg of methadone and 3 759 kg of LAAM were
used in substitution treatment. Most of the methadone is adminis-
tered as a 10 mg/ml oral solution and is prepared by the
Laboratório Militar (Military Laboratory). Some centres administer
methadone in tablet form (5 and 40 mg). There is no injectable
methadone. LAAM is administered as a 10 mg/ml oral solution
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and is imported from the United States. In 1999, 81 856 kg of
methadone and 6 074 kg of LAAM were used in substitution
treatment.
Injectable prescribing
There is no prescribing of injectable substances in Portugal.
Surveillance
Data referring to methadone- and LAAM-maintenance pro-
grammes are provided by local facilities to the SPTT, but these data
solely concern the number of clients and the administration site.
There is no national registration and data cannot be exchanged.
Problems
The problems usually identified by the services are the lack of
human resources (technical staff) and logistic problems.
Accessibility (in terms of distance and extended schedules) is
essential for the maintenance of these programmes. Since there
are no mobile dispensing units, many people are forced to travel
long distances. This problem has not yet been overcome.
To date, the centres have not experienced serious problems with
the communities who live close to the dispensing facilities, since
efforts are made to spread dispensing over the day or refer patients
to health centres, pharmacies or even their homes (with the sup-
port of the family) for administration of treatment.
Evaluation
In Portugal, there have been few studies evaluating substitution
treatment.
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Patrício et al. (1996) carried out a preliminary evaluation of the
LAAM programme at the Taipas CAT. Although the sample was rel-
atively small, it clearly showed that 60 % of patients in the pro-
gramme were totally abstinent from using heroin and cocaine.
Apparently, there was also an improvement in their social and pro-
fessional activities. Viegas et al. (1997) carried out a retrospective
study on the patients attending the Boavista CAT. In this study, the
retention rates over time were assessed at around 50 % in 24
months. This study suggests that the retention rate is higher when
high doses of methadone are used. Padre-Santo et al. (1998) con-
ducted an initial assessment of the substitution programme at the
Setúbal CAT and found:
• a high retention rate;
• a decrease in the consumption of heroin over time; and
• an apparent improvement in the quality of life of the majority of
the patients.
It is generally felt that better assessment of the substitution
programmes is needed. The following points deserve special
attention:
• retention rates over time;
• abstinence from drug consumption;
• social and professional integration;
• reduction of delinquent behaviour;
• improvement of general health; and
• relationships of patients with the programmes.
References
Comissão para a Estratégia Nacional de Combate à Droga (1999),
Estratégia nacional de luta contra a droga, Presidência do Con-
selho de Ministros e Imprensa Nacional-Casa da Moeda, Lisbon.
EMCDDA (1997), Methodological pilot study of local level preva-
lence estimates, EMCDDA, December.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
222
42d930_insights_brochure  09-11-2000  14:53  Pagina 222
ESPAD (1997), The 1995 ESPAD report, European School Survey
Project on Alcohol and Other Drugs, Stockholm (Source:
http://www.ias.org.uk/theglobe/jan98/).
Félix da Costa, N. and Ferraz de Oliveira, F. (1997), ‘Avaliação do
programa ‘‘Diz não a uma seringa em segunda mão’’, através de
um inquérito aos utilizadores’, Toxicodependências, 3(2),
pp. 23–40.
Félix da Costa, N. and Freire, S. (1998), ‘Evolução do atendi-
mento de toxicodependentes em Portugal de 1991 a 1996’,
Toxicodependências, 4(2), pp. 55–69.
Gabinete de Planeamento e de Coordenação do Combate à
Droga (GPCCD) (1998), Sumários de informação estatística,
1997, Presidência do Conselho de Ministros, Lisbon.
Godinho, J. and Costa, H. (1997), ‘Avaliação de uma população
em seguimento nos CATs Setúbal e Almada’, Toxicodependências,
3(3), pp. 49–53.
Godinho, J., Costa, H. and Padre-Santo, D. (1998), ‘Estimativa da
prevalência de consumidores de heroína no concelho de Setúbal’,
Toxicodependências, 4(3), pp. 27–32.
Padre-Santo, D., Soromenho, J., Costa, H. and Godinho, J.
(1998), ‘Programa de substituição opiácea no CAT de Setúbal’,
Toxicodependências, 4(30), pp. 33–38.
Patrício, L., et al. (1996), ‘LAAM: levo-alpha-acetyl-methadol:
experience at Centro das Taipas’, Toxicodependências, 2(2),
pp. 35–44.
Viegas, E., Viana, L., Moura e Sá, M., Pardal, M. C., Pereira, M. J.
and Sarmento, I. C. (1997), ‘Estudo dos toxicodependentes em
tratamento com metadona no CAT da Boavista’,
Toxicodependências, 3(2), pp. 41–57.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
223
42d930_insights_brochure  09-11-2000  14:53  Pagina 223
Further reading
Comissão Nacional de Luta contra a SIDA (1998), ‘SIDA’, a situ-
ação em Portugal a 30 de Setembro de 1998, Lisbon.
Costa, A. (1995), ‘O modelo integrado face à SIDA’, Toxico-
dependências, 1(1), pp. 52–55.
Ferraz de Oliveira, F., Costa, L., Teles, A., Matias, L. and Félix da
Costa, N. (1998), ‘Análise das taxas de seringas trocadas no pro-
grama ‘‘Diz não a uma seringa em segunda mão’’ ’, Toxico-
dependências, 4(1), pp. 9–14.
Godinho, J., Costa, H. and Costa, C. (1996), ‘Comportamentos de
risco de doenças infecciosas’, Toxicodependências, 2(3),
pp. 55–60.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
224
42d930_insights_brochure  09-11-2000  14:53  Pagina 224
FINLAND
Veikko Granström, Hesperian Sairaala, Helsinki
Introduction
The total population of Finland is 5.2 million, of which 1.5 million
live in the Greater Helsinki area. Only approximately 90 000 for-
eigners live in Finland and ethnic minorities are very small.
Relatively few variations in nationality, religion and languages,
and a fairly even distribution of income, contribute to making the
Finnish community very homogeneous.
National administration (parliament) is responsible for legislation,
general order in the country and the funding of services. Local
administration is responsible for organising and funding the social
services and health services, mostly with money allocated by par-
liament. Private funding of services is very limited. The social and
health services are separate in most municipalities and generally
compete for funding. However, at local level, there is considerable
cooperation. Drug services are provided by both the social and
health authorities, often in collaboration, although occasionally
one buys services from the other.
Strategy
In Finland, a decree on the treatment of opiate addicts with certain
medicines (buprenorphine, methadone and levo-alpha-acetyl-
methadol) was issued on 1 July 2000. Prior to this, treatment had
been regulated by the Ministry of Social Affairs and Health.
These earlier regulations had defined treatment of opiate addicts
with medication in two categories:
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• detoxification treatment — treatment with medication (in prac-
tice, buprenorphine) aimed at withdrawal from opiates, the
length of which is a maximum of one year; and
• substitution treatment — treatment with medication (in practice,
methadone) for patients who have failed to withdraw from opi-
ates after detoxification treatment (using normal treatment pro-
tocols); in Finland, the term ‘maintenance treatment’ was not
recognised, but neither was there a ‘drug-free’ target for substi-
tution treatment.
The 2000 decree defines the treatment of opiate addicts with med-
ication according to three categories:
• detoxification treatment — treatment with medication for a max-
imum of one month aimed at freedom from drugs (the wording
of the earlier regulations had been ‘withdrawal from opiates’);
• substitution treatment — treatment with medication for more
than one month aimed at freedom from drugs; and
• maintenance treatment — treatment with medication for more
than one month aimed mainly at reducing drug-related harm
and improving the addict’s quality of life.
Until recent years, the drug situation in Finland had been reason-
ably good. In an article in 1997 (Poikolainen, 1997), it was stated
that ‘the number of drug misusers in need of health and social wel-
fare services can be estimated at 1 200–2 400’. However, other
estimates are higher, and it is possible that heroin users exceed 
2 000. During the last three to four years, it seems that more drug
users, particularly heroin users, have sought treatment and that the
use of amphetamines has increased.
Until recently, HIV infection and hepatitis C were not very pre-
valent in Finland. There have probably been less than 1 000
reported cases, and a coincidence of HIV and heroin addiction
was found in less than 20 cases at the end of 1998, although that
number had risen to 90 at the end of 1999 and is still rising.
Studies suggest that some 60 % of injecting drug users are in-
fected with hepatitis C and about 3 % with HIV (Leinikki, 1999;
Turpeinen et al., 1999).
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Substitution
Development of substitution services
Due to the limited use of heroin in Finland to date, the history of
substitution services is short and sparse. It has two principal
phases. During the years 1974–96, there were at most 15 patients
in a methadone-maintenance programme in Helsinki. The
patients, who were all ageing, had used prescribed opiate
painkillers, a practice which was subsequently stopped by the
authorities. Methadone doses were low, there were no rehabilita-
tion services and no urine controls.
The second phase began by establishing a new programme, in
August 1995, in the psychiatric outpatient clinic of Hesperian
Hospital in Helsinki. Since December 1997, this has been a sep-
arate outpatient substitution therapy clinic. Almost all substitution
patients in Finland are on this programme, which is described
below.
The drug question has not generated much interest in Finland,
both in terms of users themselves and treatment, because the situ-
ation has not been particularly remarkable. Given the current
environment, it could be a good time to develop suitable treat-
ment programmes.
Current situation
Substitution therapy is still in its early stages in Finland. There
were about 70 patients in methadone-substitution therapy and 20
patients in buprenorphine detoxification therapy at the end of
1999.
Under the previous regulations, assessment for treatment (evalua-
tion of the need for substitution treatment) was available only in
three university hospitals and the subsequent substitution treat-
ment was then to be undertaken in other social and healthcare
units qualified for the task.
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However, in practice, there was, and still is, only one full-time unit
offering substitution treatment (according to the new decree, for
substitution, but in effect mainly for maintenance treatment).
There are also some psychiatric hospital departments that have
participated in the substitution treatment of some individual opi-
ate addicts.
It should also be mentioned that the new decree emphasises that
treatment should be moved from the treatment assessment units to
a unit that is situated nearer to the patient (e.g. a local health cen-
tre). This unit should operate in cooperation with the assessment
unit. Also, according to the new decree, in certain cases patients
demonstrating good cooperation can be allowed up to seven take-
home doses of medication.
Substitution therapy is only used for heroin addiction in Finland.
Substitution therapy in Helsinki can be divided into long-term
(open-ended) methadone substitution, in an outpatient setting, and
long-term detoxification with buprenorphine, in either a hospital
or an outpatient setting. In other parts of Finland, there have been
a few individual cases of patients treated with methadone and
buprenorphine in a variety of settings. As in Helsinki, most of this
work takes place in psychiatric units. Very few patients have been
treated in general practice.
Therapy at the Helsinki substitution-treatment clinic (with
methadone) is quite intensive, consisting of daily visits to the
clinic, counselling therapy approximately once a week, an ‘own-
nurse’ system and urine control on average four times a month.
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228 TABLE 1: ARRANGEMENT OF SUBSTITUTION THERAPY
IN HELSINKI, FINLAND
METHADONE SUBSTITUTION BUPRENORPHINE DETOXIFICATION
Assessment: University Hospital of Helsinki Assessment: Substitution therapy clinic of 
Hesperian Hospital, Helsinki
Treatment: Substitution therapy clinic Treatment: Kettutie A-polyclinic, Helsinki
of Hesperian Hospital, Helsinki Treatment: Detoxification clinic, Helsinki
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The average dose of methadone was 145 mg in 1998 and the max-
imum dose approximately 270 mg. Retention of patients is more
than 90 % in a half year, and heroin-positive samples are found in
about 10 % of urine controls. Only three of the patients were
infected with HIV.
In Helsinki, there is intensive collaboration between health and
social services in substitution therapy cases. No sanctions are used
in the treatment. For example, positive urine samples are seen as
a sign of addiction disease, requiring renewed efforts in therapy
(such as raising the methadone dose). If patients actively use her-
oin and/or amphetamines, it is considered too great a risk to give
them take-home methadone and so this has been limited.
Continuity of care has not yet been a problem during the three and
a half years of the programme. Four patients of the substitution-
treatment clinic continued receiving methadone substitution while
in prison in 1998.
The Ministry of Social Affairs and Health regulations refer to
LAAM as a substitution substance, but it is not used in Finland. It
is estimated that around 170 opiate addicts have been receiving
buprenorphine.
Substitution clients
Assessment for substitution treatment with methadone takes place
at the five university hospitals in Finland, mostly in Helsinki
University Hospital (in its Clinic of Psychiatry). This means spend-
ing two weeks as an inpatient. During the assessment period,
patients are detoxified from heroin.
Entry criteria for substitution treatment are as follows:
• must be over 20 years of age;
• must have used heroin for more than four years; and
• attempts at detoxification must already have been made.
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Relative contraindications are the massive use of amphetamines or
benzodiazepines.
Almost all patients are accepted for treatment, which in Helsinki
takes place in the substitution therapy unit of Hesperian Hospital.
Issues for the future
It has been decided that treatment slots (vacancies) in the Helsinki
substitution therapy clinic will be increased to 90 by the end of
2000. Some new minor methadone and buprenorphine pro-
grammes for 1–5 patients have been started in other parts of the
country. Substitution therapy using buprenorphine is planned,
despite difficulties in its use in long-term detoxification.
In Helsinki, there is a growing interest in research in the area of
substitution treatment and national research data would indeed be
very valuable. One area of interest would be to investigate when
substitution treatment can finish for a patient. It may ultimately be
necessary to establish a maintenance treatment programme (aim-
ing only at harm reduction) and this is now a possibility with the
new legislation of July 2000.
Surveillance
Names of doctors in charge of units giving substitution treatment
must be announced to State officials. Otherwise, surveillance is
the same as in healthcare in general.
Problems
There is a lack of treatment slots in the country as a whole, es-
pecially in smaller locations. It is also problematic organising
treatment for HIV-positive drug users.
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Evaluation
No evaluation data are available, due to the short history of sub-
stitution treatment in Finland and its very concentrated organis-
ation. National evaluation of treatment has not yet been carried
out, and local evaluation information has not yet been collated.
Information in this chapter was updated by the EMCDDA.
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SWEDEN
Marlene Stenbacka, Beroendecentrum Nord, Karolinsk Hospital,
Stockholm
Introduction
Rehabilitation of drug users in Sweden takes place in public hos-
pitals and care institutions, as well as in private institutions and
family-care units (Socialstyrelsen, 1993). In addition, municipal
authorities often fund private institutional care. Furthermore, there
are special detoxification and rehabilitation units in the psychiatric
clinics, and some of these clinics also run methadone-
maintenance programmes.
In some municipalities, special departments and institutions are
available for drug users suffering from HIV infection or AIDS, or
for those with mental problems. The social services play an impor-
tant role in the rehabilitation of drug users, in collaboration with
the medical services. It is the social services which are responsible
for the care and treatment of drug users. Some municipalities also
have specialised drug-care units. Collaboration between social
service drug-care units and the prison and probation services is
often good.
Remand centres and prisons play a very important part in drug-
treatment activities in some municipalities. Special teams at the
remand centres consist of representatives from the social services,
the prison and the probation service. They educate the inmates
about AIDS and encourage them to undergo HIV testing and to
take part in different therapies.
However, methadone-maintenance treatment is not available in
prison since one of the inclusion criteria for maintenance treat-
ment is that the patient shall not be in custody, under arrest or in
prison at the time of admission.
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Some municipalities have set up specialised outpatient teams tar-
geting young people who are at risk of developing maladjusted
behaviour. Other municipalities have set up drug-prevention pro-
grammes. Social workers try to come into contact with young
people in different settings in order to offer support and guidance.
Some municipalities also have outpatient teams for alcohol and
drug misuse. Sometimes, the drug users are offered institutional
care. Admission to treatment is voluntary.
Drug users who are taken into compulsory care often have a long
history of compulsive drug misuse and a poor social situation. The
decision to admit an addict to compulsory care is taken by the
county administrative boards. Compulsory care is provided in spe-
cial institutions run by the municipalities and county councils.
Methadone maintenance for chronic opiate users, which is the
main substitute treatment for drug abuse allowed in Sweden, was
developed at the end of the 1960s by Lars-Magnus Gunne and co-
workers at Ulleråker Hospital in Uppsala (Dole and Nyswander,
1965, 1976; Dole et al., 1968, 1969), mostly following the orig-
inal guidelines of Dole and Nyswander (Gunne and Grönbladh,
1981, 1988, 1989; Grönbladh and Gunne, 1989). A small number
of opiate abusers are treated with buprenorphine.
Since Sweden only had a few severe opiate users at that time, the
number of patients in methadone treatment was small (Gunne and
Grönbladh, 1981). Heroin began to spread on the black market
during the second half of the 1970s and, since then, it has been
the dominant opiate drug. Before that time, most opiate abusers
had used morphine, although there were also a few who used 
raw opium and morphine base, dissolved for intravenous self-
administration. About 100 opiate users were in the methadone
programme in Uppsala in 1979 (Grönbladh and Gunne, 1989).
A survey was carried out in 1968 which identified 200 opiate users
in the whole country. When a similar study was repeated in 1979,
the number had increased to 3 000, mainly heroin users (Olsson
et al., 1981). A nationwide survey in 1992 (Olsson et al., 1993)
estimated the number of heavy drug users at between 14 000 and
20 000. Of these, 77 % were using multiple drugs, mostly alcohol,
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sleeping pills and tranquillisers (Alkohol-och narkotikautveck-
lingen i Sverige, 1998). Amphetamine was the most common drug
(82 %). Heroin was used by one third of heavy drug users. This
means that there were 5 000–7 000 heroin users in Sweden at that
time. More recent reports indicate that heroin smoking is increas-
ing, especially among immigrants (Alkohol-och narkotikautveck-
lingen i Sverige, 1998).
Since 1965, the Swedish drug market has been dominated by
intravenous amphetamine use (Bejerot, 1975; Alkohol-och
narkotikautvecklingen i Sverige, 1998) and most heroin users have
a previous history of amphetamine use, often in combination with
other drugs. Polydrug use is a problem when opiate users enter
methadone treatment (Alkohol-och narkotikautvecklingen i
Sverige, 1998). Although methadone patients often stop using
heroin during methadone treatment, they may start or continue
using other drugs, such as alcohol or benzodiazepines, as well as
methadone (Grönbladh and Gunne, 1989). In September 1998,
567 opiate users in Sweden received methadone treatment (Lund
had 81 patients, Malmö 61, Stockholm 291 and Uppsala 134)
(Figures 1 and 2). In March 2000, the number of methadone
patients increased to 612 (Lund 84, Malmö 60, Stockholm 321,
Uppsala 147).
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FIGURE 1: TOTAL NUMBER OF METHADONE PATIENTS 
IN ALL SWEDISH PROGRAMMES 
(LUND, MALMÖ, STOCKHOLM AND UPPSALA) (1993–98)
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Strategy
After an evaluation of the Uppsala programme (Grönbladh and
Gunne, 1989), the Socialstyrelsen (Swedish National Board of
Health and Welfare) approved methadone treatment for opiate
users (Socialstyrelsen, 1981, 1987). Since 1983, methadone treat-
ment has been a regular form of treatment for opiate users, but
with special restrictions and guidelines enforced by the Swedish
National Board of Health and Welfare (Socialstyrelsen, 1972,
1981, 1983, 1987, 1988, 1990, 1991).
The Swedish National Board of Health and Welfare has published
guidelines for methadone treatment, including instructions regard-
ing the following:
• maximum number of patients in treatment;
• inclusion criteria; and
• number of programmes.
In 1993, the Swedish National Board of Health and Welfare de-
cided that not more than 150 patients could receive methadone
FIGURE 2: NUMBER OF METHADONE PATIENTS 
IN ALL SWEDISH PROGRAMMES 
(LUND, MALMÖ, STOCKHOLM AND UPPSALA) (1993–97)
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treatment in Sweden. This limit on the number of patients has
since been increased on four occasions:
• to a maximum of 300 patients in 1988;
• to a maximum of 450 patients in 1990;
• to a maximum of 500 patients in 1994;
• to a maximum of 600 patients in 1997; and
• to a maximum of 800 patients in 2000.
The criteria for acceptance onto a methadone-treatment pro-
gramme in Sweden have changed little over the years. Based on
the American methadone programmes introduced by Dole and
Nyswander, they are supervised by the Swedish National Board of
Health and Welfare. The acceptance criteria are as follows:
• a history of at least four years of intravenous opiate misuse;
• earlier attempts at drug-free treatment judged to be of negligible
value to the patient;
• aged at least 20 years;
• opiate as the dominant drug;
• must not be in prison when admitted to the programme (Dole
and Nyswander, 1965; Gunne and Grönbladh, 1981;
Grönbladh and Gunne, 1989; Socialstyrelsen, 1990; Eklund et
al., 1994).
During the entire methadone-treatment period, the patient should
have support from a social worker from the social welfare services
(from the drug-dependence unit).
Since 1990, the National Council of Methadone-Maintenance
Treatment has played an important role in the follow-up of
methadone treatment. Council members are representatives of the
following bodies:
• methadone programmes;
• social services;
• drug-dependence units of hospitals; and
• the Swedish National Board of Health and Welfare.
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
236
42d930_insights_brochure  09-11-2000  14:53  Pagina 236
Members meet twice a year to discuss policy, statistics from the
programmes and important matters to do with funding and recruit-
ment of new patients.
Substitution
National register
Since 1995, the Swedish National Board of Health and Welfare
has been collecting data from the methadone-maintenance pro-
grammes. This register contains basic information about the
patients themselves, their drug-use history, reasons for ending
treatment and extent of treatment periods.
The methadone programme in Uppsala
The first Swedish methadone programme started in January 1967
in Uppsala and is one of the oldest in Europe. The programme,
which grew slowly in the first few years, recruited patients from all
over the country. When raw opium, morphine base and, eventu-
ally, heroin were introduced into the country in the mid-1970s,
opiate misuse increased and more opiate users fulfilled the criteria
for methadone treatment. After a waiting period, patients who had
applied for treatment were admitted to Ulleråker Hospital in
Uppsala. Treatment started with a drug-free month, during which
time the patient was given information about treatment and detox-
ification. A thorough evaluation was made of the patient’s med-
ical, social and psychological status, and a schedule was deter-
mined for methadone dosage. During this investigation and adjust-
ment phase, the patients also met with the methadone pro-
gramme’s outpatient team, a unit which was created in January
1976. The patients obtained their methadone and gave urine sam-
ples at a pharmacy near their homes. Treatment is largely based on
the American model, which has been further refined and adapted
to suit Swedish conditions under the guidance of Professor Gunne.
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A three-year follow-up of the programme has shown that a great
number of clients (80 %) were at work or studying. A study of 46
patients who were in treatment in 1975 showed that criminality
decreased from 52 % prior to treatment to 13 % after 18 months
in treatment. By 1980, 16 % had left the methadone programme
voluntarily and 37 % had been excluded for breaking the rules
(Grönbladh and Gunne, 1989).
The methadone programme in Stockholm
In 1985, a methadone programme started in Stockholm. This pro-
gramme has more patients than the other three programmes (Lund,
Malmö and Uppsala) and is part of the Beroendecentrum Nord
(Central Clinic for Dependence Disorders). The programme offers
outpatient treatment to opiate users, but it is also possible, if nec-
essary, to give inpatient care to the patients. The programme advo-
cates close and personal support in the treatment of patients, and
collaboration between healthcare and social welfare.
A social welfare study in Stockholm identified 2 500 drug users
between October 1993 and March 1994 (Berglund et al., 1994).
Of these, 284 were opiate users in methadone treatment and 714
opiate users in contact with social services. It is unclear whether
these persons met the criteria for admission to methadone treat-
ment. This study also showed that 37 % of the 284 patients in
treatment and 10 % of the 714 opiate users who were not in treat-
ment were HIV positive. The methadone patients were somewhat
older (median age of 39 years) than the users who were not in
treatment (median age of 33 years). Of the patients in treatment,
44 % used only methadone. The most commonly used drugs
besides methadone were benzodiazepine, heroin and alcohol.
One hundred methadone patients (35 %) used intravenous drugs.
Seventy-five per cent of the methadone patients lived in their own
apartments compared with 25 % of the non-treated opiate users.
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The methadone programmes in Lund and Malmö
In 1988, the Swedish National Board of Health and Welfare de-
cided to establish a further methadone programme. In 1989, the
methadone programme in Lund had five patients in treatment and
in May 1990 the programme was formally established. A con-
trolled case study was undertaken in Lund (Andersson, 1981)
which included 21 methadone patients and a control group of 21
non-treated opiate users. After one year, the following facts were
identified by the study:
• 14 methadone patients had stopped using illicit drugs, com-
pared with 2 in the control group;
• 13 patients in the methadone group had work, compared with 2
in the control group; and
• 1 methadone patient and 4 from the control group had died dur-
ing the follow-up period.
In 1990, another programme started in Malmö, in the south of
Sweden. Most of the patients had started methadone treatment in
Uppsala but then continued in Malmö.
A descriptive and analytical evaluation of all four methadone-
treatment programmes in Sweden was finished in 1997 (Stenbacka
and Romelsjö, 1997; Stenbacka et al., 1998). One aim of this
evaluation was to analyse social characteristics, substance use and
psychological and physical health before and during methadone
treatment, as well as the effect of methadone on criminal behav-
iour, inpatient care and mortality. An interview and a study based
on register data were performed as part of the evaluation. The
study included 655 patients (465 men and 190 women) who were
treated at any time between the start of the methadone-treatment
programme and 1993. The evaluation of the Stockholm patients
also included a comparison with a group of injecting opiate users
who were aged 20 or older and had at least four years of docu-
mented intravenous opiate use, but who had not received
methadone treatment. As part of the evaluation, interviews were
conducted with a total of 209 methadone patients enrolled in
1993–94: 135 in Stockholm, 26 in Uppsala, 24 in Malmö and 24
in Lund. They were asked questions about the following:
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• their relationships with family and friends;
• employment/education status;
• financial situation;
• mental and physical health; and
• drug-use and treatment history, both before and during their cur-
rent treatment.
Of the 655 patients in the register study, 257 (195 men and 62
women) had been compulsorily discharged and had not returned
to methadone treatment, 48 (40 men and 8 women) had under-
gone at least two periods of methadone treatment and 312 (203
men and 109 women) had remained in continuous methadone
treatment. Thirty-eight patients had died while enrolled in a
methadone-treatment programme.
In all programme units, most patients (male and female) reported
marked improvement with regard to the following areas:
• housing;
• employment/educational activity;
• social relations;
• health;
• family relations;
• use of alcohol; and
• use of narcotic drugs.
In six out of the seven areas mentioned above, 38 % of patients
showed a significant improvement.
The annual mortality rate in Stockholm’s methadone programme
was 1 % for both men and women, compared with 2 % for both
sexes in the control group and 4 % in the group of patients who had
been discharged from treatment (5 % of men and 1 % of women)
(Stenbacka and Romelsjö, 1997). A follow-up of mortality among
methadone patients until 1993 showed that 29 of the methadone
patients in Stockholm had died: 17 of these during treatment and
12 after being discharged from the methadone programme.
In Uppsala, the oldest programme, 67 patients had died: 16 dur-
ing treatment and 51 after discharge. In Lund and Malmö, 
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4 patients had died: 3 during treatment and 1 after discharge. In
Stockholm, HIV/AIDS (n = 10), narcomania (overdose of narcotics,
n = 7) and liver cirrhosis (n = 5) were the most common causes of
death. After discharge, 5 persons died of narcomania. In Uppsala,
methadone narcomania (n = 18) was the most common cause of
death, then came accidental death/suicide (n = 14), liver cirrhosis
(n = 4) and intoxication with benzodiazepines (n = 4). After leav-
ing methadone treatment, 15 persons died of narcomania and 
8 persons by suicide. These diagnoses were the most common
causes of death.
The number of hospital admissions declined markedly for patients
in the Stockholm and Lund programmes, where reliable hospital-
isation data are available. Data of this kind for Uppsala and
Malmö are lacking for the period under observation.
The annual rate of inpatient care among methadone patients in
Stockholm decreased from 1.3 admissions per year before treat-
ment to 0.6 during methadone treatment, with a greater decrease
for women. This was associated with time spent in treatment and
did not decrease further for those who were more than two years
in treatment. The rate was 1.7 admissions per year for those who
stayed for less than a year, less than 1 for those who stayed more
than two years and 0.3 for those who stayed longer (more than six
years).
HIV-positive patients consumed a greater amount of inpatient
hospital care than HIV-negative patients, which may partly be due
to AIDS and its complications. There was a marked decrease in
inpatient-care admission among HIV-negative patients during
treatment. However, the number of treatment days decreased dur-
ing treatment for both the HIV-positive and HIV-negative women
but only for HIV-negative men (Stenbacka and Romelsjö, 1997;
Stenbacka et al., 1998).
The rate of hospitalisation with a diagnosis of HIV/AIDS was high-
er for the methadone patients, especially during treatment, than
for the control group. There was an increase in the incidence rate
of admissions for treatment of other infectious diseases in men and
a decrease in women. In all, 20 % of the men and 13 % of the
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women in the control group had been treated in hospital for alco-
hol diseases, compared with 10 and 4 %, respectively, prior to
treatment among the methadone patients (Stenbacka et al., 1998).
A significant reduction in convicted crimes was observed among
both women and men during treatment, compared with the time
prior to treatment. The rate of convicted crimes among all four
programmes was highest in Stockholm (2.2 crimes per year) and
lowest among the Malmö patients (1.7 crimes per year). During
treatment, the number of convicted crimes decreased to 0.3 in
Malmö, 0.5 in Lund and Uppsala and 0.6 in Stockholm. In all pro-
grammes, the reduction was significant for both sexes. Similarly,
there was a decline in the number of detentions (arrests or
remands in custody) among patients in Stockholm, where data on
this subject were available. No such improvement occurred in the
control group.
The patients who had difficulty adjusting to methadone treatment
and who were involuntarily discharged showed an increase in
recorded criminal behaviour but were convicted of fewer crimes
after discharge than before entering the treatment. Nearly 40 % of
655 methadone patients were involuntarily discharged during the
whole period under study (1966–93). On the other hand, con-
sumption of inpatient care in hospital showed a marked increase
after discharge from treatment.
The methadone patients in Lund, Malmö, Stockholm and
Uppsala, 1993–98
The number of patients in methadone treatment increased from
430 in 1993 to 567 in 1998. Lund had 81 patients, Malmö 61,
Stockholm 291 and Uppsala 134 in September 1998. About one
third of the patients in all the programmes were female.
The decision to request methadone treatment often came from the
patients themselves, or through family members, doctors or social
workers (Stenbacka and Romelsjö, 1997). The intake of new
patients increased from 109 in 1993 to 128 in 1997 (Figure 3). 
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The proportion of new admissions to methadone programmes is
highest in Stockholm (57 % in 1997) compared with 16 % in
Lund, 8 % in Malmö and 20 % in Uppsala (Figure 4).
The average age on commencement of methadone treatment
increased from 34.5 years in 1993 to 36.5 in 1997. The age was
somewhat higher in the Uppsala methadone programme in 1996
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FIGURE 3: TOTAL NUMBER OF NEW PATIENTS ADMITTED 
TO THE METHADONE-MAINTENANCE PROGRAMMES IN SWEDEN
(1993–97)
FIGURE 4: PROPORTION OF NEW ADMISSIONS OF 
OPIATE MISUSERS TO ALL SWEDISH METHADONE PROGRAMMES
(LUND, MALMÖ, STOCKHOLM AND UPPSALA) (1993–97)
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and 1997. One reason for this could be that the Uppsala
programme has accepted about 30 patients with long-term physi-
cal pain. These patients are generally somewhat older than the
heroin users when they apply for methadone treatment (Figure 5).
The age of initiation of intravenous opiate use was investigated in
1997 in 205 methadone patients. The results show that nearly
50 % had started using intravenous drugs at 19 years of age or
younger, 21 % were between 20 and 24 and the rest were 25 or
older (Andersson, 1981). These figures agree with the self-reported
age of commencement of opiate use (mean age = 21 in 1997) in
the Uppsala and Malmö methadone programmes. In Stockholm,
the average age recorded in 1997 for intravenous opiate use was
approximately 27 years.
In Lund, Malmö and Uppsala, 235 patients were receiving
methadone treatment on 1 December 1997. A one-year follow-up
of these patients showed that 7 % had been discharged. In
Stockholm, 14 % of 279 patients had ‘dropped out’ of treatment
during the same period. One explanation for the higher rate of
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drop-out among the methadone patients in Stockholm could be
that many of the drug users in Sweden live there.
The proportion of HIV-positive patients in methadone treatment
has decreased in Sweden. In 1993, 117 persons were HIV positive
and this number decreased to 73 in 1997 (Figure 6). One reason
for this reduction is that a great number of these patients had died
during the previous five years. Another reason is that a high pro-
portion of the drop-out patients are HIV positive.
The methadone programme in Stockholm has most patients with
HIV-positive diagnoses, followed by the programme in Uppsala.
Very few patients were HIV positive in Lund and Malmö. A reduc-
tion in HIV-positive patients has been observed both in Stockholm
and Uppsala (Figures 7 and 8).
Drug use other than methadone treatment seems to be the most
common reason for discharge from a programme (Figure 9). In the
Stockholm programme, voluntary interruption of treatment (the
patient fails to attend appointments or does not take medication,
etc.) and manipulation of methadone doses seem to be more com-
mon than in the other programmes.
Mortality decreased from 19 persons in 1995 to 4 in 1997 (Figures
10 and 11). However, most of those who died after being dis-
charged from treatment suffered from HIV-related diseases.
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Methadone doses seemed to be highest in Lund (98 mg/day). In
the Malmö programme, the mean dose increased from 69.3
mg/day in 1995 to 91.5 mg/day in 1997 (Figure 12).
FIGURE 11: HIV STATUS AMONG 31 PERSONS WHO DIED 
AFTER BEING DISCHARGED FROM METHADONE TREATMENT 
IN STOCKHOLM (1995–97)
FIGURE 12: METHADONE DOSE (MEAN MG/DAY) 
IN ALL SWEDISH PROGRAMMES 
(LUND, MALMÖ, STOCKHOLM AND UPPSALA) (1993–97)
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Controversy
Many studies have demonstrated positive outcome results of
methadone-maintenance treatment. Despite this, there has been a
negative public attitude towards methadone treatment in Sweden,
especially before the AIDS epidemic. When it became known that
injecting heroin users are an important risk group for transmission
of HIV, attitudes towards maintenance treatment changed in a pos-
itive way. Today, maintenance treatment is more accepted as a
medical treatment for chronic opiate misuse than it was 10–15
years ago.
Methadone-maintenance treatment in Sweden is provided in four
specialised programmes. One of the reasons for the strict regula-
tion of the programmes is to limit the chances of methadone being
diverted to the black market.
Surveillance
In 2000, the Swedish National Board of Health and Welfare began
collecting data from all the methadone-maintenance programmes
in the country.
Methadone conferences where staff from all the programmes
report current data and discuss future plans and directions of the
programmes also take place a few times a year.
A longitudinal study is being carried out on a cohort admitted to
treatment in 1989 and 1991 and followed up to 1999 according
to retention in treatment, mortality, hospitalisation, occupation,
criminality, etc.
Problems
One problem encountered in substitution treatment in Sweden is
a shortage of personnel for the methadone-maintenance pro-
grammes, particularly a lack of trained nurses. Another problem is
that county councils are often not willing to pay other communities
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to perform the treatment if a patient wishes to move from one pro-
gramme to another.
Evaluation
In Sweden, as in many other countries, evaluation of the effects of
methadone-maintenance treatment on different outcome meas-
ures has been a priority. However, few studies have investigated if
it is the methadone itself or other treatment factors, or a combin-
ation of these, which is significant for a good outcome. More eval-
uations of the ‘black box’ of treatment and treatment strategies are
needed.
Summary and conclusions
One must assume that opiate users who apply for methadone
treatment do so voluntarily. It is fair to believe that they would like
to see various improvements in their lives and are motivated to try
to change their behaviour to this end (Ball and Ross, 1991; Bell et
al., 1992; Ward et al., 1992). Treatment of patients who are thus
motivated could partly explain good outcome during methadone
treatment.
Due to successful treatment outcome, the number of methadone
patients in Sweden has increased. The Swedish National Board of
Health and Welfare offers treatment for 600 patients at present.
Four methadone programmes (in Lund, Malmö, Stockholm and
Uppsala) offer substitute treatment to chronic opiate users.
Stockholm is the largest programme, with 297 opiate users in treat-
ment and the highest number of HIV-positive patients. The
Uppsala programme is one of the oldest in Europe and accepts a
new category of methadone patient, those with chronic pain dis-
orders. An evaluation of the methadone programmes in Sweden
(Stenbacka and Romelsjö, 1997) has shown that the incidence of
criminality, inpatient care, illicit drug misuse and mortality
decreased during methadone treatment, as compared with the
time prior to treatment. However, an increase in criminality, in-
patient care and mortality occurred after discharge from treatment.
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Most patients report improvements in many areas during treat-
ment. Thus, retention in treatment is important for the health of the
patient, for a reduction in criminality, inpatient care and mortality
and for public health in the community in general.
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UNITED KINGDOM
Michael Farrell and Samantha Howes, 
National Addiction Centre, London
Introduction
The United Kingdom is made up of England, Wales, Scotland and
Northern Ireland. The principle of universal access to healthcare,
free at the point of delivery, is enshrined in all settings, but there is
some substantial variation between regions. For example, in
Northern Ireland, there is no separation between health and social
services. Over the past two decades, there has been much debate
about the funding of health services, and the UK remains one of
the countries in Europe with the lowest per capita expenditure on
healthcare.
The use of primary care as a gatekeeper to secondary-care services
is regarded as conferring a unique level of efficiency of service
utilisation. However, despite the overall limits on spending,
debate continues around value for money, priorities in healthcare
delivery and overall strategies for cost containment, in a manner
similar to most European Union Member States.
Strategy
The core of the UK’s national drug strategy for the past three
decades has been a combined approach to drug prevention and
drug treatment, with a blend of demand-reduction and supply-
reduction strategies. In a recent comprehensive spending review,
it was estimated that 75 % of resources were directed towards
enforcement and supply-reduction approaches, 13 % towards
treatment and 12 % towards prevention.
As part of a move towards improving integration and coordination
of services, a national action called ‘Tackling drugs together’
(1995) launched a three-year strategy which established drug-
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action teams in 105 localities in England and Wales; a separate
system was established in Scotland and Northern Ireland. These
bodies were charged with improving links between drug-
prevention and drug-treatment activities and reported to a national
drugs-coordination unit (based at the Office of the Lord President
of the Privy Council) which was responsible for improving central
government coordination of the drug strategy. In 1998, this
approach was modified with the introduction of a national anti-
drugs coordinator (‘drug tsar’) and deputy anti-drugs coordinator
and the production of a further 10-year drug strategy entitled
‘Tackling drugs to build a better Britain: the government’s 10-year
strategy for tackling drug misuse’. These new positions had more
political profile and public exposure than their predecessors, who
were professional civil servants (UKADCU, 1998).
The main aims of this strategy are as follows:
• to tackle the supply of drugs;
• to improve drug prevention;
• to improve treatment, particularly for young people and for pris-
oners; and
• to establish a robust information framework for measuring
progress.
The primary department responsible for drug policy remains the
Home Office, which oversees drug enforcement and control. The
Home Office also houses the Drug Prevention Advisory Service
(formerly the Drug Prevention Initiative).
Health and health promotion are the responsibility of the
Department of Health, which provides a substantial budget, cal-
culated on the basis of local demographic factors, to over 100
local health authorities. These have responsibility for organising
and delivering primary and secondary healthcare to populations
usually in the range of one quarter of a million people. The health
authority can set its own local priorities, but must work within the
framework of central guidance. The National Health Service
(NHS) has undergone many transformations and reorganisations
since its inception in 1948. In the 1990s, the NHS and the
Community Care Act established a separation between the
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purchaser and the provider of health services, and between health
and social care, which placed much of the responsibility for social
care with local authorities. The resulting division and loss of pro-
tected funding for residential psychosocial services resulted in
major changes in the residential sector:
• shorter-term funding (giving rise to annual financial problems);
• substantial overall reductions in residential services; and
• considerable expansion in daycare and other non-residential
services.
A recent key change in the health services has been the promotion
of primary-care as the shaper of services. Primary care is currently
being reorganised into groups which will have overall responsibil-
ity for the purchasing of all health services, both primary and sec-
ondary (Gerada and Farrell, 1998).
Substitution
Development of substitution services
There were few drug problems in the UK in the early part of the
20th century, except for a brief flurry of activity in the 1920s. In
1922, the Rolleston Committee (a departmental committee under
the UK’s Department of Health, which supported the use of
opiate-substitution treatment for the chronic management of
opiate addiction) produced a report confirming the role of treat-
ment in response to addiction. Problems first arose in the 1960s,
when a small number of doctors prescribed large quantities of
heroin for some of the ‘flower-power’ generation, the newly evolv-
ing youth drug culture of the day. A significant black market grew
out of this form of prescribing (Spear, 1994). At that time, how-
ever, the majority of doctors wanted as little contact as possible
with addicts. The growth of a market in prescribed heroin and
cocaine resulted in the establishment of the Brain Committee in
1966. This interdepartmental committee, chaired by Lord Brain,
recommended the creation of a network of specialist clinics for the
delivery of drug treatment as well as the establishment of the 
UK Dangerous Drugs Act. Subsequently, the right of general 
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practitioners to prescribe heroin and cocaine was restricted and
drug-dependence units with specialist doctors to prescribe for
addicted patients were established.
At this stage, the problem remained quite small, with between 
3 000 and 5 000 heroin addicts using services. Most of those
entering the newly established clinics for treatment were started
on methadone; a smaller group were prescribed heroin and a
much smaller group cocaine. The size of the clinic population
remained fairly stable, with two thirds on methadone and one
third on diamorphine or other opiates, and had a turnover of
approximately 50 % per annum.
During that period, there appears to have been limited clinical
commitment to methadone maintenance and a growing interest in
short-term opiate detoxification. The growth of the use of illicit
drugs continued through the 1970s but remained relatively stable
until the heroin epidemic, which began at the end of the decade.
Between the late 1970s and the early 1980s, there was a large
increase in the availability of smokable heroin and injectable
heroin in all parts of the UK, except Northern Ireland. This prob-
lem continued throughout the 1980s. The second half of the 1990s
saw the gradual spread of the drug culture to all areas of the
United Kingdom, including Northern Ireland. National and local
surveys indicated high rates of non-dependent drug use by young
people and a lower age of drug initiation.
There was no specialist service for drug misuse prior to 1968,
when the Dangerous Drugs Act specialist services were estab-
lished. There were three phases of service development:
• 10 % of services were developed before 1970;
• 19 % of mainly residential rehabilitation services were devel-
oped in the 1970s; and
• the majority of services (71 %) were established after the central
funding initiative in 1984.
It has been argued that the increase in HIV and AIDS has stimu-
lated the development of the public health model of drug services
(Stimson, 1996). The public health implications of HIV spreading
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among drug users precipitated a large range of proactive strategies,
such as increased funding for the expansion of community drug
services and the development of a wide network of needle-
exchange programmes.
MacGregor (1994), as part of a review for the Task Force to
Evaluate Services for Drug Misusers (1996), reported that, in the
decade since the previous review, there had been a process of
merging and consolidating services, with over 475 services iden-
tified. Of these services, 95 were residential or inpatient and the
rest were statutory or voluntary sector community-based drug
agencies.
Current situation
There have been no specific national surveys on drug misuse in
the UK, but other national surveys have included questions on
drug misuse. Sexual health and lifestyle surveys (Johnson and
Williams, 1993; Farrell et al., 1998a) indicate that less than 1 % of
the population has ever injected drugs, but that 2 % of London’s
population may have injected drugs. It is estimated that there are
approximately 150 000 opiate injectors in the UK and that there
may be a sizeable number of amphetamine injectors; it is hard to
obtain reliable data on this population. There is significant varia-
tion in the route of administration of heroin, with between 30 and
60 % of those attending services reporting smoking heroin. There
is currently a large heroin- and amphetamine-using population,
and a separate large section of the young population are involved
in hallucinogen use. Up to 30 % of the population report use of
cannabis, but a smaller proportion report regular use of cannabis.
A growing problem with cocaine use is emerging, both among the
opiate-addict population and separately. There is also a growth in
new markets for crack cocaine. The size and extent of this prob-
lem are not yet clear, but a significant shift of service responses
will probably be needed to cater for the crack-cocaine-addict
population.
The number of new people entering services for opiate-addiction
treatment in the UK continues to grow as does the number of
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young addicts entering these services. The number entering with
stimulant-type problems remains a small fraction of the overall
number but has grown at a substantial rate over the last few years.
There is considerable concern about the lack of access to current
drug services for amphetamine users (Farrell et al., 1998b; Klee,
1997). The general perception is that this is a worsening drug
problem.
Major growth has been observed over the past decade in the num-
ber of people attending for treatment, rising from 8 000 in 1984 to
43 372 in 1996. The majority of these have had opiate problems
(see below). Most were prescribed methadone, and there has been
a considerable expansion in the consumption of this substance
(Table 1). There are no clear data on the numbers receiving short-
term versus long-term methadone. A small number of people 
(approximately 250) are prescribed heroin, and this number has
remained stable over the decade. The services available consist of:
• community drug teams/outpatient services;
• inpatient and residential treatment units; and
• day centres.
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TABLE 1: NUMBER OF METHADONE PRESCRIPTION ITEMS
DISPENSED IN THE COMMUNITY IN ENGLAND (1991–96)
NUMBER OF PRESCRIPTION ITEMS (1 000)
YEAR
TABLETS MIXTURES LINCTUS INJECTIONS OTHERS TOTAL
1991 38.3 403.3 6.8 39.0 3.1 490.5
1992 47.7 495.0 5.3 54.5 4.7 607.0
1993 62.4 598.2 4.2 70.1 0.3 735.1
1994 77.3 682.4 4.0 81.7 0.7 846.0
1995 94.9 787.0 3.5 84.2 1.4 970.9
1996 97.8 891.0 3.1 83.1 1.0 1 076.1
NB: The data cover all prescription items dispensed by community pharmacists, dispensing doctors and pre-
scriptions submitted by prescribing doctors for items personally administered. The data cover all pre-
scriptions for methadone hydrochloride and do not identify those solely for drug addicts.
Source: Statistics Division 1E (1998).
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The population attending these services tend to be over-represented
in terms of socioeconomic deprivation, unemployment, low level
of educational attainment and polydrug abuse.
Methadone-prescribing services are integrated, in most settings,
with community-based multidisciplinary teams which aim to pro-
vide a range of psychosocial interventions, such as:
• brief interventions;
• motivational interviewing;
• cognitive behavioural and relapse prevention; and
• addressing legal, housing and financial problems.
Such activities may emanate from community drug teams, which
have their own medical staff, or from shared-care services with
primary-care involvement. There has been considerable emphasis
on developing shared-care services and promoting primary-care
involvement in drug services (Gerada and Farrell, 1998).
The UK has a wide network of methadone-prescribing services,
the majority of which are integrated into the mainstream of drug
services and linked also to primary-care services. Probably 95 %
of methadone prescribing occurs off-site. Prescriptions are brought
to community pharmacists, the substance is dispensed by the
pharmacist and consumed at home. There is considerable geo-
graphic variation in levels of methadone prescribing, with regions
such as Merseyside having high levels and other regions, such as
Oxford, having low levels. Most of this activity occurs through
community drug services, which are, in essence, specialist servic-
es or secondary-care services. A substantial amount of prescribing
by general practitioners (GPs) is associated with these community
drug teams. Up to 20 % of GPs are involved in methadone pre-
scribing, but over 80 % have no desire to be involved in substitute
prescribing. A small number of practitioners are involved in pre-
scribing dexamphetamine sulphate for the management of
amphetamine addiction. There is a substantial amount of benzo-
diazepine prescribing, with up to 30 % of clients of some services
reporting use of benzodiazepines. Overall, the majority of service
utilisation lies in the community-based services.
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Legislation on substitution treatment
Any doctor in the UK may prescribe methadone for the purposes
of treating addiction and there is no limitation on this treatment.
The doctor is obliged to complete the prescription on a controlled
drug prescription form and to complete a database form which is
then incorporated as part of both the regional and national data set
on treatment activity. This legislation applies nationally. The
Home Office drugs inspectorate partnership with the police regu-
larly inspects chemists to ensure that the requirements for pre-
scribing are adhered to by both doctors and chemists. Improper
procedures can be pursued through the Home Office inspectorate.
The Home Office ‘Addicts index’ collates data on drug users
throughout the UK who come into contact with a medical doctor.
The 1973 misuse of drugs regulations (notification of, and supply
to, addicts) required that all doctors notify the ‘Addicts index’ of
patients whom they considered to be addicted to one of 14 notifi-
able drugs, including heroin, methadone and cocaine. In 1997,
the ‘Addicts index’ was closed and information is now collated by
the new ‘Regional drug-misuse database’ (RDMD), which collates
similar information but includes other drugs, such as ecstasy etc.
However, data from the ‘Addicts index’ contained valuable infor-
mation on the prescribing practices of doctors treating drug mis-
users in the UK. 
Substitution clients
Between 1995 and 1996, the total number of addicts notified to
the Home Office increased by 17 % (6 200 additional addicts).
This equates to 743 addicts per million of the UK population in
1996, compared with 636 in 1995 and 583 per million in 1994.
Around 40 % of notifications each year are of new addicts joining
the register.
Heroin was the most common drug of addiction for addicts noti-
fied to the Home Office. However, in 1996, a record number of
people (18 617) were reported as dependent on methadone (alone
or with other drugs). Due to the method of reporting to the data-
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base, it is unclear whether the methadone is prescribed or if it
comes from illicit sources, although it is thought that the increase
may reflect the expansion of medical services providing
methadone on prescription. The overall trend is of a substantial
increase in the proportion of addicts reported as dependent on
methadone. This trend is most apparent amongst re-registered
addicts, where the number of addicts dependent on methadone
has increased overall from around 25 % in 1987 to 50 % in 1992,
58 % in 1995 and 55 % in 1996. This probably reflects increased
prescribing of methadone in the treatment of heroin addiction.
Age and sex of notified addicts
Since 1991, new addicts notified to the Home Office have been
getting younger. In 1996, the average age of a newly notified
addict was just under 26. Three quarters of new addicts were
under the age of 30. In 1996, there was a 35 % increase in the
number of newly notified addicts under the age of 21 compared
with 1995. New addicts aged 21–24 and 25–29 rose by 22 % in
1996 compared with 10 and 5 % respectively in 1995.
Males account for about three quarters of all notifications across
all age groups. On average, females are one year younger than
male addicts.
Guidelines for the management of drug dependence
Guidelines for the management of drug dependence have been
established since the mid-1980s. These are advisory guidelines
specifically aimed at general practitioners. They recommend that
general practitioners be involved in the short-term prescribing of
substitute drugs, as well as less-complicated methadone mainte-
nance. In both the specialist service deliveries and the community
service deliveries, there are no regulations as to how frequently a
patient must attend and there is no limit to the size of client pop-
ulation the service may have. Prescriptions are generally valid for
14 days and it is recommended that, in the early stages, all drugs
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be dispensed on a daily basis and that the consumption be super-
vised until stability has been achieved. Doctors are free to exercise
their clinical judgment. There are no specified dose limits, but
practitioners generally dispense doses ranging between 20 and
100 mg. In oral methadone, a mixture of 1 mg/ml is the normal
requirement. Most of the services have behavioural contracts.
An updated version of the guidelines was launched in late March
1999 and these recommended a move towards tighter monitoring
and supervision of methadone in the early phases of treatment.
There are also proposals for new legislation to restrict the pre-
scribing of injectable medication and certain other medications to
specialists and authorised licence holders.
Pharmacy activity
Alongside the increase in notifications of drug users to the Home
Office ‘Addicts index’, there has been an increase in the number
of prescriptions dispensed in the community for methadone
hydrochloride in its various forms. Table 1 above shows the num-
ber of items dispensed in England for different forms of methadone
in the period 1991–96.
In the UK, there have been two comparable surveys of pharmacy
activity throughout England and Wales, the first in 1988 and the
second in 1995. Table 2 shows a large increase in the percentage
of community pharmacies involved in the provision of services for
drug misusers.
TABLE 2: PERCENTAGE OF COMMUNITY PHARMACIES INVOLVED IN
SERVICE PROVISION TO DRUG MISUSERS 
IN ENGLAND AND WALES
ACTIVITY 1995 (%) 1998 (%)
Dispensing controlled drugs 23 50
Selling injecting equipment 28 34
Needle-exchange scheme 3 19
Source: Sheridan (1998).
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Substances prescribed
The data described below are taken from the 1995 national survey
of community pharmacies (Sheridan et al., 1996; Strang and
Sheridan, 1998). The data draw on a sample of 3 693 methadone
prescriptions dispensed across the UK and provide details of the
type and dose of methadone prescribed and the dispensing
arrangements used. The data also show wide variations in pre-
scribing practices across UK health authorities.
Type of methadone prescribed
Across the whole sample, 79 % of all prescriptions were for oral
methadone, 12 % were for tablets and 9 % were for methadone
ampoules.
Dispensing arrangements
Guidelines from the UK Department of Health (1999) advise doc-
tors to instruct dispensing pharmacists to provide methadone in
instalments (for example, daily dispensing). The survey showed
that GPs prescribed with longer intervals between pickups than
hospital doctors.
More than one third (37 %) of all prescriptions examined in the
study were for weekly or fortnightly pickup, with 38 % being for
daily pickup. Tablets and ampoules were less likely to be dis-
pensed on a daily basis. However, there was considerable varia-
tion across the UK in dispensing arrangements. For example, the
proportion of prescriptions dispensed daily was 16 % in one
region compared with 65 % in another.
Doses prescribed
Prescriptions for up to and including 50 mg of methadone
accounted for 67.9 % of the total prescriptions dispensed. Doses
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
264
42d930_insights_brochure  09-11-2000  14:53  Pagina 264
•
 E
M
C
D
D
A
IN
SI
G
H
TS
 S
ER
IE
S
3
•
265
of methadone dispensed varied according to the type of
methadone prescribed, with oral mixtures being most likely to be
prescribed at the lower dose range (Table 3).
Public versus private sector prescribing
The data for private prescriptions revealed considerable differ-
ences compared with those for public prescriptions:
• they were significantly more likely than NHS prescriptions to be
for tablets or ampoules;
• they were for substantially higher doses; and
• they were collected on a weekly or fortnightly basis.
Eighty per cent of all private prescriptions were from the London
area.
Primary-care involvement
Shared-care participation has been identified as an important
development area (Task Force to Evaluate Services for Drug
Misusers, 1996). Although limited in number, well-implemented
initiatives show that it is possible to deliver opioid maintenance
treatment in a general-practice setting for many patients, provided
there is ongoing case management and active collaboration with
a specialist service. The difficulty of delivering services to drug
users in non-metropolitan areas, where specialist services may
TABLE 3: DISTRIBUTION OF METHADONE DOSES BY THE TYPE 
OF METHADONE DISPENSED IN ENGLAND AND WALES
DAILY DOSE OF DAILY DOSE OF 
50 MG 100 MG 
OR LESS OR MORE
Percentage of oral methadone mixture prescribed 71.2 1.5
Percentage of methadone tablets dispensed 58.4 6.1
Percentage of methadone ampoules dispensed 52.6 8.0
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have a limited capacity, underscores the importance of further
developing reduction and maintenance treatments in the primary-
care setting. There is a major policy emphasis on expanding
primary-care involvement in the management of drug depend-
ence. This includes strategies to provide further financial support
for general-practitioner involvement and provision of financial
support to develop shared-care strategies between primary-care
and specialist services.
Two studies have been conducted comparing primary-care and
specialist service intervention. One randomised study reports sim-
ilar outcomes in both settings (Task Force to Evaluate Services for
Drug Misusers, 1996) and Gossop et al. (1997, 1998, 1999) report,
as part of the ‘National treatment outcome research study’
(NTORS), similar levels of performance between specialist and
primary-care methadone treatment.
Prisons
There has been considerable expansion in the growth of
methadone detoxification for prisoners, but only a limited amount
of methadone maintenance (Singleton et al., 1999).
Overall surveys indicate that half of the women and a third of the
men who were identified as drug dependent in the year before
entering prison received help for their drug problem during the
time of imprisonment. Also, a substantial proportion had some
contact with help agencies during their prison stay. Those with
opiate dependence were more likely to receive help in the com-
munity and were also more likely to receive help in prison, but
dependent stimulant users also reported significant levels of access
to help within the prison setting.
Substitute prescribing is one of the most common forms of treat-
ment delivered by community treatment agencies. There is a low
level of continuity between community methadone treatment and
prison methadone treatment. Data indicate that, for those who are
sentenced, there are reasonable levels of contact with outside spe-
cialist agencies.
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Service expansion for drug users within prisons has changed sig-
nificantly in the recent past, with the development of a range of
treatment programmes as part of the new strategy. There is a strong
recognition of the links between acquisitive criminality and drug
dependence. Recent work on a national treatment cohort (Gossop
et al., 1998) identified high rates of active offending among those
newly entering drug-treatment services. It has been obvious for
some time that there is a considerable drug problem associated
with the prison setting.
It has been acknowledged that the level of HIV seroprevalence
among the drug-injecting population in the UK has remained low
(at 1–2 %) (Stimson, 1996), with London figures running at
between 6 and 10 %. This is seen as resulting from a successful
HIV-prevention strategy supported by broad-based community
services and needle-exchange programmes. All of these services
are funded through the National Health Service and are free at
point of access. There is a small private treatment sector in London
which mainly focuses on prescribing injectable methadone and
amphetamines, because of the limited prescribing of these drugs
within mainstream services.
Injectable prescribing
There is considerable variation between injectable and oral
methadone prescribing, with some regions reporting up to 10 % of
injectable prescribing and some reporting minimal injectable pre-
scribing (Sheridan et al., 1996; Ford and Ryrie, 1999). Heroin pre-
scribing occurs within the specialist services, where the cost has
effectively limited the amount of such prescribing. Further studies
are exploring the desirability of injectable prescribing and two
studies have recently been completed. The first, a descriptive out-
come study of those on injectable methadone and diamorphine,
reported positive outcomes (Metrebian et al., 1998) and the sec-
ond is a small pilot randomised study of injectable versus oral
methadone (Strang et al., forthcoming).
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New medications
The UK has a history of problems with buprenorphine but further
research into its utility in the management of opiate dependence
is being considered. Subutex® is now available to clinicians. One
study of buprenorphine as a detoxification agent is in progress in
the UK, but no studies on treatment with LAAM have been con-
ducted to date. Considerable interest is also shown in further eval-
uating the role of dihydrocodeine in the management of mild
opiate dependence.
Issues of diversion
Due to the mode of dispensing in the UK, a considerable amount
of diversion of prescribed medication occurs. Methadone costs
GBP 10 (EUR 16) per 100 ml on the black market. To date, this
diversion has not been a major political issue, but there are rising
numbers of first-treatment episodes for methadone only and there
has been anecdotal evidence of deaths from recreational
methadone use. However, a continuing rise in the number of
opiate- and methadone-related deaths has resulted in a degree 
of alarm around this issue and calls for more supervision of
prescribed methadone (Fountain et al., forthcoming).
Surveillance
The new drug strategy is commissioning a range of monitoring
projects to provide an information framework. These include
school and household surveys. The topic and approach to surveil-
lance continues to be a subject of debate (Hickman et al., 1998;
Judd and Fitch, 1998).
Problems
The most critical problem facing community-based services is
restricted funding and consequent inability to expand services to
meet treatment demand.
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Many services report difficulties in engaging primary-care services
in the treatment of drug users. Continuity between the criminal
justice system and the healthcare system is seen as a clear
problem, and resources have been invested in an attempt to
improve the links between them.
Services for very young people are very sparse and there is a lack
of clarity on the legal situation concerning managing young
people under the age of 16 with methadone. It is currently being
recommended that services for young people be developed in all
localities.
Considerable interest exists in the issues of dual diagnosis
(Johnson, 1997) and ethnic minorities (Khan, 1999).
Evaluation
A major study is being conducted as part of the Task Force to
Evaluate Services for Drug Misusers. This study recruited over 1
000 patients, half of whom were in methadone treatment, and is
following their progress over five years. The study is providing
valuable information about the reduction in criminal offending
associated with methadone treatment and has resulted in a posi-
tive response to the further development of methadone-treatment
programmes.
Other, smaller-scale, studies have been conducted and there is
currently a new national research initiative to develop further
treatment evaluation studies. New studies commenced in early
2000.
Finally, two major independent bodies have recently published
reviews of current drug policy (Police Foundation, 2000; Royal
College of Psychiatrists, 2000). Both have called for increased
funding for treatment and a better focus on the health needs of
drug users, along with other recommendations for changes in drug
policy. Also, both suggest that more resources be expended on
research and evaluation.
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